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ABSTRACT 
Resistin, leptin, and also insulin have roles in cardiovascular function, feeding and 
energy balance; and can act in the brain nuclei known to be important for mediating 
these functions. Central sites of action for resistin are not well understood, in contrast 
to leptin or insulin. Moreover, in high fat diet (HFD), resistin, leptin, and insulin are 
increased, but little is known regarding the interactions between these hormones in the 
brain. 
Resistin and leptin are both involved in inflammatory responses in the periphery and 
it is known that leptin is involved in inflammatory actions in the brain, so we 
speculated that resistin may have similar effects in the brain. 
Therefore, this project investigated the distribution of neurons and their 
neurochemical content in the brain that are activated by centrally administered 
resistin, leptin or insulin alone; or a combination of these hormones, in rats fed a HFD 
compared to a normal diet (ND). In addition, this project explored the effects of leptin 
and resistin in brain inflammation. 
Methods  
Male Sprague-Dawley rats were fed a high fat diet (22% fat) or normal diet. 
Anaesthesia was induced with 2-5% isoflurane in O2 to allow femoral artery and vein 
cannulation. Urethane (1.4-1.6 g/kg initially, followed by additional doses of 0.05 ml, 
as required) was used to maintain the anaesthesia. The rats received 
intracerebroventricular (ICV) saline (5 µl), leptin (7 µg), resistin (7 µg), or insulin 
(500 mU), or a combination of resistin and leptin, leptin and insulin, or resistin and 
insulin. Three hours later, the brains were perfused and removed. 
Immunohistochemistry was performed on these brains to detect Fos protein, a marker 
of activated neurons; or CD11b (clone OX42), a marker for microglia. Dual-label 
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immunohistochemistry was performed to detect activated neurons containing tyrosine 
hydroxylase (TH), a marker for catecholamines; or tryptophan hydroxylase, a marker 
for serotonin; or orexin. In separate studies, the brains were immediately removed and 
divided into blocks of the hypothalamus, midbrain, and ventral and dorsal medulla to 
investigate the gene expression of cytokines (TNF-α, IL-1β, and IL-6) using real-time 
polymerase chain reaction (RT-PCR).  
Results  
In chapter three, the results show that in the arcuate nucleus (ARC), paraventricular 
nucleus (PVN) and lateral hypothalamic area (LHA), leptin or resistin administered 
alone or in combination significantly increased the number of Fos-positive neurons; 
and this occurred in the lamina terminalis only when leptin and resistin were 
combined. Only in the ARC was the response to resistin and leptin combined 
significantly greater than for each hormone alone. In the periaqueductal gray (PAG), 
resistin alone also significantly increased the number of Fos-positive neurons 
compared to control and this was greater than the combination of resistin and leptin. 
Interestingly, in the raphe pallidus nucleus (RPA), when both leptin and resistin were 
administered, the number of Fos-positive neurons was significantly reduced compared 
to either hormone alone.  
In chapter four, the results show that following resistin or leptin alone or in 
combination in rats fed the HFD, there were no significant increases in the number of 
Fos-positive cell nuclei in the PVN, ARC, and the LHA. This contrasted with 
observations in rats fed a ND. In the organum vasculosum of the lamina terminalis 
(OVLT) and median preoptic nucleus (MnPO) of HFD rats, there were significantly 
smaller numbers of Fos-positive cell nuclei compared to ND following the combined 
administration of resistin and leptin. In the PAG, rostral ventromedial medulla 
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(RVMM) and nucleus tractus solitarius (NTS) of HFD rats, there were significantly 
less Fos-positive cell nuclei compared to ND following resistin alone.  
In chapter five, resistin and leptin alone or in combination increased activation of 
catecholaminergic neurons in the PVN in ND and in the NTS and rostral ventrolateral 
medulla (RVLM) in both ND and HFD diets, and increased activation of orexinergic 
neurons in the LHA in ND. Only resistin and leptin in combination increased 
activation of serotonergic in the RVMM, but only leptin alone increased activation of 
serotonergic neurons in the dorsal raphe nucleus (DR), in rats fed a ND. 
In chapter six, compared to control, insulin alone or combined with leptin increased 
neuronal activation only in the PVN of rats fed a ND, and a HFD attenuated this 
effect of insulin alone. Neuronal activation in the PAG was reduced in ND and HFD. 
A reduction was also observed in the NTS and RVLM in HFD but not in ND. Insulin 
alone or in combination with leptin increased activation of catecholaminergic neurons 
in the RVLM in both diets and in the NTS in ND. Insulin combined with leptin 
increased activation of catecholaminergic neurons in the NTS in HFD. 
In chapter seven, compared to control the combination of insulin and resistin 
resulted in significantly less neuronal activation in the PAG in both diets, and in the 
NTS, RVLM, and RVMM in HFD. It was also found that compared to resistin alone, 
the combination resulted in less neuronal activation in the PVN, PAG, NTS, and LHA 
of rats fed a ND; and in the NTS and RVLM of HFD rats. Only in the PVN of ND 
rats was there less neuron activation compared to insulin alone. There was little effect 
on catecholaminergic, serotonergic, and orexinergic neurons observed. 
In chapter eight, resistin and leptin alone or in combination significantly increased 
microglial activation only in the PVN of rats fed a ND. No other brain regions 
examined showed significant activation of microglia. Gene expression of tumor 
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necrosis factor alpha (TNF-α) in the midbrain and ventral medulla, and interleukin 1 
beta (IL-1β) in the midbrain and dorsal medulla of rats fed a HFD were increased with 
resistin. The combination of resistin and leptin increased TNF-α gene expression in 
all brain regions that were examined except the hypothalamus, in addition to 
increased IL-1β and interleukin 6 (IL-6) gene expression in the ventral medulla of rats 
fed a ND. 
In conclusion, this thesis provides novel information and knowledge regarding the 
potential sites of action of resistin and the nature of the neurons activated in the brain. 
The potential sites of action in hypothalamic nuclei include the ARC, PVN, and LHA, 
and these are similar to that of leptin. In such regions, resistin was found to mainly 
activate catecholaminergic and orexinergic neurons, as observed with leptin. 
Furthermore, these responses can be reduced by a HFD. Additionally, there is 
evidence that resistin contributes to brain inflammation. 
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Chapter 1: Introduction 
This chapter will explore the function of adipokines, particularly resistin and leptin. I 
will describe where adipokines are produced and released, and their roles and 
functions especially related to metabolic and cardiovascular function. I will highlight 
that they can act in the brain and I will review potential sites of action within the brain 
and focus on the neurochemical content contained in the brain neurons that are 
activated by the adipokines.  
Leptin is a well-known adipokine involved in the central regulation of feeding 
behaviour and modulating sympathetic nerve activity to various organs, especially the 
kidney which is important in cardiovascular function. Resistin, known to be 
associated with insulin resistance, can act centrally to also modulate sympathetic 
nerve activity similar to leptin. Like both resistin and leptin, insulin is another 
hormone which exhibits sympathetic effects via central pathways and I will discuss 
these in this chapter.  
Since diets high in fat can alter responses to leptin, I will also discuss what is 
currently known of the effects of high fat diets on the adipokines and insulin 
including the brain areas activated in high fat fed conditions. Finally, the influence of 
these hormones on inflammation will be discussed as these hormones appear to 
induce pro-inflammatory conditions. 
1.1. Adipose tissue 
Adipose tissue has traditionally been considered an energy-storing tissue with unique 
properties that cannot be substituted by any other organ; one that has a virtually 
unlimited capacity to expand in a non-transformed state. The adipose tissue can 
respond very quickly and dynamically to nutritional changes through adipocyte 
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hypertrophy and hyperplasia, thus executing its role in whole-body energy 
homeostasis (1). Adipose tissue remodelling accelerates in the state of obesity and 
results in reduced angiogenic remodelling, extracellular matrix overproduction and 
increased immune cell infiltration (2). Two types of adipose tissue are found in 
mammals, white and brown(3). White adipose functions as the energy store, forms 
pads between organs, and provides insulation. At times when the body requires 
additional energy, hormones act on adipose cells to release energy-rich fatty acids and 
glycerol (4). Brown adipose is commonly found in newly born animals and humans, 
and is responsible for the generation of heat through consumption of energy. People 
have lower amounts of brown adipose tissue with increasing age (5). 
Adipose tissue distribution varies with gender, with men accumulating adipose tissue 
around the waist, while women tending to accumulate it around the hips (6). More 
importantly, adipose tissue plays a critical role in the regulation of endocrine and 
cardiovascular function by secretion of bioactive peptides called adipokines that can 
act centrally to influence these functions (6). 
1.2. Adipokines (Leptin and Resistin) 
1.2.1. Leptin 
Leptin was the first adipokine identified in 1994 (7). It is a 16 kDa protein encoded by 
the OB gene on chromosome 7 in humans and consists of 167-amino acids. The 
protein is synthesised in adipocytes, but also secreted from the mucosa of the gastric 
fundus, mammary epithelial cells, skeletal muscle cells, ovaries, bone marrow, 
lymphoid tissues, and placenta (8). Leptin is an adipokine responsible for the 
regulation of energy intake and energy expenditure and it is involved in various 
physiological processes such as the regulation of endocrine function, inflammation, 
immune responses, reproduction, and angiogenesis (9). Also, evidence suggests leptin 
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regulates metabolic and cardiovascular functions by acting centrally (10-13). These 
effects include leptin-evoked increases in heart rate, blood pressure, and sympathetic 
nerve activity (SNA) (14, 15). The action of leptin to increase SNA to the kidney is an 
important factor contributing to hypertension observed in obesity or overweight 
conditions (16, 17). Leptin can also induce increases in SNA to the vasculature of the 
hindlimb, and also increases SNA to brown adipose tissue (BAT) (15) which is 
involved in metabolic function and thermogenesis. 
Leptin is transported into the brain by a saturable, receptor-mediated, transport 
system. The most important leptin receptor isoforms are the long isoform (Ob-Rb) 
and the short isoform (Ob-Ra). The leptin receptor (Ob-Ra), short form, is mainly 
located in brain microvessels, and is the brain’s main transport mechanism to get 
leptin across membranes (18, 19). The Ob-Rb activates the janus kinase signal 
transduction and translation system (JAK/STAT) and elicits leptin’s functional 
effects. Also, the presence of the Ob-Rb isoform of the leptin receptor in brain 
microvessels during development may be related to leptin’s action as an angiogenic 
factor (7, 20). 
1.2.2. Resistin 
Resistin is an adipokine which consists of 114 amino acids and was first described in 
2001 (21). It is a member of the newly discovered family of cysteine-rich proteins 
called resistin-like molecules (21, 22). In rodents, resistin is synthesised by fat tissue, 
however in humans, it is mainly produced by macrophages that have infiltrated into 
the fat tissue. Resistin is also expressed in the liver, skeletal muscle, stomach, and 
adrenal gland (23, 24). Resistin is additionally produced by regions of the 
hypothalamus (25). 
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Resistin has the capability of reducing food intake by acting in the rodent brain (25) 
and another possible action includes altering energy balance (26). This hormone is 
also linked to obesity as it may induce insulin resistance in rodents, although it has 
not yet been clearly established that resistin is associated with insulin resistance or 
type 2 diabetes in humans (22, 27, 28). However, there is evidence from clinical 
research findings which have linked increased serum resistin levels with obesity, 
increased visceral fat, metabolic and cardiovascular dysregulation such as 
hypertension and myocardial infarction, and inflammatory and immune-mediated 
diseases (21, 22, 29, 30). The mechanisms that may contribute to those diseases are 
not known. Recent studies have found increased lumbar sympathetic nerve activity 
(LSNA) and RSNA, but decreased SNA to the BAT, as well as body temperature, 
following intracerebroventricular (ICV) administration of resistin (26). These 
observations provide supporting evidence that resistin may be involved in 
cardiovascular and metabolic function. 
1.3.  Insulin 
Insulin was discovered in 1923 and is a well a known peptide hormone. It is 
synthesised by beta cells in the pancreas and consists of 51 amino acids. It has 
important metabolic functions that regulate fat and carbohydrate metabolism (31). As 
well, it plays a major role in the uptake of glucose into body cells (32). Impaired 
insulin function can cause diseases such as diabetes mellitus. There are two types of 
diabetes mellitus, type one which is characterised by insulin deficiency and type two 
which is characterised by insulin resistance (33, 34). Moreover, recent findings 
indicate that insulin acts in the brain, particularly in the hypothalamus to regulate food 
intake and energy homeostasis (35). Also, insulin can regulate the autonomic nervous 
system. Like leptin, insulin can act to increase sympathetic outflow to the kidney, 
skeletal muscle vasculature, and BAT, by activating receptors within the central 
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nervous system (CNS) (36, 37). Thus, insulin can also act in the CNS to influence 
cardiovascular and metabolic function.  
1.4.  Brain regions involved in metabolic and cardiovascular action 
1.4.1. The lamina terminalis (OVLT and MnPO) 
The lamina terminalis is located in the midline of the anterior wall of the third 
ventricle (38). The lamina terminalis is involved in neuronal circuitry that regulates 
cardiovascular function, body fluid balance and thermogenesis. The lamina terminalis 
includes the organum vasculosum of the lamina terminalis (OVLT), and the median 
preoptic (MnPO) nucleus and it is known that both nuclei have poly-synaptic 
connections to sympathetic nerves innervating the kidneys (39).  
In the MnPO, there are efferent neural pathways that project from this region and 
terminate at parvocellular neurons in the hypothalamic paraventricular nucleus (PVN) 
which may activate autonomic pathways regulating cardiovascular function (40). It 
has been reported that electrical stimulation of the MnPO causes a depressor response 
and decreases SNA to the hindlimb, although there was an increase in RSNA (41). 
Lesions of the MnPO, together with the OVLT, lead to increases in blood pressure 
and heart rate (42, 43). These results suggest that MnPO may have a tonic depressor 
function. However, electrical stimulation and lesion techniques affect both neurons 
and fibres of passage and this can complicate the interpretation of the findings. This 
can be avoided by using techniques that affect neurons only. Indeed, when MnPO 
neurons were inhibited by muscimol, there was a fall in arterial pressure. These 
results suggest that a pressor output originates from neurons in the MnPO (44).  
1.4.2. Hypothalamus 
The hypothalamus is located in the medial inferior part of the diencephalon floor, and 
extends from the anterior margin of the optic chiasm to the posterior margin of the 
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mammillary bodies. It consists of a medial and a lateral zone, with the former having 
three regions (anterior, middle, and posterior) (45-47). One of the main sites of action 
of adipokines in the brain is the hypothalamus. The hypothalamus influences a range 
of behaviours and autonomic functions such as feeding and drinking, reproductive 
behaviour, endocrine functions, thermoregulatory responses, and responses to stress 
(45, 48).  
1.4.2.1. Paraventricular nucleus (PVN) and supraoptic nucleus (SON) 
The anterior zone of the hypothalamus consists of the preoptic nucleus, 
suprachiasmatic nucleus, paraventricular nucleus (PVN) and supraoptic nucleus 
(SON) (47, 49). The PVN contains groups of large neurons known as magnocellular 
neurons expressing oxytocin and vasopressin, and smaller neurons named 
parvocellular neurons synthesising a variety of neurochemicals (50). These 
parvocellular neurons can project to regions in the CNS including the 
intermediolateral cell column of the spinal cord which regulates SNA (51, 52). The 
PVN also projects to the rostral ventrolateral medulla (RVLM), an area in the medulla 
oblongata of the brain involved in regulating blood pressure and sympathetic outflow 
(53). Thus, there are neurons in the PVN which have the anatomical connections to be 
able to directly and indirectly affect SNA (50). 
The PVN is involved in cardiovascular regulation, as stimulation of neurons in this 
brain region can induce increases in heart rate, blood pressure and RSNA (54, 55). In 
contrast, earlier studies found decreases in blood pressure due to inhibition of SNA to 
the kidney following electrical and chemical stimulation of the PVN (56, 57). Thus 
both inhibition and excitation of SNA and the resultant blood pressure changes can be 
elicited from the PVN and the differential effects are likely due to the intensity of the 
stimulation of the PVN (58). Furthermore, a decrease in RSNA, but increases in 
cardiac SNA following PVN stimulation can occur, suggesting the effects of the PVN 
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on SNA to different organs is not generalized (59). Thus, neurons in the PVN play an 
important role in regulating cardiovascular function. 
The SON consists of neurons with secretory granules containing oxytocin and 
vasopressin. The vasopressinergic neurons receive information regarding blood 
volume and blood pressure from brain regions such as the ventrolateral medulla and 
nucleus tractus solitarius (NTS) (60), and release vasopressin in response to changes 
in these variables. Vasopressin or antidiuretic hormone acts to increase water 
reabsorption in the kidneys (61), and is also a powerful vasoconstrictor (62). The 
SON, therefore, plays an important role in body fluid homeostasis and cardiovascular 
regulation. 
1.4.2.2. The arcuate nucleus (ARC), ventromedial (VMH) and dorsomedial 
(DMH) hypothalamic nucleus  
The tuberal region of the hypothalamus consists of the arcuate nucleus (ARC), 
ventromedial hypothalamic nucleus (VMH), and the dorsomedial hypothalamic 
nucleus (DMH). The ARC is an important region in the hypothalamus as it is 
involved in the regulation of cardiovascular function, body weight and food intake 
(63, 64). The ARC projects to several areas in the brain such as the PVN, DMH, 
periaqueductal gray (PAG) of the midbrain, and the rostral ventrolateral medulla 
(RVLM) and nucleus tractus solitarius (NTS) of the medulla oblongata which are 
involved in regulating sympathetic nerve activity (SNA) (65). The ARC also contains 
neurons which can project to the lateral hypothalamic area (LHA) with possible roles 
in regulation of feeding and body weight (66-68). 
Stimulation of ARC neurons using local injections of N-methyl-D-aspartate can 
increase arterial pressure, heart rate, and greater splanchnic SNA (69). These actions 
of the ARC are tonically regulated by inhibitory inputs into the ARC. Evidence for 
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this is that inhibition of Gamma-Aminobutyric Acid (GABA)-ergic activity in the 
ARC leads to increases in those cardiovascular variables (64). Thus, the ARC may be 
important in contributing to the regulation of blood pressure and SNA. 
The ARC plays an essential role in the regulation of body weight and food intake as it 
receives hunger- and satiety-related signals from brainstem regions and the periphery, 
and it is also known to respond to hormones such as leptin, which are involved in 
regulating these functions (63, 70). 
The VMH, being the largest and best defined region of the hypothalamus, is known as 
a satiety centre (71), which indicates that this brain area is important for regulating 
metabolic function. Stimulation of the VMH in animals reduces feeding behaviour, 
while a lesion to this nucleus leads to excessive weight gain (72, 73), hyperphagia 
(74, 75), and obesity. The VMH is also involved in BAT function as electrical 
stimulation of this region leads to increased BAT thermogenesis (76).  
The VMH is also involved in autonomic and cardiovascular function. VMH 
destruction can lead to sympathetic hypoactivity and parasympathetic hyperactivity 
(77-79). Studies have reported an increase in cardiac vagal activity (80), and a 
decrease in SNA to the heart (79) following VMH lesions, resulting in reduced heart 
rate (80). In contrast, one study observed increased heart rate, as well as blood 
pressure, due to lesions in this region (81), whilst electrical stimulation of the VMH 
also produces the same effects on blood pressure and heart rate (81, 82). The findings 
suggest the exact role of the VMH in cardiovascular regulation is controversial. 
However, the evidence implies that the VMH is involved in parasympathetic and 
sympathetic modulation. 
The DMH is another important region in the hypothalamus in regulating metabolic 
function. Lesions in the DMH lead to hypophagia and reduced body weight which are 
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mediated by decreased expression of NPY in the DMH (83), whilst overexpression of 
NPY in the DMH leads to the opposite effects (84). The DMH also plays a role in 
NPY-dependent glucose homeostasis, as knockdown of DMH NPY leads to improved 
glucose tolerance and insulin sensitivity (85). Furthermore, a role of the DMH in 
thermogenesis has been reported involving activation of excitatory amino acid 
receptors in this region and thus indicates that activation of DMH neurons induces 
increases in SNA to BAT (86, 87). 
With respect to cardiovascular regulation, activation of neurons in the DMH results in 
increased arterial pressure, heart rate, RSNA and cardiac SNA (88-90). On the other 
hand, inhibition of DMH neurons reduces blood pressure and heart rate (91). The 
pressor and sympatho-excitatory responses are likely to be mediated by pathways 
connecting the DMH to the rostral ventrolateral medulla (RVLM), as inhibition of 
RLVM neurons attenuates the increases in the blood pressure and RSNA (88). 
1.4.2.3. The lateral hypothalamic area (LHA) 
Jones et al. (92) indicated that the lateral tier of the hypothalamus is divided into the 
lateral preoptic and lateral hypothalamic areas, with many neurons in the latter area 
projecting through the medial forebrain bundle to the basal forebrain, cerebral cortex, 
brainstem, or spinal cord (92). The lateral hypothalamic area (LHA) is a large, 
heterogeneous area and also considered a feeding centre of the hypothalamus known 
to modulate feeding behaviour, as well as regulate autonomic and cardiovascular 
function (93-95).  
Electrical stimulation of the LHA elicits increased food intake (95-98). However, 
another study showed that electrical stimulation of the septal nuclei, which are located 
in the LHA, elicits reduced food consumption (99), suggesting that regulation of 
feeding behaviour is dependent on the site of stimulation in the LHA. Furthermore, 
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lateral hypothalamus lesions lead to a marked decrease in food intake and body 
weight (93). The lesion also resulted in increased SNA to BAT (93). Taken together, 
the evidence suggests that the LHA is involved in regulating food intake and body 
weight. 
The LHA also plays an important role in cardiovascular regulation, as chemical 
stimulation of different sites of the LHA can lead to different cardiovascular 
responses. Stimulation of the tuberal and posterior regions of the LHA resulted in 
decreased blood pressure and heart rate, but stimulation of the medial regions 
surrounding the fornix resulted in increased blood pressure and heart rate (94, 100, 
101). It was reported that pressor neurons in the medial LHA and depressor neurons 
in the tuberal and posterior LHA are responsible for the differential effects on heart 
rate and blood pressure (94), and these neurons connect to various regions of the 
brain, as shown in studies using retrograde neuronal transport tracing techniques (94, 
101). These regions include the brainstem which is known to influence cardiovascular 
function (94). For example, LHA neurons project to rostral ventrolateral medulla 
(RVLM) cardiovascular neurons to reduce firing rate of these neurons and arterial 
pressure and heart rate (102). Thus, evidence indicates that the LHA is involved in 
neural pathways in the brain which regulate cardiovascular function. 
1.4.3. Midbrain regions 
1.4.3.1. Periaqueductal gray (PAG) 
The midbrain contains the periaqueductal gray (PAG) that is subdivided into three 
subnuclei (lateral, ventral and dorsal). The PAG has an important role in pain 
modulation, vocalization, anxiety and fear; and it is also involved in cardiovascular 
regulation (53, 103). The PAG modulates defensive behaviour, which can be caused 
by external stimuli such as pain and fear, and in turn influences cardiovascular and 
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respiratory factors to influence blood flow, blood pressure, heart rate and oxygen 
supply to various organs (104). 
The PAG has projections which extend into the hypothalamus, especially the PVN 
and the VMH; as well as projections to all medullary nuclei, particularly the nucleus 
tractus solitarius (NTS) and the rostral ventrolateral medulla (RVLM) (105-107). The 
connections between the PAG and these nuclei may mediate the effects on 
cardiovascular function. For example, the RVLM contains cardiovascular sympathetic 
premotor neurons which receive direct projections from the PAG (53).  
The PAG contains different columns of nuclei in the dorsolateral, lateral, and 
ventrolateral regions (108). These columns of nuclei are known to have different 
effects on cardiovascular function. The stimulation of the dorsolateral, dorsomedial, 
and lateral PAG nuclei resulted in increased blood pressure, heart rate, and RSNA 
(103, 109, 110). In contrast, stimulation of ventrolateral PAG nuclei causes a decrease 
in blood pressure and heart rate (103, 109). 
The PAG has been also suggested to contribute to metabolic regulation. Electrical and 
chemical stimulation using the excitatory amino acid, D,L-homocysteic acid, of the 
lateral region of the caudal PAG elicited an increase in SNA to BAT resulting in 
thermogenesis (111). These studies suggest that neurons located in the caudal PAG 
are responsible for this effect. 
1.4.3.2.  Dorsal raphe nucleus (DR) 
The dorsal raphe nucleus (DR) is located in the ventral part of the PAG in the 
midbrain and its neurons project throughout the brain and spinal cord through several 
ascending and descending pathways (112). The DR is involved in cognitive functions 
including memory, learning, and mood; and may contribute to disorders such as 
depression (112, 113).  
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The DR is known to regulate reward behaviours, associated with feeding and 
drinking, and these are mediated by serotonergic neurons located in the DR (114), 
which are of particular interest for this thesis. It is also a target site for neuropeptides 
involved in feeding behaviour. For example, Carlini et al. (115) found that 
administration of the orexigenic hormone, ghrelin, directly into the DR induced 
increases in food intake (115). A more recent study investigated the effects of 
neuromedin U, an anorectic neuropeptide, which reduced not only food intake but 
also the motivation for high fat food by acting directly in the DR (116). These studies 
highlight the potential role of the DR in regulating feeding behaviour. 
The DR is also involved in cardiovascular regulation. Electrical stimulation of the DR 
elicited increased blood pressure, heart rate and RSNA (117-120). These effects are 
most likely due to activation of neurons in the DR since neuronal activation by 
microinjection of glutamate into the DR reproduced the pressor response (117, 121). 
The DR also receives inputs from other brain areas, such as the ventral tegmental area 
(VTA) and substantia nigra (122), in addition to the nucleus tractus solitarius (NTS) 
(123), which are areas also known to be involved in the regulation of blood pressure. 
1.4.4. Medulla oblongata 
1.4.4.1. Raphe pallidus nucleus (RPA) 
The medulla oblongata contains the midline area known as raphe pallidus nucleus 
(RPA) (124). The RPA contains serotonergic neurons that project to the 
intermediolateral cell column of the spinal cord where sympathetic preganglionic 
neurons are located (124-126). Stimulation of the RPA can elicit sympatho-excitatory 
inputs to the heart and kidney (127). Evidence of this, is that disinhibition of the RPA 
leads to increased cardiac SNA and heart rate (128). However, it is also known that 
stimulation of the RPA can induce both increases or decreases in blood pressure and 
SNA (121, 129-131). The exact responses are dependent on the precise location of the 
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stimulation within the RPA (130, 131). The RPA is also part of the descending 
pathway modulating cardiovascular responses from the DMH such as heart rate and 
RSNA (132, 133). Thus, it is suggested that the RPA is an important region involved 
in cardiovascular regulation. 
The RPA has marked effects on metabolism by influencing BAT SNA. Activation of 
the RPA with bicuculline, which blocks GABA receptors, leads to a huge increase in 
BAT SNA (134). The RPA has excitatory effects on BAT SNA but it is under tonic 
inhibition. Thus, the sympathetic premotor neurons in the RPA which innervate the 
BAT receive tonic inhibitory GABAergic (135, 136), inputs directly from the MnPO 
(136-139). Other sources of inhibitory inputs include glycinergic inputs from the 
rostral ventromedial PAG itself (139), or the glycinergic interneurons located in the 
rostral RPA (140) 
1.4.4.2. Rostral ventromedial medulla (RVMM) 
The rostral ventromedial medulla (RVMM) is a collection of neurons situated near to 
the midline in the ventral region of the medulla oblongata (53, 141). These neurons 
are known to project to sympathetic preganglionic neurons located in the spinal cord 
(142-145), suggesting that the RVMM can influence cardiovascular function. This is 
supported by studies investigating the effects of RVMM in response to electrical or 
chemical stimulation which elicited increases in arterial pressure and SNA (53, 145-
147). Furthermore, inactivation with lidocaine (146, 148), and lesions (149) of the 
RVMM leads to falls in blood pressure. 
The RVMM is closely connected with the rostral ventrolateral medulla (RVLM), an 
important region in cardiovascular control (see below). It was reported that the 
inactivation of the RVMM attenuates electrically-stimulated pressor responses from 
17 
 
   
the RVLM, while there was no effect vice versa (146), suggesting that the RVMM is 
likely to modulate a portion of the cardiovascular responses elicited by the RVLM. 
1.4.4.3. Rostral ventrolateral medulla (RVLM) 
The rostral ventrolateral medulla (RVLM) is an area of the medulla oblongata, which 
is ventral and ventrolateral to the nucleus ambiguus. The RVLM is populated with 
sympathetic premotor neurons, which project to the intermediolateral cell column of 
the spinal cord, and are involved in cardiovascular regulation (53, 150, 151). The 
RVLM is known to be important in the tonic regulation of SNA and blood pressure 
(152). This is highlighted by the marked decreases in blood pressure that can be 
induced by bilateral inhibition of the RVLM (153, 154). The catecholaminergic C1 
neurons in the RVLM are involved since chemical or electrical stimulation of these 
neurons induces increases in blood pressure and SNA (155-158). 
Additionally, the RVLM receives projections from the caudal ventrolateral medulla 
(CVLM) and nucleus tractus solitarius (NTS), which influence baroreflex functions. 
Barosensitive neurons in the RVLM receive tonic GABAergic inhibitory inputs (155) 
from the CVLM which receives tonic excitatory inputs from the NTS (159). 
Activation of these NTS inputs to CVLM result in decreased blood pressure and SNA 
(53, 160-163). These studies indicate that the neurons in the RVLM are tonically 
active and receive afferent cardiovascular sensory inputs from arterial baroreceptors 
through pathways involving the NTS and CVLM. 
1.4.4.4. Nucleus tractus solitarius (NTS) 
The nucleus tractus solitarius (NTS) is located in the dorsal medulla and plays an 
important role in cardiovascular regulation. The NTS has extensive connective 
pathways including to and from the PVN and RVLM, which are important areas 
involved in blood pressure and SNA regulation (50, 164-166).  
18 
 
   
The NTS is known to receive afferent inputs from baroreceptors and chemoreceptors 
located in the cardiovascular system (167, 168). These inputs provide information 
about the level of blood pressure, oxygen and carbon dioxide (169). Neurons in the 
NTS also respond to autonomic afferent activity from cardiac receptors which provide 
information on blood volume (170, 171). Thus, the NTS is involved in cardiovascular 
regulation by receiving afferent inputs from sensory receptors located within the 
cardiovascular system.  
This afferent sensory information can be integrated into efferent outputs from the 
NTS which, in turn, influence cardiovascular function. For example, the activation of 
NTS neurons leads to the stimulation of inhibitory neurons in the caudal ventrolateral 
medulla (CVLM), which project inhibitory inputs to RVLM neurons and result in 
decreased blood pressure and SNA (53, 160, 161). This is supported by studies 
showing that lesions of the NTS neurons can attenuate the baroreflex responses in 
anaesthetized animals (172, 173).  
1.5. Adipokines and insulin; potential brain regions involved 
The brain regions discussed above mediate many of the actions of leptin, resistin and 
insulin. The exact nuclei and neurons involved have been investigated with various 
techniques including detection of the protein Fos (174-182) following ICV 
administration of leptin, resistin, and insulin. More precise information has been 
obtained from microinjection studies into specific brain nuclei but this has occurred 
only for leptin and insulin (183-189). The distribution of leptin and insulin receptors 
in brain nuclei also provides information on sites of action for these hormones (186, 
190-194). The receptor for resistin has not been unequivocally identified at present.  
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1.5.1. Fos is a marker for increased neuronal activity 
Fos, the protein product of the immediate early gene (IEG), c-fos proto-oncogene, is 
critical to the regulation of the expression of genes that contain binding sites for the 
transcription factor, activator protein-1 (AP-1) (195). The complex of Fos combined 
with Jun; also a protein product of an IEG, forms to AP-1 to regulate the expression 
of target genes (196). Following neuronal activation, the expression of IEG is 
increased rapidly within neurons (197). The time course of Fos induction peaks within 
two hours and returns to basal levels within four hours (198, 199). Thus, it is a marker 
for acutely activated neurons. Other forms of Fos exist which are long lasting and 
these can be used to identify chronically activated neurons (199).  
The availability of antibodies to Fos protein is helpful, as simple 
immunohistochemistry procedures can be used to detect it, providing several 
advantages; (i) Fos can be utilised to describe the distribution of activated neurons 
within specific brain nuclei following acute stimulation, such as drug administration 
(199); and (ii) it can also be combined with other antibodies that detect neurochemical 
content to identify subpopulations of the activated neurons. On the other hand, a 
disadvantage of Fos is that it cannot be used to detect neurons that are inhibited (200). 
1.5.2.  Leptin; which brain nuclei are affected?  
1.5.2.1. The lamina terminalis (OVLT and MnPO) 
Leptin receptors are strongly expressed in the neurons located in the OVLT and the 
MnPO of the lamina terminalis (201). The MnPO neurons expressing leptin receptors 
play a role in the thermoregulatory functions of BAT via the sympathetic nervous 
system. The MnPO sends projections to the rostral RPA neurons (202), which are 
known to regulate BAT SNA as described previously (134). As discussed in section 
1.4, the OVLT and MnPO are known to be important in regulating cardiovascular 
function, affecting SNA, blood pressure and heart rate. As these areas contain a high 
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density of leptin receptors, the activation of neurons in these areas may contribute to 
the cardiovascular actions of leptin. 
1.5.2.2. Hypothalamic nuclei: arcuate (ARC) nucleus 
Leptin is a regulator of energy balance by signalling through pathways projecting to 
the feeding centre in the hypothalamus and involves orexigenic (enhances food 
intake) and anorexigenic (inhibits food intake) neuropeptides in the ARC (203, 204). 
Leptin inhibits neurons in the ARC that coexpress the orexigenic neurotransmitters 
neuropeptide Y (NPY) and agouti-related peptide (AgRP), and leptin activates 
anorexigenic pro-opiomelanocortin (POMC) neurons that coexpress cocaine- and 
amphetamine-related transcripts (CART) in the ARC (205). 
Furthermore, microinjections of leptin into the ARC elicits cardiovascular effects, in 
addition to decreases in food intake (206). Local injections of leptin into the ARC 
increases arterial pressure and SNA to the kidney and BAT (184). In another study 
involving direct injections of leptin into the ARC, leptin induced a small increase in 
lumbar sympathetic nerve discharge, however there were no changes in blood 
pressure (183). Thus, there appears to be a consensus that leptin can act in the ARC to 
increase SNA but whether this is sufficient to increase blood pressure appears to be 
more contentious. 
1.5.2.3. Hypothalamic nuclei: paraventricular nucleus (PVN), ventromedial 
(VMH) and dorsomedial (DMH) hypothalamic nucleus 
Immunohistochemistry and in situ hybridization techniques have shown that there are 
leptin receptors located in many areas of the hypothalamus, including the VMH, 
DMH, PVN, SON and LHA (186, 190, 207). These areas are known to have key roles 
in autonomic function and energy regulation (190, 208-210) as discussed in section 
1.4.  
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These brain areas have also been investigated in many studies using Fos detection to 
show activated neurons following leptin administration. These studies show high 
numbers of Fos-positive cell nuclei in the PVN, VMH and the DMH following ICV 
injection of leptin (175, 176, 211). Other studies show that Fos production is 
increased in the PVN and DMH following intravenous (IV) leptin administration as 
well (174, 212).  
Microinjection studies with leptin have also been investigated and they show that 
leptin can lead to increases in SNA. For example, local injections of leptin into the 
VMH and into the perifornical area of the LHA produced large increases in lumbar 
sympathetic nerve discharge while injections into the PVN produced lesser increases 
(183). Microinjections of leptin into the VMH also produced increased arterial 
pressure and RSNA (185). These data suggest these hypothalamic areas contribute to 
the cardiovascular actions of leptin.  
Microinjection of leptin into hypothalamic regions can also influence metabolic 
function. For example, Satoh et al. (206) provided evidence that microinjections of 
leptin into the VMH and LHA decreases body weight gain and food intake (206). 
Additionally, microinjection of leptin into the VMH increased glucose uptake in 
peripheral tissues such as the skeletal muscle, heart, spleen and BAT (213). 
1.5.2.4. The midbrain (PAG and DR) 
In situ hybridization studies show that there are leptin receptor-expressing neurons in 
the midbrain areas; the PAG and DR (190, 214, 215). Further evidence from 
immunohistochemistry experiments support this finding in the DR (190, 207). 
Furthermore, serotonergic neurons located in the DR contain leptin receptors (216, 
217). Not many studies have evaluated the function of leptin in these midbrain areas, 
however since the midbrain is involved in cardiovascular regulation as described in 
22 
 
   
section 1.4, it is possible that they are a site of action for leptin in modulating 
cardiovascular regulation. 
1.5.2.5. The nucleus tractus solitarius (NTS)  
Numerous studies show that leptin receptors are present in the NTS. The density of 
leptin receptor mRNA in the hindbrain, including the NTS can differ between species 
since rats reportedly have less leptin receptors than mice (218). Elmquist et al. (190) 
have also investigated the distribution of leptin receptor mRNA in the caudal 
brainstem and their results show that neurons in the dorsal vagal complex express 
leptin receptors (190). Many neurons in the NTS also express Phosphorylated Signal 
Transducer and Activator of Transcription 3 (p-STAT3) immunoreactivity, which is a 
marker for leptin signalling (219). 
The NTS and dorsal motor nucleus of the vagus are likely to play important roles in 
the cardiovascular and metabolic actions of leptin since both systemic and central 
administration of leptin activates neurons in these brain areas (10, 175, 176, 211). 
Grill et al. (220, 221) established that microinjection of leptin into the dorsal vagal 
complex lead to a reduction in food intake, suggesting that this area may also be 
involved in the anorectic action of leptin. This conclusion is supported by the finding 
that ICV leptin can increase the activation of NTS neurons that respond to gastric 
loads, and thus enhance feedback signals associated with food intake (222). 
Evidence from studies involving leptin microinjections suggests that leptin acts 
directly in the NTS to influence SNA (223). Microinjection of leptin in the NTS 
elicited an increase in RSNA which was associated with an increase in arterial 
pressure (224). However, this only occurred when injected into the caudal NTS as the 
rostral NTS produced no effects (224). This suggests that there are site-specific 
effects of leptin within the NTS. 
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1.5.2.6. The raphe pallidus nucleus (RPA) and rostral ventromedial medulla 
(RVMM) 
The RPA does not appear to contain leptin receptors. But the RPA is innervated by 
neurons that express leptin receptors (202).  According to Morrison (225), the neurons 
in the RPA, and the surrounding RVMM, are able to mediate an increase in heart rate, 
energy expenditure, and BAT SNA and thermogenesis induced by IV leptin. These 
neurons are possibly sympathetic premotor neurons which regulate BAT 
thermogenesis and lipid metabolism (225). 
1.5.2.7. The rostral ventrolateral medulla (RVLM)  
Leptin receptors have been found to be localised on catecholaminergic neurons in the 
ventrolateral medulla, which were identified as adrenergic C1 in (RVLM) and 
noradrenergic A1 neurons in the CVLM known to project to several brain areas (226, 
227). Further, some of the catecholaminergic neurons in the RVLM that express 
leptin receptors project to the sympathetic preganglionic motor neurons in the spinal 
cord that directly affect SNA to the kidney (227). Additionally, local injection of 
leptin into the RVLM increased RSNA and blood pressure while injection of a leptin 
antagonist, SLAN-4, inhibited these effects (152, 227). This suggests that neurons in 
the RVLM contribute to the RSNA effects induced by leptin. 
The neurons in the RVLM are also influenced by circulating leptin since an 
intracarotid injection of leptin excited presympathetic neurons of the RVLM and 
increased RSNA while not significantly altering heart rate and blood pressure (228). 
The RVLM also receives inputs from NTS neurons that are activated by leptin and 
receive  chemoreceptor inputs (229). Thus, leptin may also be a mediator of reflex 
pathways involving the NTS and RVLM that control sympathetic outflow. 
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1.5.3. Resistin; which brain areas are influenced? 
Unlike leptin, the sites of action of resistin within the brain are not clearly identified. 
There are no studies in which resistin has been microinjected into specific brain 
nuclei. Thus, the actions of resistin in regions of the brain that are important in the 
regulation of cardiovascular and metabolic functions have been investigated using the 
detection of the protein Fos only.  
1.5.3.1. The ARC nucleus 
The ARC is one area investigated as a potential site for resistin action. An acute ICV 
injection of resistin raises the number of Fos-positive neurons in the ARC in the 
fasted state (178, 180). This result is controversial since another fasting study did not 
find an increase in Fos-positive neurons (177). Recently, findings from our laboratory 
has indicated that ICV resistin increases Fos production in the ARC, providing 
supporting evidence to the earlier studies (179). 
The identity of the neurochemical content in ARC neurons that are potentially 
activated by resistin has also been investigated. Central infusion of resistin increased 
activation and expression of NPY neurons which are responsible for orexigenic 
effects such as increased appetite and weight gain in the ARC (180), although it is 
known that ICV injection of resistin reduces food intake (25). Furthermore, 
immunohistochemical investigations have shown that there is resistin 
immunoreactivity within POMC neurons in the ARC (230), although, ICV resistin 
does not influence the mRNA of POMC, which is known to be involved in the 
inhibition of food intake (178, 180). These studies suggest that resistin may 
potentially increase food intake via NPY neurons, which contrasts with functional 
studies showing that central resistin reduces food intake (25). 
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1.5.3.2. The PVN and other hypothalamic nuclei 
Kosari et al. (177) published recent research findings about the rat hypothalamic 
nuclei that show Fos expression after administration of ICV resistin (177). There were 
increased numbers of Fos-positive neurons in the PVN, SON and LHA compared to 
controls. The results were consistent with the finding of  Singha et al. (180) who also 
showed an increase in Fos expression in the PVN. Additionally, Singha et al. (180) 
has also shown a rise in Fos expression in the DMH. However, it is not known which 
neurochemicals are contained in neurons activated by resistin and further 
investigations are required. Thus, there is a clear gap in our knowledge of potential 
sites of resistin action in the brain. 
1.5.4. Insulin; which brain areas are affected? 
1.5.4.1. The ARC nucleus 
Insulin is classified as a peptide hormone and it works on the brain by activation of 
receptors. Insulin receptors are present in the hypothalamus and also in the 
cerebellum, hippocampus and cerebral cortex (181, 182), and they are highly 
expressed in the ARC indicating that this area is a major target site for insulin to exert 
its effects in the hypothalamus (231). This view is supported by work involving the 
use of ICV insulin receptor-antisense oligodeoxynucleotide to inhibit insulin receptor 
formation (232). The findings indicated a reduced expression of insulin receptors in 
the ARC and this lead to increased food intake, and to insulin resistance (232).  
Insulin also inhibits the orexigenic neuropeptides NPY and AgRP in the ARC, thus 
suppressing food intake and increasing energy expenditure. However, insulin 
activates anorexic POMC-containing neurons that coexpress CART. This implies 
insulin may activate the same neurons that are activated by leptin (181).  
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In addition to the role of ARC neurons in the metabolic actions of insulin, this 
hormone can also act in the ARC to influence cardiovascular effects. For example, it 
was found that insulin microinjected into the ARC can increase LSNA and baroreflex 
function, and this was attenuated by local injection of GABA receptor agonist, 
muscimol (233). This sympatho-excitation response induced by insulin was also 
found to be inhibited by an anti-insulin affibody microinjected into the ARC (234). 
Furthermore, ICV injection of insulin increases RSNA and heart rate associated with 
increased neuronal activation in the ARC, thus the action of insulin in the ARC may 
be responsible for these changes (235). These studies suggest that insulin action in the 
ARC is important in influencing cardiovascular function. 
1.5.4.2. The PVN and other hypothalamus areas 
Insulin can act in the hypothalamus to influence metabolic and cardiovascular 
function. Insulin receptors are located in the PVN, VMH, DMH, and LHA (191-193). 
Insulin injections into the PVN decreased food intake and body weight, and also 
induced thermogenesis, highlighting the role of insulin in the PVN in regulating 
metabolic function (236). The PVN also appears to mediate insulin-induced increases 
in LSNA, as inhibition of this region with a GABA receptor agonist or with a 
melanocortin 3/4 receptor antagonist reverses this effect (237). However, 
microinjection of insulin directly into the PVN was not able to increase LSNA and 
arterial blood pressure, thus it is suggested that the cardiovascular effects of insulin 
may be an indirect action involving the melanocortin-dependant pathway (237). This 
sympatho-excitatory effect could also involve a glutamatergic input into the PVN, as 
injection of a glutamate receptor antagonist into the PVN also abolished the LSNA 
increases induced by insulin (238).Thus, activation of both melanocortin 3/4 receptors 
and glutamate receptors in the PVN may contribute to insulin sympatho-excitatory 
actions.  
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Insulin infusions into the VMH decreased food intake and body weight, however 
infusions into the lateral hypothalamus produced no effects (239). The VMH also 
contains glucose-sensing neurons (240) which respond to hypoglycaemia (241) and it 
was shown that microinjections of insulin into the VMH elicits decreases in blood 
glucose (188). Furthermore, Paranjape et al. (242) found that insulin can act in the 
VMH to inhibit glucagon secretion from α-cells. Taken together, the data suggest 
insulin can act within the VMH to regulate glucose homeostasis.  
Insulin acting through the VMH can also affect energy expenditure. Insulin 
microinjected into the VMH reduces SNA to BAT (187), indicating that insulin can 
act on VMH neurons to modulate thermogenesis. 
In the LHA, insulin receptors are present on glucose-sensitive neurons and these 
neurons contribute to the ability of insulin to regulate plasma glucose (193). This was 
suggested by studies using microinjection of insulin into the LHA causing reductions 
in blood glucose levels (188). In contrast, another study showed that insulin 
microinjected into the lateral hypothalamus resulted in increased blood glucose levels 
and serum insulin (243). The reasons for these contrasting findings is unknowon at 
present but may depend on the specific sites of the LHA influenced by insulin. 
1.5.4.3. The medulla oblongata 
The medulla oblongata expresses insulin receptors which were mainly detected in the 
NTS, but also in the RPA and RVLM which expressed low densities of this receptor 
(194, 244). A study investigated the effect of insulin in the RVLM, in which 
microinjection of insulin into the RVLM elicited no effect on LSNA or blood 
pressure, thus this may be due to the low expression of insulin receptors in the RVLM 
(244).  
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The NTS is another potential site of action for insulin to regulate metabolic and 
cardiovascular function. Insulin microinjected directly into the NTS or vagal complex 
activates the extracellular signal-regulated protein kinases 1 and 2 to inhibit glucose 
production in the liver (245). With the respect to cardiovascular function, 
microinjections of insulin into the NTS induced decreases in arterial pressure and 
heart rate (246, 247). It has been suggested that these effects are mediated through 
neuronal nitric oxide synthase (nNOS) in the NTS (246, 247). 
1.6. The neurochemical content of neurons important in autonomic 
and cardiovascular function 
Based on the literature, leptin and insulin can act in various brain nuclei and affect 
neurons containing specific neurochemicals to influence metabolic, autonomic and 
cardiovascular functions. However, very little is known about the neurochemical 
content of brain neurons affected by resistin. Tyrosine hydroxylase (TH)-, serotonin 
(5HT)-, and orexin-containing neurons are known to be important neurotransmitters 
in the brain regulating metabolism and cardiovascular function (248-251). Leptin acts 
on neurons that contain these neurochemicals, and since leptin and resistin have 
similar effects on LSNA and RSNA, we have focused on neurons containing those 
neurochemicals to investigate the effects of resistin. 
1.6.1. Tyrosine hydroxylase (TH)-containing neurons  
Tyrosine hydroxylase (TH) is an enzyme that is involved in catecholamine 
biosynthesis. These catecholamines are noradrenaline, adrenaline, and dopamine 
(252). Catecholamines are known to be involved in several physiological processes 
such as energy homeostasis and cardiovascular function including increasing heart 
rate and blood pressure (248). Tyrosine hydroxylase is also used as a marker of 
catecholaminergic neurons in the brain and these neurons are located in the locus 
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coeruleus, ventral tegmental area (VTA) and substantia nigra (253), the PAG and DR 
in the midbrain, as well as in the PVN of the hypothalamus, and in the NTS and 
ventrolateral medulla (254-257).  
In the PVN, the catecholaminergic neurons are involved in cardiovascular and 
autonomic function. For example, using a transneuronal viral labelling technique 
involving injection of pseudorabies virus into the adrenal gland to detect cell groups 
which innervate the sympathetic preganglionic neurons in the CNS combining this 
technique with neurotransmitter immunohistochemistry, showed that there were TH-
positive neurons in the PVN, that were infected by the virus (142), and thus can 
influence SNA to the adrenal gland. Catecholaminergic inputs into the PVN can also 
alter blood pressure. This is evidenced by studies in which there were increases in 
arterial pressure following microinjection into the PVN of anti-dopamine β-
hydroxylase saporin which is taken up by catecholaminergic terminals and 
retrogradely transported to the cell bodies subsequently destroying the 
catecholaminergic inputs to the PVN (258).  
Catecholaminergic input into the PVN may also be involved in hypoxia-induced 
increases in heart rate (258). Furthermore, inhibition of the catecholaminergic input in 
the PVN prevents pressor responses induced by chemoreceptor stimulation (259). 
These studies provide evidence that catecholaminergic transmission in the PVN can 
affect cardiovascular function. The PVN receives projections from the NTS which 
contains catecholaminergic neurons (260), and it is likely that this pathway relays the 
chemoreceptor information to the PVN (261).  
TH-positive neurons in the hindbrain are also involved in regulating autonomic and 
cardiovascular function. In the RVLM, TH-positive neurons are involved in the 
regulation of SNA (249, 262). Chemical stimulation of the neurons located in the C1 
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area of the RVLM led to increased arterial pressure and heart rate as well as increased 
SNA (156, 263).  
1.6.2. 5-hydoxytryptamine (5HT)-containing neurons 
Serotonin, also referred to as 5-hydoxytryptamine (5HT), is a neurotransmitter 
commonly found in the peripheral and central nervous system and is known to 
regulate many functions such as hormone secretion, mood, food consumption and 
energy homeostasis (264). Also of interest, 5HT has been found to interact and 
modulate various neurotransmitters, including acetylcholine, noradrenaline, 
dopamine, GABA and glutamate (264). Moreover, 5HT plays a role in the regulation 
of sympathetic nerve outflow to the heart (250) and in regulating blood pressure 
(265). Interestingly, ICV or IV administrations of 5-hydroxytryptophan was able to 
decrease blood pressure and it was suggested that the conversion of 5-
hydroxytryptophan to 5HT by tryptophan hydroxylase, which is also a marker of 
serotonergic neurons, is required for the blood pressure response (265). Activation of 
5HT receptors in the brain leads to various effects on heart rate, blood pressure and 
SNA to organs involved in cardiovascular regulation (266, 267). Serotonergic neurons 
are present in the PAG, DR, RPA and also in the RVMM (268).  
The serotonergic neurons in the PAG are involved in modulating anxiety and pain as 
well as cardiovascular regulation (269). Furthermore, electrical stimulation of the 
dorsal PAG increased the activation of serotonergic neurons located in the ventral 
medulla (270). This area appears to be important in mediating the defensive behaviour 
evoked by PAG stimulation as described in section 1.4. The serotonergic neurons in 
the ventral medulla are responsible for inhibiting the baroreflex-mediated 
bradycardia, which results in increased heart rate that is observed during the defensive 
behaviour induced by stimulation of the dorsal PAG (270).  
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It has been shown that the DR is the main source of 5HT in the brain (112, 271, 272). 
Serotonergic neurons in the DR are involved in metabolic and cardiovascular 
regulation. These neurons project to the VMH and can release serotonin to regulate 
feeding behaviour (273). Moreover, electrical stimulation of the DR produces 
increases in blood pressure, and selective lesions of serotonergic neurons in the DR 
attenuate the pressor response (274, 275).  
Serotonergic neurons in the medulla oblongata, specifically the RPA and the RVMM, 
project directly to sympathetic preganglionic motor neurons as shown using a 
transynaptic retrogradely-transported virus injected into the adrenal gland and 
immunohistochemistry for serotonergic neurons (142). Similarly, studies have shown 
that serotonergic neurons in the RPA also project polysynaptically to BAT. These 
studies suggest that serotonergic neurons in the medulla are involved in BAT and 
adrenal function via actions on SNA (276). 
The RVMM can exhibit pressor effects via activation of serotonergic neurons which 
project to sympathetic preganglionic neurons (53). Additionally, the RVMM and the 
RPA both contain inhibitory 5HT1A receptors expressed on serotonergic neurons, and 
activation of those receptors leads to decreased blood pressure (250, 277-279). 
Additionally, serotonergic activation of these receptors in the RPA can result in 
inhibition of BAT thermogenesis (280). 
1.6.3. Orexin-containing neurons 
Orexin, also known as hypocretin, is a neuropeptide that plays a role in the regulation 
of sympathetic nervous system and energy homeostasis (251). There are two types of 
orexin; orexin-A and orexin-B. Their receptors are distributed throughout the brain 
with orexin receptor type 1 (OX-R1) abundant in the ARC, VMH, suprachiasmatic 
nucleus, VTA, DR and spinal cord, and type 2 (OX-R2) are abundant in the PVN, 
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cortex and amygdala (281, 282). Both receptors are also present in the NTS (283) and 
the RVLM (284). It is known that OX-R1 is selective for orexin-A, however OX-R2 
is non-selective and shows high affinity for orexin-A and orexin-B (285). 
The distribution of orexinergic neurons, however, is more restricted and they are 
located in the lateral and posterior hypothalamic area with some within the 
subthalamus areas (286). Orexin neurons located in the LHA are known to connect to 
several areas in the brain responsible for regulating cardiovascular function, such as 
the NTS, which is an area known to influence heart rate and blood pressure (287, 
288), as well as the PVN, ARC, VTA, central gray, DR, and the locus coeruleus 
which are involved in regulating a range of different functions such as food intake, 
blood pressure, and thermogenesis (289). 
It has been suggested that orexin is involved in metabolic and cardiovascular function. 
A study has demonstrated that ICV orexin-A exhibits its orexigenic effects via 
activation of OX-R1 in both male and female rats (290). Additionally, ICV orexin-A 
can increase SNA to BAT which, in turn, stimulates thermogenesis. This is mediated 
by prostaglandins, as inhibition of the synthesis of these lipid hormones, particularly 
prostaglandins of the E series, leads to attenuation of this response (291). ICV orexin-
A also increases arterial pressure, heart rate, RSNA and plasma catecholamines while 
orexin-B was demonstrated to only increase arterial pressure and heart rate (292). A 
similar effect was observed following stimulation of neurons in the lateral 
hypothalamus and perifornical regions (293), suggesting the orexin neurons in these 
regions may be involved in these cardiovascular effects.  
It has also been reported that increased blood pressure is associated with increased 
expression of orexin-A neurons in the lateral hypothalamus of hypertensive rats (294). 
Orexin-A, secreted from orexin neurons in the LHA, can act on adrenergic C1 
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neurons in the rostral ventral medulla to increase blood pressure, and can also induce 
increases in heart rate via projections from the rostral ventral medulla to the 
sympathetic preganglionic neurons in the intermediolateral cell column of the spinal 
cord (295). Orexin-A acting in the RVLM can also produce sympatho-excitatory 
responses, in addition to the pressor responses (296). Orexin-A can also act in the 
PVN (295), and microinjection studies involving this region elicited increases in 
RSNA and arterial blood pressure (251) Thus, these studies indicate that elevated 
orexin-A levels may contribute to hypertension and this may be through the PVN and 
RVLM. 
1.7. The neurochemical content of neurons that are activated by 
leptin  
As discussed in the previous sections, leptin affects metabolic and cardiovascular 
functions, such as food intake, energy homeostasis and increasing SNA to peripheral 
tissues (kidney, BAT, muscle vasculature). Leptin can influence these functions 
through modulation of neurons that contain neurochemicals, such as NPY, AgRP, and 
POMC neurons located in the ARC which are responsive to leptin (205). However, 
this thesis will focus on neurons containing catecholamines in the PVN and other 
hypothalamic nuclei, the midbrain, and medulla; 5HT in the midbrain and medulla; 
and orexin in the LHA; which are areas known to contain leptin receptors. The leptin 
receptors in these brain areas are described in section 1.5. The neurons containing 
these neurochemicals in these brain areas and potential functional rules were 
described in section 1.6. 
1.7.1. Catecholaminergic neurons in the PVN and other hypothalamic nuclei 
Hay-Schmidt et al. (216) has found that most of the TH-positive neurons, mainly 
dopamine neurons, in the PVN of rats expressed leptin receptor immunoreactivity. 
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This finding has also been confirmed in sheep brain, in which 73% of TH-positive 
neurons located in the hypothalamic areas including the PVN, ARC, SON, DMH, and 
the VMH contain leptin receptor immunoreactivity (297). These neurons may be 
involved in leptin-induced changes in body weight and neuroendocrine function 
(297).  
Not only may leptin influence catecholaminergic neuronal activity in the 
hypothalamus, it can also influence noradrenaline release as shown by Clark et al. 
(298) who found that both ICV and intraperitoneal (IP) injections of leptin inhibited 
the release of noradrenaline in the PVN. Such an effect has also been observed by 
others (216, 299, 300). It is known that noradrenergic stimulation of the PVN can 
induce feeding (301), thus these changes by leptin may result in suppression of 
appetite. 
1.7.2. Catecholaminergic neurons in the midbrain 
Figlewicz et al. (302) found co-localization of leptin receptors in TH-positive 
dopaminergic neurons located in the VTA and the substantia nigra pars compacta of 
rats (302). Investigations of the mouse brain have also shown very high proportions of 
TH-positive neurons coexpressing leptin receptors in the midbrain. It was found that 
approximately 67% of cells in the VTA, 8% of cells in the PAG, 31% of cells in the 
DR and all the cells in the substantia nigra coexpressed TH and leptin receptors (214). 
Electrophysiological recordings show that leptin acts directly on dopaminergic 
neurons in the VTA to reduce firing rate of these neurons (303, 304). Additionally, 
direct injections of leptin into the VTA reduces food intake and knockdown of leptin 
receptors in the VTA produces the opposite effect (303). Together these studies 
suggest that feeding behaviour induced by leptin may involve these dopaminergic 
neurons. 
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 The PAG and DR areas of the midbrain, which are both known to be involved in 
blood pressure control, can also be influenced by the action of leptin. Thus, there is 
the potential of leptin acting on catecholaminergic neurons located in these brain 
areas to exhibit effects on cardiovascular function, although this has not been well 
established. 
1.7.3. Catecholaminergic neurons in medulla oblongata 
Co-localization of TH-positive cells with leptin receptors has been found in the so-
called A2 noradrenergic and the C2 adrenergic neurons located in the NTS (216). 
Williams et al. (305) demonstrated that ICV leptin targeted catecholaminergic 
neurons in the NTS and increased the expression of Fos protein in these neurons, 
indicating increased activation of these neurons (305). It is suggested that leptin may 
be a mediator of catecholaminergic neuronal activity in the NTS which is known to 
project to other areas in the brain such as the PVN and RVLM to modulate metabolic 
and cardiovascular effects.  
Leptin receptors are also co-localized with the TH-positive neurons in the RVLM, and 
microinjections of leptin into the RVLM modulated the activity of TH-positive 
neurons and elicited an increase in renal sympathetic tone and blood pressure (226, 
227). This suggests catecholaminergic neurons in the medulla oblongata are important 
in the cardiovascular actions of leptin. 
1.7.4. Serotonergic neurons in the midbrain 
Serotonergic neurons that express leptin receptors have been reportedly found in all of 
the raphe nuclei in rat brain, including the DR (216, 306). Studies have detected 
neurons in DR that coexpress leptin receptor mRNA, and serotonin transporter 
mRNA (used as a marker for serotonergic neurons) (216, 307). Moreover, projections 
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from these leptin receptor-expressing serotonergic neurons may influence food 
consumption, body weight and neuroendocrine function (216, 306, 307).  
However, the expression of leptin receptors on serotonergic neurons in the DR have 
been brought into question by patch clamp studies which report that leptin acts on DR 
neurons that do not contain serotonin, although the activated neurons are adjacent to 
serotonergic neurons (272). Thus, the ability of leptin to directly activate serotonergic 
neurons in the DR is controversial.  
1.7.5. Serotonergic neurons in the medulla oblongata 
It is known that the activation of serotonergic neurons in the RPA can modulate SNA 
(308), and ICV leptin can also affect SNA (14, 16). Since serotonergic neurons that 
express leptin receptors have been found in specific areas in the medulla oblongata 
including the RPA (216), the data suggests that leptin may contribute to the increase 
in SNA mediated through serotonergic neurons in the RPA. This view is supported by 
evidence showing leptin’s ability to increase BAT SNA which is mediated by 
projections from the DMH to the RPA (202, 225, 309). 
In contrast, IV and ICV administration of leptin does not elicit an increase in Fos 
expression in the RPA (10, 176, 179). The reasons for this discrepancy are unclear. 
1.7.6. Orexinergic neurons in the LHA 
Previous studies have suggested interactions between leptin and orexin. For example, 
Horvath et al. (310) showed that orexin neurons in the LHA express leptin receptors. 
Iqbal et al. (297) also found that all orexin neurons in the LHA are co-localized with 
leptin receptors. In contrast, other studies suggest that orexin neurons are separate 
from leptin receptor-expressing neurons in the LHA, however these latter neurons 
innervate the orexin neurons, thus it is possible that leptin indirectly acts on the orexin 
neurons in LHA (311-314).  
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Regarding the action of leptin in the LHA, it has been shown that IP administration of 
leptin reduces orexin-A levels, suggesting that leptin interferes with orexin activity in 
this area (315). This is supported by the finding that continuous infusion of leptin into 
the third ventricle resulted in hyperpolarization of orexin neurons, a reduction in 
firing rate, and a substantial decline in orexin expression in the hypothalamus 
especially the LHA (316).  
Moreover, models of mice overexpressing orexin have been shown to have increased 
energy expenditure, and additionally, ICV administration of an OX-R2 agonist 
resulted in similar observations (312). Therefore, orexin signalling is involved in 
altering energy balance. These mice, with overexpression of orexin, also show 
enhanced weight loss following ICV leptin infusions (312) indicating that increased 
orexin signalling is associated with increased leptin sensitivity. The evidence to date 
suggests that leptin signalling via orexin neurons in the LHA is necessary to ensure 
appropriate regulation of energy homeostasis (313). 
1.8. The neurochemical content of neurons that are activated by 
resistin 
In contrast to leptin, very little is known about the neurochemical content of neurons 
affected by resistin. One study determined that resistin inhibits dopamine and 
noradrenaline release in the hypothalamus, which may contribute to its effects on 
feeding behaviour (317). Although, this study assessed the effect of resistin on 
catecholamines in the hypothalamus, it did not examine specific brain nuclei within 
the hypothalamus. 
Thus, further studies investigating the actions of resistin on catecholaminergic, 
serotonergic, and orexinergic neurons located in specific nuclei of the brain is 
required to fully gain an insight into the actions of resistin in the brain. 
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1.9. The neurochemical content of neurons that are activated by 
insulin 
As discussed in the previous sections, insulin can act in the brain to regulate 
metabolic and cardiovascular function, including food intake, energy homeostasis and 
increasing SNA to peripheral tissues (kidney, BAT, muscle vasculature), which is 
very similar to the actions of leptin. Insulin can influence these functions through 
modulation of neurons containing NPY, AgRP, and POMC neurons located in the 
ARC (181), similar to leptin, however, there is little known about the effects of 
insulin on neurons in other brain regions and their neurochemical content. This thesis 
will focus on neurons containing catecholamines in the PVN and other hypothalamic 
nuclei, the midbrain, and medulla; 5HT in the midbrain and medulla; and orexin in 
the LHA. These areas are known to contain insulin receptors, and neurons containing 
these neurochemicals as described in sections 1.5 and 1.6. 
1.9.1. Catecholaminergic neurons in the PVN and other hypothalamic nuclei 
It is widely known that insulin receptors are located in hypothalamic nuclei such as 
the PVN, ARC, VMH, DMH, and LHA, found in rats (191-193). It has been known 
for many years that insulin can influence catecholamine turnover. In the 
hypothalamus, local micro-infusion of insulin into the PVN enhanced the release of 
noradrenaline (318, 319). This suggests that the activity of noradrenergic neurons in 
the PVN can be influenced by insulin acting directly in the PVN (318, 320, 321). It is 
known that noradrenaline stimulates feeding by acting in the PVN (301), thus this 
mechanism could contribute to the effect of insulin on feeding behaviour. However, 
the effects of insulin on catecholaminergic neurons in the PVN appears to be indirect 
because, there is no evidence that insulin receptors are co-localized on the TH-
positive neurons in the PVN. 
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1.9.2. Catecholaminergic neurons in the midbrain 
Figlewicz et al. (302) has found co-localization of insulin receptors in TH-positive 
dopaminergic neurons located in the VTA and substantia nigra regions of the 
midbrain. Patch-clamp studies show that insulin increases the firing rate of 
dopaminergic neurons in the VTA (322-324). Further, selective ablation of the insulin 
receptors on dopaminergic neurons resulted in increased body weight and 
hyperphagia (322). Together, these findings suggest that insulin may act on VTA 
dopaminergic neurons to decrease food consumption and body weight. 
In the PAG or DR of the midbrain, there does not appear to be any evidence of 
localization of insulin receptors on TH-positive neurons. Furthermore, reports indicate 
there is a low density of insulin receptors in the PAG, and the DR of the midbrain 
(192, 194). 
1.9.3.  Catecholaminergic neurons in the medulla oblongata 
In the medulla oblongata, insulin receptors are present in the NTS (194), however 
they have not been found co-localized with TH-positive neurons in this region. On the 
other hand, the RVLM was found to contain TH-positive neurons expressing insulin 
receptors (325). Thus, it has been reported that insulin activates RVLM neurons that 
project to the intermediolateral cell column in the spinal cord (325). This is raises the 
possibility that TH- positive neurons in the RVLM may be involved in insulin’s 
actions, however, this has not been directly investigated.  
TH-positive neurons in the RVLM and NTS may also be glucose-sensitive and the 
activity of these neurons in the medulla oblongata is increased by insulin-induced 
hypoglycaemia. Thus, catecholaminergic neurons in the medulla may be affected by 
insulin directly as well as indirectly (326-328).  
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1.9.4. Serotonergic neurons in the midbrain 
The PAG and DR of the midbrain express low levels of insulin receptors (192, 194) 
and it is not known whether these receptors are expressed on serotonergic neurons. 
Thus, insulin’s role in the midbrain, involving serotonergic neurons, has not been 
clearly defined. 
1.9.5. Serotonergic neurons in the medulla oblongata 
Insulin receptors have been detected in the RPA of the medulla oblongata (194), 
however, serotonergic neurons in RPA have not been found to express these 
receptors. These neurons have been found to be indirectly affected by insulin 
administration. A reduction in the firing rate of the serotonergic neurons in the RPA 
was observed following systemic administration of insulin, which induced 
hypoglycaemia (329, 330).  
In the RVMM, where serotonergic neurons are also found, there does not appear to be 
any evidence to date indicating that insulin acts within this medullary region.  
1.9.6. Orexinergic neurons in the LHA 
The LHA has a low density of insulin receptors (192, 194), but it is not known 
whether insulin receptors are expressed on orexin neurons present in the LHA. 
However, there is evidence that orexin neurons in the LHA are indirectly affected by 
the administration of insulin. 
Cai et al. (331) proposed that a distinct population of orexin neurons in the LHA of 
the brain are glucose-sensitive neurons which are responsive to the insulin-induced 
changes in blood glucose levels. A decline in blood glucose levels stimulates the 
orexin neurons in this area, while rises in blood glucose inhibited these neurons (331, 
332). Furthermore, insulin-induced changes in plasma glucose can also affect the 
amount of orexin in LHA neurons as shown by increases in orexin mRNA induced by 
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insulin (333). Thus, insulin may indirectly affect the activity of orexin neurons in the 
LHA. However, there is some disagreement since one study showed that IP 
administration of insulin failed to induce significant activation of orexin neurons in 
the LHA which suggests that these neurons are not primarily involved in 
hypoglycaemia and are not a primary target site for the action of insulin (334).  
1.10. Adipokines and insulin in HFD 
The studies discussed above have demonstrated the ability of adipokines (leptin; 
resistin) and insulin to influence neurons in the brain of animals fed a normal chow 
diets. However, it is also of interest to investigate the effects of the hormones in 
animals fed a high fat diet (HFD) or with diet-induced obesity (DIO) because these 
hormones are elevated in these conditions. 
In 2014 and 2015, health surveys by the Australian Bureau of Statistics determined 
that approximately 2 out of 3 adult Australians and that 1 in 4 children aged 5-17 
were overweight or obese (335). This is a major health burden because obesity is 
associated with hemodynamic changes, in which there is increased peripheral 
resistance and constriction of blood vessels which leads to decreased cardiac output 
(336). Obesity is also associated with hormonal changes such as increased plasma 
levels of leptin, resistin, and insulin (21, 337, 338). Furthermore, it has been described 
that obesity increases the risk of developing type 2 diabetes and cardiovascular 
disease, as well as cancer (339-341).  
Overweight is a condition due to excessive growth of the adipose tissue (73). 
Adipokines are important in this condition as they play a central role in the regulation 
of appetite and energy expenditure (342), and may also reduce insulin sensitivity 
(343), oxidative capacity (344), and lipid uptake (345). These adipokines are also 
implicated in inflammation, hypertension and other cardiovascular diseases associated 
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with overweight / obese condition (346). The adipokine profile in humans and 
rodents, changes in response to the amount and condition of adipose tissue (346). The 
essential role that adipokines play in metabolic and physiological processes suggests 
that understanding the central pathways and the neurochemicals mediating their 
actions in the brain is important not only in the normal lean condition but also in the 
obese and overweight conditions (346).  
1.10.1. Leptin and HFD 
In obese conditions, there is resistance to leptin (7, 347, 348). Friedman et al. (7) and 
many others (349-352) described the characteristics of leptin resistance which include 
increased plasma leptin and reduced response to the appetite effects of exogenous 
leptin in DIO. Despite elevated leptin plasma levels in obesity (7, 337, 352-355), and 
the reduced response to the metabolic functions of leptin, the leptin-induced increase 
in RSNA in obesity is not attenuated compared to the responses in lean animals (12, 
13, 356). This observation has come to be known as selective leptin resistance (12, 
13, 356).  
Selective leptin resistance has been reported to be due to the inability of leptin to 
activate the JAK/STAT3 and phosphatidylinositol 3-kinase (PI3K) signalling 
pathways (357). It has also been reported that suppression of cytokine signalling 3 
(SOCS3) protein and protein tyrosine phosphatase 1B (PTP1B) negatively regulate 
leptin receptor signalling, and increased intracellular levels of SOCS3 and PTP1B 
appear to mediate the decreased sensitivity to the anorexigenic effects of leptin 
observed in overweight and obese conditions (341). Scarpace et al. (358) reported that 
selective leptin resistance is also due to leptin’s failure to modulate ARC 
neuropeptides (POMC and NPY) in obesity. 
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An additional study using p-STAT3 immunohistochemistry to detect cells responsive 
to leptin reported that the ARC is the major site of leptin resistance, compared to 
other hypothalamic nuclei such as the VMH and DMH, which were found to be still 
responsive to leptin (349). Interestingly, Morabito et al. (359) recently found that 
weight loss was able to restore leptin signalling in some brain regions. However, 
restoration of signalling did not occur in other key brain regions including the ARC 
and the DMH, and only partial restoration was observed in the NTS (359). This 
suggests that weight loss alone cannot solely restore leptin signalling in the brain to 
levels seen in normal lean controls. 
Furthermore, many studies have investigated the actions of exogenous leptin in HFD-
induced obesity. A study done by Rahmouni et al. (13) investigated the effects of IP, 
IV and ICV leptin in obese mice (13). HFD mice were found to be resistant to the 
anorexigenic effects of leptin. However RSNA and blood pressure increased 
following leptin, just as seen in mice fed a normal diet (13). The sensitivity to the 
sympatho-excitatory actions of leptin, however, was not uniform since the responses 
induced by leptin on LSNA and BAT SNA were reduced in DIO mice (13).  
The sympatho-excitatory and pressor effects of leptin are mediated by the CNS in 
rabbits (360). These effects are also observed in HFD-induced obese rabbits, and the 
leptin-induced increase in RSNA was potentiated by HFD feeding (17). 
Obesity induced by HFD feeding can also influence other actions of leptin in the 
CNS. In normal lean animals, ICV leptin increases neuronal activation, determined by 
the detection of the protein Fos, in the ARC, PVN, and VMH (175, 176, 211, 235). 
However, Prior et al. (17) found that ICV injection of leptin into HFD animals 
decreased Fos expression in the ARC by 54%, PVN by 69%, and DMH by 65%; and 
it was suggested that this reduction in neuronal activation caused by leptin may be 
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due to leptin resistance. This study also reported that other hypothalamic nuclei; the 
MnPO and SON are susceptible to leptin resistance (17).  
Thus, HFD-induced obesity has been shown to affect leptin signalling in the brain. 
Therefore, in the current project, I will explore the neurons activated by leptin and 
their neurochemical contents in different brain nuclei, in animals fed a HFD compared 
to the lean condition to determine the effect of high fat diet.  
1.10.2. Resistin and HFD 
It has been shown that circulating resistin levels are elevated in DIO mice, and it is a 
known mediator of insulin resistance, as reported by Steppan et al. (21) and others 
(361, 362). Elevated levels of resistin are also observed in humans (363, 364), 
although whether resistin is associated with insulin resistance in humans is still 
controversial.  
IP injections of resistin reduced insulin sensitivity in the liver and adipocytes (21, 
362). Furthermore, neutralization of resistin in DIO mice resulted in reduced blood 
glucose levels and improved insulin sensitivity, indicating resistin can be involved in 
insulin resistance (21). However, ICV resistin in HFD rats was shown to improve 
insulin sensitivity in the liver (365), Thus, the association of resistin with insulin 
resistance may be dependent on in the peripheral or CNS site of actions of resistin.  
Furthermore, ICV resistin in rats fed a HFD elicited an initial short-term, but not 
long-term, reduction in food intake with no changes in body weight (365), which was 
also observed in normal rats (178). This suggests that HFD feeding not influence the 
metabolic effects of central resistin. 
Apart from the studies discussed above, the effects of central resistin has not been 
extensively studied, in obesity and animals fed a HFD. Thus, additional studies are 
required to understand the mechanisms by which resistin exerts its effects and 
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evaluate its role in overweight / obesity. The current project will investigate the 
influence of resistin on central neuronal pathways and examine the neurochemical 
content of neurons activated in different brain nuclei of animals fed a HFD compared 
to a normal diet.  
1.10.3. Insulin and HFD 
Obesity and diabetes are characterised by insulin resistance as well as increases in 
food intake, body weight and plasma glucose. In DIO or HFD-fed rats, resistance to 
the hypophagic effects of ICV insulin have been observed (338, 366). Additionally, 
insulin transport from the periphery to the CNS was impaired in DIO rats (338), 
genetically obese rats (367), and in HFD-fed dogs (368). 
Despite insulin resistance, evidence suggests that insulin plays a role in the 
cardiovascular disturbances associated with high fat feeding. In a study in HFD fed 
rabbits, the associated hypertension induced by the diet was attenuated by central 
administration of an insulin antagonist (369). However, this was independent of the 
elevated RSNA which was not affected (369). This study strongly suggested that 
insulin is involved in the hypertension in HFD-induced obesity, albeit to a smaller 
degree than has been observed for leptin (369). 
In this project, I will investigate the central neuronal pathways activated by insulin 
and interactions with leptin and resistin. I will also explore the neurochemical content 
of neurons activated in different brain nuclei by these hormones in HFD and compare 
them to lean controls. 
1.11. High Fat Diet (HFD) induces inflammation  
It is known that animals fed a HFD can induce inflammation in the peripheral and 
central nervous systems. Obesity can be considered a chronic low-grade inflammatory 
state (370-372). This is evidenced by studies where high fat diets fed to rodents, 
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induced inflammatory reactions in peripheral tissues like the liver and adipose (373-
375), and in the brain (370-372). In obese humans, peripheral inflammation is also 
observed (376, 377). 
1.11.1. Inflammation 
Inflammation is a pathological condition that occurs in response to injury or damage 
of body tissue and is the body’s defence mechanism against foreign organisms and 
harmful substances. Many immune cells are found throughout the body; such as 
macrophages in peripheral tissue and microglia in the brain which are known to have 
similar actions and are structurally related. Macrophages are phagocytic immune 
cells, derived from precursors that are produced by the bone marrow. They are found 
in peripheral tissues, and respond to various stimuli including invading pathogens 
(378). Microglia have a neuroprotective role and are the first-line defence against 
foreign pathogens in the brain, and are also activated by damage to the brain (379). 
These immune cells are responsible for releasing the pro-inflammatory cytokines such 
as tumor necrosis factor-alpha (TNF-α), interleukin 1 beta (IL-1β) and interleukin 6 
(IL-6) in response to tissue injury (380).  
1.11.2.  Brain inflammation 
Acute and chronic brain inflammation are commonly characterised by local oedema, 
tissue breakdown, migration of immune cells from the periphery to the CNS, and the 
occasional signs of repair observable after damage (381). Inflammation in the brain is 
known to be associated with several CNS diseases, such as multiple sclerosis, 
Alzheimer's disease, Parkinson’s disease and also stroke (382-384). Microglial cells 
in the brain play an important role in brain inflammation as they release a range of 
pro-inflammatory cytokines as part of an immune response (379, 385, 386). However, 
excessive production of TNF-α, IL-1β and IL-6 can lead to neurotoxicity and worsen 
the condition (387, 388).  
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1.11.3.  Microglia  
Microglia are the primary immunocompetent defence cells in the CNS providing 
protection from pathogens. They undergo functional and structural changes in order to 
respond effectively to aggravation by pathological conditions (382, 386). Their roles 
are synonymous with those of macrophages in peripheral tissues (383). For instance, 
they act as phagocytes and antigen-presenting cells and also produce 
immunoregulatory molecules (382, 385).  
Microglia form a network of cells with a monocyte/macrophage lineage. They have a 
small cell body, long slender processes that have secondary branches and lamellipodia 
(383). After activation, they alter their shape to an ovoid form and their processes 
retract (Figure 1.1) (389). In the brain, upon activation, microglia morph into 
phagocytic antigen-presenting cells that exhibit amoeboid movement (383). These 
non-activated and activated microglia can be detected in the brain using CD11b as a 
marker of these cells, an antibody directed against CD11b can be used to detect 
microglia in the brain. Only microglia express CD11b in healthy brain, however in a 
damaged brain, it may be difficult to distinguish between microglia and other immune 
cells that have migrated from the periphery (390).  
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Figure  1.1: Diagram of non-activated and activated microglia 
This diagram shows the shape and morphological changes of non-activated and 
activated microglia. Microglia with a small cell body and that are highly branched are 
defined as non-activated (ramified resting). Microglia with a larger cell body and 
lesser but thicker branches are determined to be activated. This diagram was modified 
from (391). 
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The importance of microglia in obesity has also been evaluated recently. It has been 
shown that HFD feeding increased microglia proliferation in the hypothalamus, 
specifically the ARC, and inhibition of the proliferation of microglia resulted in 
reduced food consumption, decreased body weight gain and fat mass whilst peripheral 
and central inflammation was also attenuated (392).  
Microglia are important for the production, and are also targets, of cytokines such as 
TNF-α, IL-1β and IL-6. In addition, microglia can produce neurotoxic substances 
such as proteases, reactive oxygen species and nitric oxide (NO) which can also 
contribute to the development of brain injury and neurodegenerative diseases (389, 
393). 
Microglia may also contribute to cardiovascular disease. The cells play a key role in 
cerebral ischemia via the release and action of TNF-α, which exhibits a 
neuroprotective effect, and assists in neuronal survival following ischemia (394). 
There is also marked microglial activation in the PVN region in the brain following 
myocardial infarction, contributing to the local production of pro-inflammatory 
cytokines which in turn induce local inflammatory responses (395, 396). Since the 
PVN is known to regulate RSNA and we know that RSNA is abnormally elevated in 
chronic heart failure (396); it has been suggested that microglia in the PVN plays a 
role in increasing RSNA in chronic heart failure through the production and release of  
cytokines like TNF-α and IL-1β, which elicit an increase in SNA when locally 
injected (397).  
1.11.4.  The role of inflammatory markers TNF-α, IL1β and IL6 
Tumor necrosis factor-alpha (TNF-α) is a pro-inflammatory cytokine (398). TNF-α is 
produced by macrophages in peripheral tissue and by microglia and some neurons in 
the brain (399). It is produced in response to infections and tissue damage (394). Two 
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receptors that bind TNF-α have been identified; TNF receptor 1 (TNF-R1) and 
receptor 2 (TNF-R2). TNF-R1 is located on the majority of cells and is said to be the 
main site of action of TNF-α (400). TNF-R2 is located on the lymphoid cells (400). 
TNF-α, through the activation of its receptors, induces systemic and central 
inflammation by influencing responses of immune cells. The subsequent effects of 
TNF-α in the CNS can involve regulating learning and memory, synaptic plasticity, 
sleep, and feeding. TNF-α is also associated with various diseases in which 
inflammatory processes occur such as Alzheimer’s disease, Parkinson’s disease, 
multiple sclerosis and cerebral ischemia (401). A characteristic of these diseases is 
elevated levels of TNF-α (401). Additionally, TNF-α is able to stimulate its own 
release and the release and expression of other cytokines like IL-1β and IL-6 (398, 
401-403).   
Interleukin 1 beta (IL-1β) is a member of interleukin 1 family of pro-inflammatory 
cytokines. IL-1β mediates inflammation in response to traumatic stimuli, such as 
brain injury (404). Similar to TNF-α and other cytokines, IL-1β is synthesised by 
immune cells such as macrophages in peripheral tissue and by microglia and some 
neurons in the brain (405). IL-1β, much like TNF-α, can induce its own synthesis and 
production of other cytokines including IL-6 (387, 406). IL-1β plays an important role 
in systemic and central inflammation by stimulating IL-1 receptors (404, 405, 407). 
With respect to metabolic function, IL-1β has an anorexic effect in rats (408).  
In regards to the cardiovascular system, a study have shown that IL-1β is upregulated 
in heart failure (409). Its role in heart failure may include its ability to inhibit β-
adrenergic stimulation of cardiac muscle contraction (410), and thus impairing cardiac 
function. IL-1β may also be implicated in brain ischemia (411), and other 
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inflammatory diseases such as rheumatoid arthritis since a characteristic of these 
conditions is increased levels of this cytokine (412).  
Interleukin 6 (IL-6) is a common cytokine that is pro-inflammatory and anti-
inflammatory. It is produced by immune cells in the periphery, namely T cells and 
macrophages (406). In the brain, it is produced by microglia and astrocytes; and 
induces neurotrophic, neuroprotective and regenerative effects (382, 413). IL-6 is also 
produced by skeletal muscle where it has anti-inflammatory actions (414). IL-6 
exhibits its effects via a complex signalling system which mainly involves the 
membrane-bound IL-6 receptors and gp130 (415, 416). Unlike other cytokines which 
promote cytokine synthesis and release, IL-6 appears to inhibit the synthesis of TNF-
α (417). 
IL-6 is also implicated in inflammatory diseases such as rheumatoid arthritis (418), in 
addition to several autoimmune and cardiovascular diseases (419), similar to IL-1β. 
Such cardiovascular diseases include coronary heart disease in which the risk is 
elevated with high concentrations of plasma IL-6 (420). Also, patients with congestive 
heart failure showed increased levels of IL-6 as well as soluble IL-6 receptors, 
suggesting that IL-6 is involved in this condition (421). IL-6 has also been reported to 
play a role in ischemia in the brain which showed induction of IL-6 mRNA 
expression following ischemic insult (402). 
1.11.5. Cytokines in HFD 
In HFD-fed rats, the expression of TNF-α, IL-1β, and IL-6 mRNA in the brain was 
significantly increased, especially in the hypothalamus and the lamina terminalis, 
compared to rats fed a normal diet (422). In the ARC of the hypothalamus HFD 
feeding, elicited a significant increase in the number of appetite-regulating AgRP and 
NPY neurons coexpressing TNF-α (423). Additionally, in the PVN and lamina 
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terminalis, the levels of TNF-α, IL-1β, and IL-6 were all increased with HFD feeding 
(424). TNF-α is known to be involved in modulating feeding behaviour (401), thus it 
is suggested that brain inflammation in the hypothalamic nuclei such as the ARC and 
PVN which are also known to be involved in regulating metabolic function, can 
ultimately lead to obesity by influencing feeding behaviour.  
1.11.6. Adipokines and inflammation 
Evidence strongly suggests that leptin is linked to various inflammatory and 
cardiovascular diseases. In particular, leptin stimulates proliferation and migration of 
endothelial cells (425), in addition to platelet aggregation (426), and it stimulates 
atherogenesis (427). Macrophages are known to be involved in atherosclerosis (428-
430), they accumulate in atherosclerotic lesions (431), and secrete cytokines that are 
implicated in this condition (432). Leptin receptors are expressed on macrophages 
(433) and their activation induces the production of cytokines and enhances 
phagocytosis ability of macrophages (434). These studies suggest that these actions of 
leptin are likely to contribute to atherosclerosis. 
Leptin is believed to play an important role in central immune responses through the 
stimulation of brain microglia, via leptin receptors (435, 436), to produce and release 
TNF-α, IL-1β, and IL-6 (436-438). These findings suggest that leptin can modulate 
microglial and immune function. However, the actions of leptin may not be 
generalised since central leptin infusion significantly increased TNF-α, IL-1β, and IL-
6 mRNA expression in the lamina terminalis and the PVN (424),but reduced TNF-α 
expression in the ARC and VMH regions of the hypothalamus (439). 
Resistin may also be pro-inflammatory. It contributes to atherosclerotic inflammatory 
processes by upregulating vascular cell adhesion molecule 1 and monocyte 
chemoattractant protein-1 which are key modulators in the formation of 
53 
 
   
atherosclerosis (440). Resistin also seems to be implicated in psoriasis, another 
inflammatory condition. Psoriasis patients display increased plasma levels of resistin 
(441).  
Resistin has been found to be expressed in macrophages (442) and stimulates the 
production and release of several pro-inflammatory cytokines such as TNF-α and IL-6 
from macrophages and this appears to be mediated by TLR4 (343). It has also been 
reported that TNF-α and IL-6, can induce increased resistin plasma levels in humans 
(443), further highlighting a link between resistin and peripheral inflammation. 
Little is known about the role of resistin in central inflammation. However, microglia 
contain toll-like receptors (TLR) which are implicated in several CNS inflammatory 
conditions (444). Since resistin activates TLR4 on macrophages, contributing to 
inflammation (343), it is possible that resistin can also activate TLRs on microglia, 
although this remains to be investigated. Therefore, in this study, the effects of 
resistin on microglia and the changes in cytokine expression in the brain will be 
investigated to determine whether resistin can influence inflammation in the brain. 
In summary, there is little information on the distribution of neurons activated by 
centrally administered resistin and there is a huge gap in our understanding of the 
types of neurons that are activated by resistin (ie what is their neurochemical 
content?). Furthermore, the effects of high fat feeding on the distribution and 
neurochemical content of neurons activated by resistin have not been investigated.  
In contrast, more is known about the central pathways activated by leptin and to some 
extent, insulin. However, the effects of combined administration of these with resistin 
have not been studied. Since these three hormones are elevated in conditions in which 
adiposity is increased, there is a need to investigate the effects of the combined 
administration of the hormones.  
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We hypothesise that resistin, in addition to insulin which is also implicated in central 
regulation of SNA, will activate the same neurons that are activated by leptin in some 
brain nuclei but differ in others, and this may reflect functional differences. Therefore, 
this project will investigate the neurochemical content of neurons that are activated by 
resistin or insulin in comparison with leptin. The areas of the brain that are activated 
by these hormones may include the hypothalamus, midbrain, and medulla. Also, it has 
been known that leptin and resistin are implicated in peripheral inflammation and 
since leptin is involved in brain inflammation, resistin may also induce inflammation 
in the brain. 
1.12. General aims: 
 
Thus, the general aims of the project are: (A) to investigate the distribution and 
neurochemical content of neurons that are activated by resistin or insulin compared 
with leptin and to determine the influence of diet.  
(B) To explore whether resistin induces inflammation in the brain and compare it with 
leptin.  
1.13. Specific aims: 
(Ai) To investigate the effects of leptin, resistin, and insulin alone or in combination 
on the distribution of activated neurons. 
(Aii) To determine whether catecholaminergic, serotoninergic or orexinergic neurons 
are activated by resistin, insulin, and leptin  
(Aiii) To explore the effect of high fat diet on the distribution of activated neurons, 
and on catecholaminergic, serotoninergic and orexinergic neurons activated by 
resistin, leptin, and insulin alone and combined.  
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(B) To investigate the effects of leptin and resistin on microglia and expression of the 
cytokines TNFα, IL1-β, IL-6 in the brain. 
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Chapter 2: General methods 
2.1. Animals  
Male Sprague-Dawley rats were obtained from the animal resources centre (ARC; 
W.A, Australia). During the experimental protocols, they were caged in pairs at the 
Animal Facility (located at RMIT University, Victoria, Australia). The rats were 
divided into two groups. One group was fed a high fat diet (22% fat) and the other 
group was fed normal diet. All rats were fed ad libitum in a 12 h -12 h light-dark 
cycle. The amount of food consumed and body weights of the rats were each 
measured weekly for 8-10 weeks. 
All the experimental protocols were performed in accordance with the Prevention of 
Cruelty to Animals Act 1986 (Australia). The procedures conform to the “Guiding 
Principles for Research Involving Animals and Human Beings” and the guidelines set 
out by the Australian Code of Practice for the Care and Use of Animals for Scientific 
Purposes, 2013 (National Health and Medical Research Council of Australia) and 
were approved by the RMIT University Animal Ethics Committee. 
2.2. Body fat measurement 
Whole-body fat composition was measured with magnetic resonance imaging (MRI) 
using an EchoMRI™ machine (EchoMRI LLC; Texas, USA). A pre-scan test was run 
on the day of the test to ensure proper operation of the scanner. Each rat was placed in 
a clear plastic tubular holder which was inserted into the EchoMRI™ machine. The 
data for the fat content was adjusted for each rat’s body weight, yielding the body fat 
percentage for each rat. 
2.3. Cannulation of femoral artery and vein 
Anaesthesia was induced by placing each rat into a clear plastic chamber and using 
5% isoflurane with O2 at a flow rate of 0.8 L/min. After 5 minutes, and once the rats 
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were unconscious, they were removed from the chamber and placed on a prepared 
heat pad, and connected to a nose cone with isoflurane reduced to 2% with O2 at a 
flow rate of 0.4 L/min. 
Next, the skin of the groin area around the right leg was shaved, swabbed with 70% 
alcohol, and a 2-cm incision was made. The femoral vein and artery were separated 
from the surrounding tissue and two pieces of fine thread (silk 3/0, Dynek; SA, 
Australia), 10-15 cm in length, were placed under the vein. The proximal thread was 
lifted to prevent blood flow, and then the distally placed thread was tied. Finally, a 
catheter was inserted in the vein with the aid of sharp needle (27 Gauge) bent at the 
tip. Then, the proximal thread was released to allow the catheter to be advanced into 
the vein. Both threads were tied around the catheter to secure it in place. Similarly, 
the femoral artery was cannulated to record blood pressure and heart rate. The skin 
incision was closed using stitches (silk 0-USP, Dynek; SA, Australia) at the end of the 
cannulation procedures.  
To maintain anaesthesia, the anaesthetic was changed to a 25% solution of urethane 
which was administered intravenously (1.4-1.6 g/kg initially, followed by additional 
doses of 0.05 ml, as required). The depth of anaesthesia was maintained to ensure the 
lack of reflex responses to the paw pinch test and corneal reflex.  
2.4. Administration of adipokines and insulin via 
intracerebroventricular (ICV) microinjection  
After shaving, the head of each rat was placed in a Stoelting stereotaxic frame 
(Stoelting; Illinois, USA). A midline incision was used to expose the skull. The 
bregma and lambda were then positioned on the same horizontal level. A tiny hole of 
2.0 mm diameter, located 1.4 mm lateral from the midline and 0.7 mm caudal to the 
bregma, was drilled through the skull to expose the surface of the brain. A fine-glass 
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micropipette (50-70 μm tip diameter) (Clay Adams; New Jersey, USA) was inserted 
into the lateral brain ventricle (3.9 mm ventral to the surface of the dura) to administer 
the adipokines, leptin in saline (7 µg/5µl), resistin in saline (7 µg/5µl), resistin 
combined with leptin or saline (5 µl) on its own. Insulin in saline (500 mU/5µl) was 
administered alone, or in combination with leptin or resistin in the appropriate studies. 
The doses were chosen based upon previous work (177) and preliminary dose- 
response work performed in the laboratory. Following this, the renal nerves were then 
exposed, using procedures described by Habeeballah et al. (235), to allow recording 
of renal sympathetic nerve activity (RSNA). Data from those recordings are not part 
of the present studies. 
2.5. Perfusion and tissue collection  
Three hours after the ICV microinjection, rats were deeply anaesthetised by an 
intravenous dose of sodium pentobarbitone (325 mg) (Virbac; NSW, Australia). Each 
rat was placed on its back and a midline incision was made through the abdominal 
wall. Then, the diaphragm was cut from the chest wall and the heart was visualised.  
A needle was inserted through the left ventricle of the heart into the ascending aorta, 
and secured there by using a clamp. A cut was made in the right atrium of the heart to 
allow draining of blood. The perfusion was begun by pumping 200–250 ml of 0.1 M 
phosphate buffered saline (PBS) into the aorta with pressures between 80-100 mm 
Hg. Then, 200-250 ml of 4% paraformaldehyde in 0.1 M PBS was infused to fix the 
brain. 
After perfusion, a pair of scissors was used to remove the head from the body. 
Subsequently, the remaining muscle was trimmed off the neck to expose the base of 
the occipital skull. Rongeurs were used to remove the skull bone. All nerves and 
fibres around the brain were cut and the brain was gently removed from the skull 
cavity. The brain was placed in a 4% paraformaldehyde solution for 3.5-4 hours at 
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4°C. The brain was then stored in phosphate buffer containing 20% sucrose at 4°C 
until required. Lastly, the white adipose tissue (epididymal fat) was removed around 
the testicles and weighed.   
2.6. Sectioning of brains 
Each brain was separated into two parts, one containing the medulla, and the other 
consisting of the hypothalamus and midbrain, including the periaqueductal grey 
(PAG). A Leica CM 1900 cryostat (Leica Microsystems; Nussloch, Germany) was 
used to cut serial coronal sections (40 µm thick). All sections were stored in a 
cryoprotectant solution at -4°C (short term storage) or -20°C (long term storage) until 
required for immunohistochemical processing.  
2.7. Immunohistochemistry  
2.7.1. Immunohistochemistry for Fos  
Immunohistochemistry for Fos was performed using either sections mounted on 
gelatin-coated slides or on free floating sections (see next section). In the case of 
sections mounted onto the gelatin-coated slides, they were placed in an oven at 60°C 
for 30 minutes. Immunohistochemistry was performed to detect Fos protein, the 
marker of neuronal activation using the following procedure and all of the following 
treatments were dissolved in 0.1 M PBS. All the sections were washed three times 
with 0.1 M PBS between all steps. Sections were first covered with 0.5% hydrogen 
peroxide (H2O2) (Sigma-Aldrich; NSW, Australia) for 15 minutes to destroy 
endogenous peroxidase activity. Following that, sections were covered with 0.5% 
Triton X (Sigma-Aldrich; NSW, Australia) for 30 minutes to enable antibody 
penetration, then incubated with 10% normal horse serum (Sigma-Aldrich; NSW, 
Australia) for 60 minutes to block non-specific binding. Sections were incubated 
overnight with anti Fos primary antibody raised in rabbit (1:400) (Santa Cruz 
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Biotechnology; California, USA). The following day, sections were incubated with 
biotinylated anti-rabbit secondary antibody raised in goat (Sigma-Aldrich; NSW, 
Australia) (1:400) for 2 hours and then covered with ExtrAvidin (1:400) (Sigma-
Aldrich; Missouri, USA) for 1 hour. Sections were then incubated for 10 minutes in 
0.05% 3,3′-diaminobenzidine hydrochloride (Sigma-Aldrich; NSW, Australia) in 
PBS. 5 µl of 30% H2O2 (Sigma-Aldrich; NSW, Australia) was added and the reaction 
allowed to proceed for 15 minutes.The reaction was stopped by washing the sections 
in 0.1 M PBS. Finally, sections were allowed to dry overnight, dehydrated in a series 
of ethanol solutions of increasing concentration (50%, 70%, 90%, 100% (w/v), 
followed by dipping the slides into xylene (Sigma-Aldrich; NSW, Australia). Cover 
slips were fixed onto the slides using DePex (Thermo Fisher Scientific; VIC, 
Australia) as a mounting medium.  
2.7.2. Dual-label immunohistochemistry  
Double-staining immunohistochemistry was performed to detect the protein Fos, and 
neurochemical content, and was performed using free-floating sections. One in five 
serial sections was taken and placed in a 24-well plate. All solutions were prepared in 
0.1 M PBS and all the sections were washed three times with 0.1 M PBS between all 
steps. The sections were placed into a solution of 0.5% H2O2 (Sigma-Aldrich; NSW, 
Australia) for 15 minutes to destroy endogenous peroxidase activity. Following that, 
sections were placed into a solution of 0.5% Triton X (Sigma-Aldrich; NSW, 
Australia) to enable antibody penetration and 10% normal horse serum (Sigma-
Aldrich; NSW, Australia) for 60 minutes. Then, sections were incubated overnight 
with anti Fos first primary antibody raised in rabbit (1:5000) (Santa Cruz 
Biotechnology; California, USA). The following day, sections were incubated with 
biotinylated anti-rabbit secondary antibody raised in goat (1:400) (Sigma-Aldrich; 
NSW, Australia) for 90 minutes. These sections were then incubated with ExtrAvidin 
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(1:400) (Sigma-Aldrich; Missouri, USA) for 45 minutes. Sections were then 
incubated for 10 minutes in 0.1 M PBS containing 0.01% 3,3′- diaminobenzidine 
hydrochloride (DAB; Sigma-Aldrich; NSW, Australia), 0.02% NH4NiSO3 and 0.02% 
CoCl. The reaction was started by adding 5 µl of 30% H2O2 and the reaction was 
stopped after 15 minutes with washes in 0.1 M PBS. Subsequently, the sections were 
incubated with a primary antibody to tyrosine hydroxylase (TH) raised in rabbit 
(1:4000) (Santa Cruz Biotechnology; California, USA) or tryptophan hydroxylase 
raised in mouse (1:2000) (Sigma-Aldrich; NSW, Australia) or orexin raised in rabbit 
(1:1000) (Sapphire Bioscience; NSW, Australia). The following day, sections were 
incubated with the appropriate biotinylated secondary antibody, either anti-rabbit 
raised in horse (1:400) (Abacus ALS; QLD, Australia) or anti-mouse raised in horse 
(1:400) (Vector Laboratories; California, USA) for 90 minutes, and then incubated 
with ExtrAvidin (1:400) (Sigma-Aldrich; Missouri, USA) for 45 minutes. The 
sections were then incubated for 10 minutes in 0.05% 3,3′-diaminobenzidine 
hydrochloride (DAB; Sigma-Aldrich; NSW, Australia) in 0.1 M PBS. The reaction 
was started by adding 5 µl of 30% H2O2 (Sigma-Aldrich; NSW, Australia), and 15 
minutes later, the reaction was stopped by washing in 0.1 M PBS. The sections were 
then mounted onto gelatine coated glass slides. Finally, the sections were allowed to 
dry overnight, dehydrated in a series of ethanol solutions of increasing concentration 
(50%, 70%, 90%, 100% (w/v)), followed by dipping the slides into xylene (Sigma-
Aldrich; NSW, Australia). On the following day, the glass slides were cover-slipped 
with DePex mounting medium (Thermo Fisher Scientific; VIC, Australia).  
2.7.3. Immunohistochemistry for CD11b (clone OX42) 
To identify microglia, immunohistochemistry to detect the integrin protein CD11b 
was performed on free floating sections. One in five serial sections were placed in a 
24-well plate. All brain sections were washed three times in 0.1 M PBS (each wash 
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for 5 min), then the endogenous peroxidase activity was destroyed by incubating with 
0.5% H2O2 (Sigma-Aldrich; NSW, Australia) for 15 minutes at room temperature. 
The sections were incubated with 10% normal horse serum (Sigma-Aldrich; NSW, 
Australia) and 0.5% Triton X (Sigma-Aldrich; NSW, Australia) for 1 hour at room 
temperature to prevent nonspecific binding and allow antibody penetration 
respectively. Sections were washed three times in 0.1 M PBS between all steps. A 
mouse monoclonal primary antibody (CD11b, OX42 clone 1:4000 in 2% normal 
horse serum and 0.3% Triton X-100 in 0.1 M PBS) (Chemicon; Temecula, USA) was 
applied and the sections were incubated for 36-48 hours at 4°C. Sections were then 
washed three times with 0.1 M PBS and incubated with a biotinylated anti-mouse 
secondary antibody raised in horse (1:400) (Vector Laboratories; California, USA) in 
2% normal horse serum in PBS for 90 mins at room temperature. Next, the sections 
were washed three times with PBS and incubated with ExtrAvidin (1:400 in 2% 
normal horse serum in PBS) (Sigma-Aldrich; Missouri, US) for 45 mins at room 
temperature. The sections were then washed three times with PBS and were placed in 
0.05% 3,3′-diaminobenzidine hydrochloride (DAB; Sigma-Aldrich; NSW, Australia) 
in 0.1 M PBS for 10 minutes. Then, 5 µl of 30% H2O2 was added to start the reaction 
for 15 minutes at room temperature. The reaction was then stopped by three washes in 
0.1 M PBS and the sections were mounted onto glass slides. The slides were left 
overnight at room temperature to dry and then dehydrated in a series of ethanol 
solutions of increasing concentration (50%, 70%, 90%, and 100% (w/v)) followed by 
dipping into xylene (Sigma-Aldrich; NSW, Australia). Cover slips were then applied 
with DePex mounting medium (Thermo Fisher Scientific; VIC, Australia).  
2.8. Brain areas examined with immunohistochemistry 
The areas of the brain which were examined in detail for this thesis are shown in 
Figures 2.1-2.8. These brain areas include organum vasculosum of the lamina 
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terminalis (OVLT) (Figure 2.1), median preoptic nucleus (MnPO) (Figure 2.2), 
supraoptic nucleus (SON) (Figure 2.3), paraventricular nucleus (PVN) (Figure 2.4), 
arcuate nucleus (ARC) (Figure 2.5), dorsomedial hypothalamic nucleus (DMH) 
(Figure 2.6), lateral hypothalamic area (LHA) (Figure 2.6), periaqueductal gray 
(PAG) (Figure 2.7), dorsal raphe (DR) (Figure 2.7), rostral ventromedial medulla 
(RVMM) (Figure 2.8), nucleus tractus solitarius (NTS) (Figure 2.8), raphe pallidus 
(RPA) (Figure 2.8), and rostral ventrolateral medulla (RVLM) (Figure 2.8). 
The brain areas were examined using an Olympus BX60 (Olympus Inc; Pennsylvania, 
USA) and neuronal activation was detected using Fos protein as a marker; 
neurochemical content included tyrosine hydroxylase (TH; for catecholamines), 
tryptophan hydroxylase (for serotonin), and orexin; and microglia were identified by 
the presence of CD11b (clone OX42). 
2.9. Immunohistochemistry data collection and analysis  
The Fos-positive cell nuclei, neurochemical-positive cells and activated 
neurochemical-positive neurons; characterised with the presence of Fos protein within 
the cell nuclei, were detected by using a normal light microscope. 
CD11b-positive microglia was characterised in accordance to the methods described 
by Rana et al. (445). Non-activated microglia were identified by their small soma and 
exhibited highly branched, long, and thin processes. Activated microglia were defined 
by two main criteria; (i) stronger immunohistochemical staining for the marker 
CD11b (clone OX42) and (ii) the presence of a clearly enlarged soma and marked 
changes in the appearance of microglia with thicker and shorter branched processes. 
Only microglia with these changes were defined as activated. 
The Fos-positive cell nuclei, neurochemical content and microglia were counted in 
two sections of the organum vasculosum of the lamina terminalis (OVLT), median 
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preoptic nucleus (MnPO), supraoptic nucleus (SON), arcuate nucleus (ARC), 
dorsomedial hypothalamic nucleus (DMH) and rostral ventromedial medulla 
(RVMM); in four sections of the paraventricular nucleus (PVN), lateral hypothalamic 
area (LHA), nucleus tractus solitarius (NTS), raphe pallidus (RPA) and rostral 
ventrolateral medulla (RVLM); and in up to ten sections of the periaqueductal gray 
(PAG) and dorsal raphe (DR). Counting was performed unilaterally in each brain area 
except those located in the midline (OVLT, MnPO, DR, and RPA).  
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Figure  2.1: Diagram of the organum vasculosum of the lamina terminalis (OVLT) of 
the rat brain 
This diagram shows the approximate region of laminae terminalis ( OVLT) in which 
fos-positive cell nuclei and OX42-labelled microglia were counted. The 
photomicrograph is an example of a section counted. The approximate rostrocaudal 
level relative to bregma is given in mm. Figure is modified from Paxinos and Watson 
(446). 
 
Figure  2.2: Diagram of the median preoptic nucleus (MnPO) of the rat brain 
This diagram shows the approximate region of the median preoptic nucleus (MnPO) 
in which Fos-positive cell nuclei and OX42-labelled microglia were counted. The 
photomicrograph is an example of a section counted. The approximate rostrocaudal 
level relative to bregma is given in mm. Figure is modified from Paxinos and Watson 
(446). Abbreviations: aca, anterior commissure. 
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Figure  2.3: Diagram of the supraoptic nucleus (SON) of the rat brain 
This diagram shows the approximate region of the supraoptic nucleus (SON) in which 
Fos-positive cell nuclei and OX42-labelled microglia were counted. The 
photomicrograph is an example of a section counted. The approximate rostrocaudal 
level relative to bregma is given in mm. Figure is modified from Paxinos and Watson 
(446). Abbreviations: opt, optic tract.  
 
Figure  2.4: Diagram of the paraventricular nucleus (PVN) of the rat brain  
This diagram shows the approximate region of the paraventricular nucleus (PVN) in 
which Fos-positive cell nuclei, OX42-labelled microglia, and catecholaminergic 
neurons were counted. The photomicrograph is an example of a section counted. The 
approximate rostrocaudal level relative to bregma is given in mm. Figure is modified 
from Paxinos and Watson (446). Abbreviations: 3v, thrid ventricle. 
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Figure  2.5: Diagram of the arcuate nucleus (ARC) of the rat brain 
This diagram shows the approximate region of the arcuate nucleus (ARC) in which 
Fos-positive cell nuclei and OX42-labelled microglia were counted. The 
photomicrograph is an example of a section counted. The approximate rostrocaudal 
level relative to bregma is given in mm. Figure is modified from Paxinos and Watson 
(446). 
 
 
Figure  2.6: Diagram of the dorsomedial hypothalamic nucleus (DMH) and lateral 
hypothalamic area (LHA) of the rat brain 
This diagram shows the approximate region of the dorsomedial hypothalamic nucleus 
(DMH) and lateral hypothalamic area (LHA) in which Fos-positive cell nuclei and 
OX42-labelled microglia were counted. Orexinergic neurons were counted in the 
LHA. The photomicrograph is an example of a section counted. The approximate 
rostrocaudal level relative to bregma is given in mm. Figure is modified from Paxinos 
and Watson (446). Abbreviations: Fx, Fornix. 
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Figure  2.7: Diagram of the periaqueductal gray (PAG) and dorsal raphe (DR) of the 
rat brain 
This diagram shows the approximate region of the periaqueductal gray (PAG) and 
dorsal raphe (DR) in which Fos-positive cell nuclei and OX42-labelled microglia 
were counted. Catecholaminergic and serotonergic neurons were also counted in these 
regions. The photomicrograph is an example of a section counted. The approximate 
rostrocaudal level relative to bregma is given in mm. Figure is modified from Paxinos 
and Watson (446). 
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Figure  2.8: Diagram of the rostral ventrolateral medulla (RVLM), nucleus tractus 
solitarius (NTS), the medullary midline area raphe pallidus nucleus (RPA) and rostral 
ventromedial medulla (RVMM) of the rat brain 
This diagram shows the approximate region of the rostral ventrolateral medulla 
(RVLM), nucleus tractus solitarius (NTS), the medullary midline area raphe pallidus 
nucleus (RPA) and rostral ventromedial medulla (RVMM) in which Fos-positive cell 
nuclei and OX42 were counted. Catecholaminergic neurons were counted in the NTS 
and RVLM. Serotonergic neurons were counted in the RPA and RVMM. The 
photomicrograph is an example of a section counted. The approximate rostrocaudal 
level relative to bregma is given in mm. The rectangular box represents the area in the 
RVLM for counting purposes. Figure is modified from Paxinos and Watson (446). 
Abbreviations: AP, area postrema; ION, inferior olivary nucleus; NA, nucleus 
ambiguous; Pyr, pyramidal tract. 
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Images were obtained for counting purposes (Fos-positive cell nuclei and OX42-
labelled microglia) using a digital camera (Sensi Cam, PCO CCD Imaging; Kelheim, 
Germany) attached to an Olympus BX60 microscope (Olympus Inc; Pennsylvania, 
USA) at ×200 magnification. Counting was performed using ImageJ software 
(National Institutes of Health; Maryland, USA). However, counting of neurochemical 
content was performed with light microscopy (Olympus Inc; Pennsylvania, USA) at 
×200 magnification. 
2.10. Polymerase chain reaction (PCR) protocol 
Rats received intracerebroventricular (ICV) injection of saline, leptin and resistin 
alone or in combination. After three hours, the rats were culled, using an intravenous 
dose of sodium pentobarbitone (325 mg) (Virbac; NSW, Australia), and the brains 
removed, washed with saline and placed in the brain block for sectioning. Each brain 
was separated into several blocks (hypothalamus, ventrolateral medulla, dorsomedial 
medulla and midbrain) with each tissue block divided into 2 halves; one half was used 
to detect the gene expression of cytokines by PCR. The brain tissue blocks were 
placed into 2 mL Eppendorf tubes (Axygen; Montreal, Canada) with a tiny hole 
punctured into the lid. Subsequently, the Eppendorf tubes were placed in liquid 
nitrogen. Finally, the brain tissues were stored at -80°C.  
The samples were collected in liquid nitrogen from storage at -80°C and the weights 
were recorded. The samples were then mixed in Safe–Lock Eppendorf tubes 
(Eppendorf; New York, USA) with 1 mL of QIAzol Lysis (QIAGEN; VIC, Australia) 
and homogenised using a 5 mm bead (QIAGEN; VIC, Australia). Then, the upper 
phase was transferred, while avoiding the interphase, to a new Eppendorf tube 
(Axygen; Montreal, Canada). Then, one volume of 70% ethanol (equal to sample 
volume) was added and half of the sample volume was transferred into an RNeasy 
Mini Spin tube (QIAGEN; VIC, Australia). This was repeated with the remaining half 
71 
 
   
of the sample. Ribonucleic acid (RNA) was then extracted according to the 
manufacturer’s instructions. 
Following RNA extraction, The Nano Drop One (Thermo Fisher Scientific; 
Pennsylvania, USA) was used to measure the RNA concentration and assess purity of 
each sample. RNA (1 µg) was transcribed to complementary deoxyribonucleic acid 
(cDNA) using the high capacity cDNA reverse transcription kit (Applied Biosystems; 
California, USA).  
Quantitative PCR was performed using the Taqman Gene Expression Assays 
(Applied Biosystems; VIC, Australia) in a 384 well plate with a maximum volume of 
10 µl / well. A Quantstudio 7 (Applied Biosystems; California, USA) was used to 
assess gene expression of TNF-α (Gene code: Rn01525859_g1), IL-1β (Gene 
code: Rn00580432_m1), and IL-6 (Gene code: Rn01410330_m1) (Thermo Fisher 
Scientific; Massachusetts, USA) relative to the housekeeping gene, 18S (Gene 
code: Hs03003631_g1) (Thermo Fisher Scientific; Massachusetts, USA). The 
samples were run as triplicates (three wells for one sample, for each gene). Relative 
expression of target genes was determined using the comparative delta delta-cycle 
threshold (ΔΔCt) method by comparison with the housekeeping gene, 18S. 
2.11. Statistical analysis  
The statistical analysis was made using GraphPad Prism, version 7 (GraphPad 
Software Inc.; California, USA). Data was expressed as the mean ± SEM. The 
specific details of analyses are given in each chapter. In general, the average data was 
analysed between all groups within diet using One-way ANOVA. When an overall 
significance was detected then comparisons between individual groups was performed 
using the Holm-Sidak test for multiple comparisons. Comparisons between diets 
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within each treatment group were analysed using unpaired t-test. Multiple 
comparisons were taken into account by using the Holm-Sidak test. 
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Chapter 3: The distribution of activated neurons after 
central administration of resistin, leptin and the 
combination of resistin and leptin in the brain of rats fed a 
normal diet (ND).  
3.1. Introduction  
Leptin, a hormone that plays a crucial role in the regulation of food intake and energy 
homeostasis (9), is well known to act on the brain and to activate brain neurons. By 
contrast, little is known about the action of resistin on the brain. This study 
investigated the effects of resistin and a combination of resistin and leptin on specific 
brain areas, including the forebrain, midbrain and medulla oblongata.  
The areas investigated include: the organum vasculosum of the lamina terminalis 
(OVLT) and the median preoptic nucleus (MnPO) of the lamina terminalis which are 
involved in the neuronal circuitry that regulates cardiovascular functions and body 
fluid balance (447, 448). The hypothalamus, which influences a range of behaviours 
and autonomic functions, such as feeding, reproductive behaviour and cardiovascular 
function, and comprises a collection of nuclei: the paraventricular nuclei (PVN), the 
arcuate nuclei (ARC) and the supraoptic nuclei (SON) (48). The periaqueductal grey 
(PAG) and dorsal raphe nucleus (DR) which also play an important function due to 
connections with other brain nuclei that may mediate effects on cardiovascular 
function (109). Finally, the medulla contains several regions, such as the medullary 
midline raphe pallidus nuclei (RPA), nucleus tractus solitarius (NTS), rostral 
ventromedial medulla (RVMM), and the rostral ventrolateral medulla (RVLM), which 
have important roles in cardiovascular and endocrine functions (129).  
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All these brain areas were investigated for increased neuronal activation following 
central administration of the adipokines, resistin and leptin, alone or in combination, 
and this increased neuronal activation can be followed using the protein Fos as a 
marker. 
3.2. Methods 
In this study, rats fed a normal diet (ND) received intracerebroventricular (ICV) 
injection of saline (control; n = 5), leptin (7 μg; n = 5), resistin (7 μg; n = 4) and the 
combination where leptin was administered 15 min after resistin (n = 5) into the left 
lateral ventricle of the brain. Three hours later, the brains were perfused (as described 
in Chapter 2) and then immunohistochemistry was performed on one in five serial 
sections to detect Fos protein as a marker for neuronal activation. Fos-positive cell 
nuclei were visualized and counted unilaterally at ×200 magnification, except in the 
mid-line structures; raphe pallidus (RPA), dorsal raphe (DR), median preoptic nucleus 
(MnPO) and organum vasculosum of the lamina terminalis (OVLT). At least two 
sections for each brain area were used for analysis (as described in Chapter 2).  
The average number of Fos-positive cell nuclei per section was calculated for each 
brain nucleus in each animal, and comparisons between the groups were performed 
using one-way ANOVA. When an overall significant difference between groups was 
detected, comparisons were made between individual groups, using Holm–Sidak’s 
test for multiple comparisons. All results are expressed as means ± SEM. A value of P 
< 0.05 was considered to be statistically significant. PRISM software was used 
(GraphPad San Diego, California, USA). 
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3.3. Results 
3.3.1. Distribution of Fos-positive cell nuclei in the brain following ICV 
injection of resistin and leptin alone or in combined: 
The lamina terminalis 
In the OVLT and the MnPO, the numbers of Fos-positive cell nuclei following leptin 
or resistin alone were not significantly different compared with control (Figure 3.1). 
However, when both leptin and resistin were administered, there was an increase in 
Fos-positive cell nuclei compared with the control in the OVLT (P < 0.005) and 
MnPO (P < 0.05) (Figures 3.1 and 3.2). 
The hypothalamus 
In the ARC, leptin (P < 0.01) and resistin (P < 0.001) alone increased the number of 
Fos-positive cell nuclei compared to control (Figure 3.3). When both leptin and 
resistin were combined, the increase in Fos-positive cell nuclei was 3 fold greater than 
in the control (P < 0.0001) and compared with each drug alone (1.8 fold greater for 
resistin (P < 0.005), 1.4 fold greater for leptin (P < 0.0001)) (Figure 3.3). 
In the hypothalamic PVN, leptin and resistin alone induced an increase in the number 
of Fos-positive cell nuclei compared to the control (P < 0.005) (Figures 3.3 and 3.4). 
When both leptin and resistin were administered, the increase in the number of Fos-
positive cell nuclei was also greater than the control (P < 0.01) but did not differ from 
the result observed with leptin or resistin alone (Figures 3.3 and 3.4). Also, in the 
lateral hypothalamic area (LHA), leptin and resistin alone or in combination induced 
an increase in the number of Fos-positive cell nuclei compared with the control (P < 
0.05) (Figures 3.5). However, in the SON and dorsomedial hypothalamic nucleus 
(DMH), the number of Fos-positive cell nuclei after each treatment were not 
statistically significantly different between groups (Figures 3.3 and 3.5). 
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Figure  3.1: Effect of leptin and/or resistin on the distribution of Fos-positive cell 
nuclei in the lamina terminalis (OVLT and MnPO) of rats fed a normal diet (ND).  
The number of Fos-positive cell nuclei per section in the lamina terminalis (OVLT 
and MnPO) of rats fed a normal diet (ND) after intracerebroventricular (ICV) 
injection of saline (control, n = 6; 5 μl), leptin (n = 5; 7 μg in 5 μl), resistin (n = 4; 7 
μg in 5 μl), or leptin combined with resistin (n = 5). * P < 0.005 and P < 0.05 
compared with control for OVLT and MnPO respectively. Abbreviations: OVLT, 
organum vasculosum of the lamina terminalis; MnPO, median preoptic nucleus; Con, 
control; Lep, leptin; Res, resistin.  
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Figure  3.2: Photomicrographs of the effect of leptin and/or resistin on the distribution 
of Fos-positive cell nuclei in the organum vasculosum of the lamina terminalis 
(OVLT) of rats fed a normal diet (ND)  
The photomicrographs show Fos-positive cell nuclei in the organum vasculosum of 
the lamina terminalis (OVLT) of rats fed a normal diet (ND) following centrally 
administered saline (5 μl; control), leptin (7 μg), resistin (7 μg) and leptin combined 
with resistin. Scale bar represents 200 μm. Dashed lines outline the OVLT.  
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Figure  3.3: Effect of leptin and/or resistin on the distribution of Fos-positive cell 
nuclei in the hypothalamus (ARC, PVN and SON) of rats fed a normal diet (ND) 
The number of Fos-positive cell nuclei per section in the hypothalamus (ARC, PVN 
and SON) of rats fed a normal diet (ND) after intracerebroventricular (ICV) injection 
of saline (control, n = 6; 5 μl), leptin (n = 5; 7 μg in 5 μl), resistin (n = 4; 7 μg in 5 μl), 
or leptin combined with resistin (n = 5). For the PVN, the groups were as follows: 
saline (control, n = 4), leptin (n = 4) due to technical reasons. * 0.0001 < P < 0.005 
compared with control in the ARC; 0.005 < P < 0.01 compared with control in the 
PVN; + 0.0001 < P < 0.005 compared with leptin + resistin in the ARC. 
Abbreviations: ARC, arcuate nucleus; PVN, paraventricular nucleus; SON, supraoptic 
nucleus; Con, control; Lep, leptin; Res, resistin.  
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Figure  3.4: Photomicrographs of the effect of leptin and/or resistin on the distribution 
of Fos-positive cell nuclei in the paraventricular nucleus (PVN) of rats fed a normal 
diet (ND)  
The photomicrographs show Fos-positive cell nuclei in the paraventricular nucleus 
(PVN) of rats fed a normal diet (ND) following centrally administered saline (5 μl; 
control), leptin (7 μg), resistin (7 μg) and leptin combined with resistin. Scale bar 
represents 200 μm. Dashed lines outline the PVN. Abbreviations: Fx, fornix. 
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Figure  3.5: Effect of leptin and/or resistin on the distribution of Fos-positive cell 
nuclei in the LHA and DMH of rats fed a normal diet (ND) 
 The number of Fos-positive cell nuclei per section in the LHA (upper panel) of rats 
fed a normal diet (ND) after intracerebroventricular (ICV) injection of saline (control, 
n = 4; 5 μl), leptin (n = 4; 7 μg in 5 μl), resistin (n = 4; 7 μg in 5 μl), or leptin 
combined with resistin (n = 5). For the DMH (lower panel), the groups were as 
follows: saline (control, n = 6), leptin (n = 5), resistin (n = 4) and leptin combined 
with resistin (n = 5). * P < 0.05 compared with control in the LHA. Abbreviations: 
LHA, lateral hypothalamic area; DMH, dorsomedial hypothalamic nucleus; Con, 
control; Lep, leptin; Res, resistin.  
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The midbrain 
In the PAG, resistin alone caused an increase in the numbers of Fos-positive cell 
nuclei compared to the control (P < 0.005) (Figure 3.6). In addition, there was an 
increase in the number of Fos-positive cell nuclei (P < 0.05) after the central 
administration of resistin alone compared to the administration of resistin and leptin 
combined (Figure 3.6). However, leptin alone or in combination with resistin caused 
no significant changes in the number of Fos-positive cell nuclei in the PAG compared 
to control (Figure 3.6). 
In the dorsal raphe nucleus (DR), the numbers of Fos-positive cell nuclei after each 
treatment were not statistically significantly different between groups (Figure 3.6). 
The medulla oblongata  
In the RPA, following leptin or resistin alone, the average number of Fos-positive cell 
nuclei was not significantly different from controls. However, when both leptin and 
resistin were combined, the number of Fos-positive cell nuclei was reduced compared 
with leptin (P < 0.01), or resistin (P < 0.01) alone but was not significantly different 
from control (Figure 3.7).   
In all other medullary nuclei including the RVLM, NTS and RVMM, there were no 
significant differences in the number of Fos-positive cell nuclei between the 
treatments (Figure 3.7 and 3.8). 
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Figure  3.6: Effect of leptin and/or resistin on the distribution of Fos-positive cell 
nuclei in the midbrain (PAG and DR) of rats fed a normal diet (ND) 
The number of Fos-positive cell nuclei per section in midbrain (PAG and DR) of rats 
fed a normal diet (ND) after intracerebroventricular (ICV) injection of saline (control, 
n = 4; 5 μl), leptin (n = 4; 7 μg in 5 μl), resistin (n = 4; 7 μg in 5 μl), or leptin 
combined with resistin (n = 5). * P < 0.005 compared with control in the PAG; + P < 
0.05 compared with leptin + resistin in the PAG. Abbreviations: PAG, periaqueductal 
gray; DR, dorsal raphe; Con, control; Lep, leptin; Res, resistin.  
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Figure  3.7: Effect of leptin and/or resistin on the distribution of Fos-positive cell 
nuclei in the NTS and RPA of rats fed a normal diet (ND) 
The number of Fos-positive cell nuclei per section in the medulla oblongata (NTS and 
RPA) of rats fed a normal diet (ND) after intracerebroventricular (ICV) injection of 
saline (control, n = 4; 5 μl), leptin (n = 4; 7 μg in 5 μl), resistin (n = 4; 7 μg in 5 μl), or 
leptin combined with resistin (n = 5). + P < 0.01 compared with leptin + resistin for 
the RPA. Abbreviations: NTS, nucleus tractus solitarius; RPA, raphe pallidus; Con, 
control; Lep, leptin; Res, resistin 
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Figure  3.8: Effect of leptin and/or resistin on the distribution of Fos-positive cell 
nuclei in the RVLM and RVMM of rats fed a normal diet (ND) 
The number of Fos-positive cell nuclei per section in the medulla oblongata (RVLM 
and RVMM) of rats fed a normal diet (ND) after intracerebroventricular (ICV) 
injection of saline (control, n = 4; 5 μl), leptin (n = 4; 7 μg in 5 μl), resistin (n = 4; 7 
μg in 5 μl), or leptin combined with resistin (n = 5). Abbreviations: RVLM, rostral 
ventrolateral medulla; RVMM, rostral ventromedial medulla; Con, control; Lep, 
leptin; Res, resistin.  
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3.4. Discussion  
This study extensively investigated the distribution of activated neurons following 
ICV injection of resistin alone, leptin alone and the combination of leptin and resistin 
(177, 178, 180). The main finding in the present study is that resistin significantly 
increased the number of activated neurons in the hypothalamic ARC, PVN and LHA, 
compared to the control and this was similar to leptin. It was also found that resistin 
significantly increased the number of activated neurons in the PAG compared to 
control. When the combination of leptin and resistin was administered, there was a 
significant increase in the number of activated neurons in the OVLT, MnPO, ARC, 
PVN, and LHA compared to control. In contrast to all other brain areas that were 
examined, the number of activated neurons in the ARC following leptin and resistin 
combined was significantly more than when leptin or resistin were administered 
alone. The opposite effect occurred in the RPA, where the number of activated 
neurons was significantly reduced when leptin combined with resistin compared to 
that observed with each hormone alone. 
The numbers of Fos-positive cell nuclei in the ARC and PVN in the hypothalamus 
were significantly increased after ICV injection of resistin, as reported in previous 
work (177, 180). In contrast to the present findings, resistin has been reported to 
reduce the level of p-STAT3, a known marker of leptin signalling in neurons, in the 
ARC (449). These contrasting findings could be due to that p-STAT3 is a marker of 
direct activation of neurons by leptin, whilst Fos protein is a marker of increased 
neuronal activation which can be induced indirectly. 
The numbers of Fos-positive cell nuclei in the LHA and PAG were significantly 
increased after ICV injection of resistin alone. However, no significant changes were 
noted in the numbers of Fos-positive cell nuclei in the other brain areas examined 
following resistin administration.  
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The numbers of Fos-positive cell nuclei in the ARC and PVN were also significantly 
increased after ICV injection of leptin, as previously reported (174, 175, 183, 450). 
The findings are in agreement with previous studies that investigated microinjections 
of leptin into specific brain regions, as well as the distribution of leptin receptors 
throughout the brain (174, 175, 183, 450). However, I could not find significant 
increases in Fos-positive cell nuclei in the medulla oblongata, which is known to be a 
site of leptin action to influence cardiovascular and respiratory function (451-453).  
To date, microinjection of resistin into specific brain nuclei has not been reported, nor 
has the receptor for resistin been identified. Thus, the present study may provide some 
insight into the potential sites of resistin action. Note that Fos is used here as a marker 
of increased neuronal activation and not as a marker for direct action of the hormones.  
The numbers of Fos-positive cell nuclei were significantly greater in the lamina 
terminalis, ARC, PVN and LHA following ICV injection of leptin and resistin 
combined compared to the control; however, the combination of leptin and resistin 
failed to show significant differences in other brain areas examined. The ICV 
injection of leptin and resistin in combination significantly increased the number of 
Fos-positive cell nuclei in the ARC over that observed when either drug was injected 
alone. This finding suggests that there is a sub-population of neurons that is activated 
by leptin which differs from the sub-population of neurons activated by resistin in the 
ARC. However, in the PVN and LHA, the number of Fos-positive cell nuclei 
following ICV injection of leptin or resistin alone was similar to the numbers seen 
following the combination of both drugs. This result suggests that leptin and resistin 
activate the same population of neurons in the PVN and LHA.  
The ARC has neuronal projections to the PVN and LHA (66-68, 454); so we expected 
a greater number of Fos-positive cell nuclei in these regions following administration 
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of leptin and resistin combined compared to each hormone alone, which was observed 
in the ARC but not the PVN and LHA. An explanation for the result in the PVN and 
LHA is that Fos protein is a marker for increased neuronal activation but does not 
measure the level of increased activation of neurons. Thus, ICV injection of leptin and 
resistin together could have activated the same population of neurons but to a much 
greater level than was detected after ICV injection of leptin or resistin alone. This is 
further discussed in chapter nine.   
Unlike the case in the other brain nuclei examined, the numbers of Fos-positive cell 
nuclei in the RPA were significantly lower following ICV injection of the 
combination of leptin and resistin compared to leptin or resistin administered alone. 
This finding suggests the occurrence of a negative interaction in the RPA, which is an 
area that is well known to play a key role in the regulation of SNA to BAT (455). The 
current findings of resistin and leptin combined agree with studies that show a 
sympatho-excitatory action of leptin and an opposing sympatho-inhibitory effect of 
resistin on BAT (177, 309). However, in the current work, ICV injection of resistin 
alone did not reduce the number of Fos-positive cell nuclei in the RPA compared to 
control. This suggests that the basal Fos activity may be indicative of other functional 
roles of the RPA in additional to BAT SNA and thus a reduction in the number of 
Fos-positive neurons following resistin alone was not easily detectable.  
In regard to the activation of neurons in the lamina terminalis, ARC and PVN, the 
physiological functional correlates associated with neuronal activation are not known. 
However, it is known that the ARC is involved in regulating feeding behaviour, in 
addition to cardiovascular function. The ARC is one of the main sites of action for 
leptin to induce its anorexigenic effects (456). Resistin can also act centrally to reduce 
food intake (178). Therefore, the increased activation of neurons in the ARC 
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following administration of leptin and resistin together may be related to effects on 
food intake but this requires further investigation.   
Since the ARC also plays an important role in cardiovascular regulation (457), the 
increased neuronal activity in the ARC correlates with increased renal sympathetic 
nerve activity (RSNA) observed following administration of leptin and resistin 
combined compared to each hormone alone (179).  
The lamina terminalis, which contains the OVLT and MnPO, have neural connections 
to renal sympathetic nerves (39). The OVLT and MnPO contribute to the regulation 
of body fluid homeostasis, in addition to osmoregulation (39). In the present work, a 
marked increase in the numbers of Fos-positive cell nuclei in the OVLT and MnPO 
following resistin and leptin may correlate with the greater increase in RSNA that has 
been observed following ICV injection of leptin and resistin in combination (179). 
However, further work is required to establish this connection. Additionally, further 
investigation is required regarding the influence of leptin or resistin on thirst.   
In conclusion, the present study may provide some insight into the potential sites of 
action of resistin in the lamina terminalis, ARC, PVN, LHA and PAG. It is suggested 
that leptin and resistin activate the same population of neurons in the PVN and LHA, 
but different sub-population of neurons may be activated in the ARC by resistin and 
leptin. Although, further studies are required to investigate the functional relevance of 
the present findings, based on the effects of resistin and leptin combined, on RSNA, 
the present work suggests the ARC may be important. 
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Chapter 4: High fat diet decreases neuronal activation in the 
brain induced by resistin and leptin 
4.1. Introduction 
Resistin and leptin are adipokines synthesised in adipose tissue and both have actions 
in the brain to modulate metabolic functions, such as food intake and energy 
homeostasis, and they can also influence cardiovascular regulation.  
Resistin, first described in 2001 (21), has been shown to act in the brain to reduce 
food intake and thermogenesis. Resistin, however, increases sympathetic nerve 
activity to the muscle vasculature (177) and to the kidneys (458). The effect on renal 
sympathetic nerve activity (RSNA) is mediated by phosphatidylinositol 3-kinase 
(PI3K) (177, 458).  
Leptin is a much better characterised hormone than resistin. A primary role of leptin 
in healthy weight individuals is to reduce food intake by supressing appetite (7). 
Leptin increases energy expenditure by increasing thermogenesis (309, 459).  
Leptin can also influence cardiovascular function. Intracerebroventricular (ICV) 
injection of leptin increases sympathetic nerve activity to the muscle and splanchnic 
vasculature (16), as well as the kidneys (14), a key organ for long term blood pressure 
control (460). The mechanisms responsible for the increase in RSNA induced by 
leptin involves P13K (461).  
Thus, resistin and leptin have similar actions on cardiovascular outputs like RSNA but 
opposing actions on metabolic outputs like thermogenesis. This suggests some 
similarity in the brain sites of action of resistin and leptin, as well as differences.     
A primary site of action of leptin is the hypothalamic arcuate nucleus (ARC) (462) 
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but other brain nuclei are also affected by leptin as shown by studies using 
microinjections of leptin or the studies describing the distribution of its receptor (174-
176). In contrast, the sites of action for resistin in the brain have not been extensively 
studied.  However, potential sites of action have been investigated using the detection 
of the protein, Fos, as a marker of activated neurons (177-180). The results suggest 
that resistin and leptin may activate similar nuclei in the hypothalamus and medulla 
oblongata (179).  
In metabolic disorders induced by high fat diets, studies investigating the distribution 
of Fos following central leptin administration have shown a reduction in the number 
of activated neurons in several hypothalamic areas involved in metabolic and 
cardiovascular regulation such as the paraventricular nuclei (PVN), supraoptic 
nucleus (SON), ARC and the dorsomedial hypothalamic nucleus (DMH) (17), which 
may correlate with the reported attenuation of the anorexigenic actions and the lumbar 
sympatho-excitatory actions of leptin (13). Thus, high fat diets can influence the 
distribution of activated neurons following centrally administered leptin but the effect 
of diets high in fat on the distribution of Fos in response to resistin has not been 
investigated. 
The aims of the present work, therefore, were to determine the effect of high fat diet 
on the distribution in the brain of neurons activated by centrally administered (i) 
resistin and (ii) resistin versus leptin, and (iii) resistin combined with leptin.  
4.2. Methods 
In this study, the distribution of Fos protein, used as a marker for neuronal activation, 
in various brain areas examined were compared between rats fed a normal diet (ND) 
(data from Chapter 3) and rats fed a high fat diet (HFD). Rats on a HFD were 
anaesthesized and received intracerebroventricular (ICV) injection of saline (control; 
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n = 6), leptin (7 μg; n = 5), resistin (7 μg; n = 4) and the combination of leptin and 
resistin (n = 5). After three hours, the brains were perfused (as described in Chapter 2) 
and then immunohistochemistry was performed to detect Fos protein.  
Fos-positive cell nuclei were visualized and counted unilaterally at ×200 
magnification, except in the mid-line structures [raphe pallidus (RPA), dorsal raphe 
(DR), median preoptic nucleus (MnPO) and organum vasculosum of the lamina 
terminalis (OVLT)]. At least two sections for each brain area were used for analysis 
(as described in Chapter 2). The average number of Fos-positive cell nuclei was 
compared between treatment groups within diet by using one-way ANOVA.  Multiple 
comparisons were accounted for by the Holm-Sidak test.  Between diets, the average 
number of Fos-positive cell nuclei was compared by using unpaired t-test and the P 
value was adjusted for multiple comparisons using the Holm-Sidak test. 
4.3. Results  
4.3.1. Effects of resistin and leptin alone or combined on the distribution of 
Fos-positive cell nuclei in rats fed a high fat diet (HFD) 
Lamina terminalis (OVLT and MnPO) 
Compared to the control, there was no significant difference in the numbers of Fos-
positive cell nuclei present in the OVLT or MnPO in rats fed the HFD when resistin 
or leptin were administered alone or in combination (Figure 4.1). However, the 
combination of resistin and leptin exhibited lower numbers of Fos-positive cell nuclei 
in the OVLT compared to resistin or leptin administered alone (P < 0.05) (Figure 4.1). 
Similarly, in the MnPO the combination of resistin and leptin resulted in smaller 
numbers of Fos-positive cell nuclei compared to resistin or leptin alone (P < 0.005) 
(Figure 4.1).  
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Figure  4.1: Effect of leptin and/or resistin on the distribution of Fos-positive cell 
nuclei in the lamina terminalis (OVLT and MnPO) of rats fed a normal diet (ND) and 
a high fat diet (HFD) 
The numbers of Fos-positive cell nuclei per section in the lamina terminalis (OVLT 
and MnPO) from rats fed a normal diet (ND) and a high fat diet (HFD) administered 
intracerebroventricular (ICV) saline (control, n = 6 ND, n= 4 HFD ; 5 μl), leptin (n = 
5 ND, n= 5 HFD; 7 μg in 5 μl), resistin (n = 4 ND, n= 4 HFD; 7 μg in 5 μl) and leptin 
combined with resistin (n = 5 ND, n= 6 HFD). ∗ P < 0.005 and P < 0.05 compared 
with control for OVLT and MnPO respectively. # P < 0.005 HFD compared to ND 
for OVLT and MnPO. + P < 0.05 and P < 0.005 compared with leptin + resistin for 
OVLT and MnPO respectively. Abbreviations: OVLT, organum vasculosum of the 
lamina terminalis; MnPO, median preoptic nucleus; Con, control; Lep, leptin; Res, 
resistin.  
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Hypothalamus 
In the high fat fed animals, there was no significant difference in the numbers of Fos-
positive cell nuclei present in the ARC, PVN, SON and DMH following resistin or 
leptin alone, or in combination (Figures 4.2 and 4.3). In the LHA, resistin or leptin 
alone did not significantly affect the number of Fos-positive cell nuclei compared to 
control (Figure 4.3). However, when both adipokines were combined, there was a 
reduction in the number of Fos-positive cell nuclei compared to control, and resistin 
alone (P < 0.05) (Figure 4.3).  
Periaqueductal Gray (PAG) and Dorsal Raphe (DR) 
In rats fed the HFD, there were no significant differences in the number of Fos-
positive cell nuclei in the PAG or the DR following resistin and leptin alone or in 
combination (Figure 4.4).  
Medulla Oblongata 
ICV injection of resistin or leptin alone or both combined did not significantly affect 
the number of Fos-positive cell nuclei in the NTS compared to control in rats fed the 
HFD (Figure 4.5). The combination of resistin and leptin resulted in a lower number 
compared to leptin alone (P < 0.005) but not compared to resistin alone (Figure 4.5). 
In the RPA, there was no significant difference in the number of Fos-positive cell 
nuclei between the groups (Figure 4.5). 
In the RVMM, there was a decrease in the number of Fos-positive cell nuclei 
following resistin (P < 0.005) or leptin (P < 0.05) alone or in combination (P < 0.005) 
compared to the controls in rats fed the HFD (Figure 4.6). By contrast, in the RVLM, 
there were no significant differences between the groups in rats fed HFD (Figure 4.6). 
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Figure  4.2: Effect of leptin and/or resistin on the distribution of Fos-positive cell 
nuclei in the SON, PVN and ARC of rats fed a normal diet (ND) and a high fat diet 
(HFD) 
The numbers of Fos-positive cell nuclei per section in the SON, ARC from rats fed a 
normal diet (ND) and a high fat diet (HFD) administered intracerebroventricular 
(ICV) saline (control, n = 6 ND, n= 4 HFD ; 5 μl), leptin (n = 5 ND, n= 5 HFD; 7 μg 
in 5 μl), resistin (n = 4 ND, n= 4 HFD; 7 μg in 5 μl) and leptin combined with resistin 
(n = 5 ND, n= 6 HFD). Due to technical issues, in the PVN; saline (n = 4 ND) and 
leptin (n = 4 ND) due to technical issues. ∗ 0.0001 < P < 0.005 compared with control 
in the ARC; 0.005 < P < 0.01 compared with control in the PVN. # P < 0.0001 and P 
< 0.01 HFD compared to ND in the ARC and PVN respectively. + 0.0001 < P < 0.005 
compared with leptin + resistin. Abbreviations: SON, supraoptic nucleus; ARC, 
arcuate nucleus; PVN, paraventricular nucleus; Con, control; Lep, leptin; Res, 
resistin.  
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Figure  4.3: Effect of leptin and/or resistin on the distribution of Fos-positive cell 
nuclei in the LHA and DMH of rats fed a normal diet (ND) and a high fat diet (HFD) 
The numbers of Fos-positive cell nuclei per section in the LHA (upper panel) from 
rats fed a normal diet (ND) and a high fat diet (HFD) administered 
intracerebroventricular (ICV) saline (control, n = 4 ND, n = 4 HFD; 5 μl), leptin (n = 
4 ND, n = 5 HFD; 7 μg in 5 μl), resistin (n = 4 ND, n = 4 HFD; 7 μg in 5 μl), leptin 
combined with resistin (n = 5 ND, n = 6 HFD). In the DMH (lower panel); saline 
(control, n = 6 ND, n= 4 HFD ; 5 μl), leptin (n = 5 ND, n= 5 HFD; 7 μg in 5 μl), 
resistin (n = 4 ND, n= 4 HFD; 7 μg in 5 μl) and leptin combined with resistin (n = 5 
ND, n= 6 HFD). ∗ P < 0.05 compared with control. # P < 0.0005 HFD compared to 
ND. + P < 0.05 compared with leptin + resistin. Abbreviations: LHA, lateral 
hypothalamic area; DMH, dorsomedial hypothalamic nucleus; Con, control; Lep, 
leptin; Res, resistin.   
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Figure  4.4: Effect of leptin and/or resistin on the distribution of Fos-positive cell 
nuclei in the PAG and DR of rats fed a normal diet (ND) and a high fat diet (HFD) 
The numbers of Fos-positive cell nuclei per section in the PAG and DR from rats fed 
a normal diet (ND) and a high fat diet (HFD) administered intracerebroventricular 
(ICV) saline (control, n = 4 ND, n = 4 HFD; 5 μl), leptin (n = 4 ND, n = 5 HFD; 7 μg 
in 5 μl), resistin (n = 4 ND, n = 4 HFD; 7 μg in 5 μl), leptin combined with resistin (n 
= 5 ND, n = 6 HFD). ∗ P < 0.005 compared with control; # P < 0.005 HFD compared 
to ND. + P < 0.05 compared with leptin + resistin. Abbreviations: PAG, 
periaqueductal gray; DR, dorsal raphe; Con, control; Lep, leptin; Res, resistin.   
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Figure  4.5: Effect of leptin and/or resistin on the distribution of Fos-positive cell 
nuclei in the NTS and RPA of rats fed a normal diet (ND) and a high fat diet (HFD) 
 The numbers of Fos-positive cell nuclei per section in the NTS and RPA from rats 
fed a normal diet (ND) and a high fat diet (HFD) administered intracerebroventricular 
(ICV) saline (control, n = 4 ND, n = 4 HFD; 5 μl), leptin (n = 4 ND, n = 5 HFD; 7 μg 
in 5 μl), resistin (n = 4 ND, n = 4 HFD; 7 μg in 5 μl), leptin combined with resistin (n 
= 5 ND, n = 6 HFD). # 0.01 < P < 0.05 HFD compared to ND in the NTS; 0.005 < P 
< 0.05 HFD compared to ND in the RPA. + P < 0.05 and P < 0.01 hormone alone 
compared with leptin + resistin for NTS and RPA respectively.  Abbreviations: NTS, 
nucleus tractus solitarius; RPA, raphe pallidus; Con, control; Lep, leptin; Res, resistin. 
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Figure  4.6: Effect of leptin and/or resistin on the distribution of Fos-positive cell 
nuclei in the RVLM and RVMM of rats fed a normal diet (ND) and a high fat diet 
(HFD) 
The numbers of Fos-positive cell nuclei per section in the RVLM and RVMM from 
rats fed a normal diet (ND) and a high fat diet (HFD) administered 
intracerebroventricular (ICV) saline (control, n = 4 ND, n = 4 HFD; 5 μl), leptin (n = 
4 ND, n = 5 HFD; 7 μg in 5 μl), resistin (n = 4 ND, n = 4 HFD; 7 μg in 5 μl), leptin 
combined with resistin (n = 5 ND, n = 6 HFD). ∗ 0.005 < P < 0.05 compared with 
control. # 0.005 < P < 0.05 HFD compared to ND. Abbreviations: RVLM, rostral 
ventrolateral medulla; RVMM, rostral ventromedial medulla; Con, control; Lep, 
leptin; Res, resistin.  
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4.3.2. Comparison of the effects of resistin and leptin on Fos-positive cell 
nuclei distribution in rats fed the high fat diet (HFD) versus rats fed a 
normal diet (ND) 
Lamina terminalis 
In the OVLT of rats fed a normal diet (ND), following the combination of resistin and 
leptin, the number of Fos-positive cell nuclei was greater than in rats fed the HFD 
(P < 0.005) (Figures 4.1 and 4.7). Similar differences were observed in the MnPO 
(P < 0.005) (Figures 4.1 and 4.8). In contrast, there were no significant differences 
between the diets in the number of Fos-positive cell nuclei present in the OVLT and 
MnPO when resistin or leptin were administered alone (Figure 4.1). 
Hypothalamus 
In the ARC, PVN and LHA, there was an increase in the number of Fos-positive cell 
nuclei in rats fed a ND following administration of resistin or leptin alone (P < 0.005 
compared to control) (Figures 4.2 and 4.3, and is described in chapter 3). Such an 
effect was not observed in high fat fed rats, and thus there were no significant 
differences detected between the diets in those brain regions (Figures 4.2 and 4.3). 
However, when resistin and leptin were administered in combination, there was an 
increase in the number of Fos-positive cell nuclei in rats fed a ND compared to 
control, and this was  significant compared to the response in the HFD (P < 0.0001, 
P < 0.01 and P < 0.005 ARC, PVN and LHA respectively) (Figures 4.2, 4.3, 4.9-
4.11).  
In the DMH and SON, there were no significant differences in responses of the 
hormones in rats fed the different diets (Figures 4.2 and 4.3).   
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Figure  4.7: Photomicrographs of the effect of leptin and resistin on the distribution of 
Fos-positive cell nuclei in the OVLT of rats fed a high fat diet (HFD) and rats fed a 
normal diet (ND) 
The photomicrographs show Fos-positive cell nuclei in the organum vasculosum of 
the lamina terminalis (OVLT) of rats fed a high fat diet (HFD) and rats fed a normal 
diet (ND) following centrally administered saline (5 μl; control) or leptin combined 
with resistin (7 μg). Scale bar represents 100 µm. Abbreviations: Con, control; 
Lep+Res, leptin + resistin.  
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Figure  4.8: Photomicrographs of the effect of leptin and resistin on the distribution of 
Fos-positive cell nuclei in the MnPO of rats fed a high fat diet (HFD) and rats fed a 
normal diet (ND) 
The photomicrographs A-D show Fos-positive cell nuclei in the median preoptic 
nucleus (MnPO) (outlined by dashed lines) of rats fed a high fat diet (HFD) and rats 
fed a normal diet (ND) following centrally administered saline (5 μl; control) or leptin 
combined with resistin (7 μg). *Area is shown in higher magnification in E and F 
respectively. Scale bar represents 100 µm. Abbreviations: AC, anterior commissure; 
Con, control; Lep+Res, leptin + resistin.  
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Figure  4.9: Photomicrographs of the effect of leptin and resistin on the distribution of 
Fos-positive cell nuclei in the ARC of rats fed a high fat diet (HFD) and rats fed a 
normal diet (ND) 
The photomicrographs show Fos-positive cell nuclei in the arcuate nucleus (ARC) 
(outlined by dashed lines) of rats fed a high fat diet (HFD) and rats fed a normal diet 
(ND) following centrally administered saline (5 μl; control) or leptin combined with 
resistin (7 μg). Scale bar represents 100 µm. Abbreviations: Con, control; Lep+Res, 
leptin + resistin.  
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Figure  4.10: Photomicrographs of the effect of leptin and resistin on the distribution 
of Fos-positive cell nuclei in the PVN of rats fed a high fat diet (HFD) and rats fed a 
normal diet (ND) 
The photomicrographs show Fos-positive cell nuclei in the paraventricular nucleus 
(PVN) (outlined by dashed lines) of rats fed a high fat diet (HFD) and rats fed a 
normal diet (ND) following centrally administered saline (5 μl; control) or leptin 
combined with resistin (7 μg). Scale bar represents 100 µm. Abbreviations: Con, 
control; Lep+Res, leptin + resistin.  
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Figure  4.11: Photomicrographs of the effect of leptin and resistin on the distribution 
of Fos-positive cell nuclei in the LHA of rats fed a high fat diet (HFD) and rats fed a 
normal diet (ND) 
The photomicrographs show Fos-positive cell nuclei in the lateral hypothalamic area 
(LHA) (outlined by dashed lines) of rats fed a high fat diet (HFD) and rats fed a 
normal diet (ND) following centrally administered saline (5 μl; control) or leptin 
combined with resistin (7 μg). Scale bar represents 100 µm. Abbreviations: Fx, 
fornix; Con, control; Lep+Res, leptin + resistin.  
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Periaqueductal Gray (PAG) and dorsal Raphe (DR) 
In the rats fed a ND, the numbers of Fos-positive cell nuclei in the PAG following 
resistin alone and in combination with leptin were lower than in rats fed the HFD (P 
< 0.005) (Figures 4.4 and 4.12). There was no significant difference between the diets 
following leptin alone. 
In the DR, there were no significant differences in responses of the hormones in rats 
fed the different diets (Figure 4.4).   
Medulla oblongata 
In the RPA, the numbers of Fos-positive cell nuclei following resistin (P < 0.001) or 
leptin alone (P < 0.05) were less in rats fed the HFD compared to the ND (Figures 4.5 
and 4.13). But when the hormones were combined, there was no difference in the 
numbers of Fos-positive cell nuclei between the diets (Figure 4.5). 
In the NTS, the numbers of Fos-positive cell nuclei following resistin alone (P < 0.01) 
and resistin in combination with leptin (P < 0.01), were less in rats fed the HFD 
compared to the ND (Figures 4.5 and 4.14). However, this was not observed for leptin 
alone (Figure 4.5). 
In the RVMM, the number of Fos-positive cell nuclei following resistin alone was 
less in rats fed the HFD compared to the ND (P < 0.01)  (Figures 4.6 and 4.15). In the 
groups administered leptin alone or in combination with resistin, there were no 
significant differences in the number of Fos-positive cell nuclei between the diets 
(Figure 4.6). Interestingly, though, in control rats fed the HFD, the number of Fos-
positive cell nuclei was significantly greater than in the rats fed the ND (Figures 4.6 
and 4.15). In the RVLM, the number of Fos-positive cell nuclei following resistin and 
leptin combined was less in rats fed the HFD compared to the ND (P < 0.005) 
(Figures 4.6 and 4.16). No other significant effects between the diets were observed 
(Figure 4.6). 
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Figure  4.12: Photomicrographs of the effect of leptin or resistin on the distribution of 
Fos-positive cell nuclei in the PAG of rats fed a high fat diet (HFD) and rats fed a 
normal diet (ND) 
The photomicrographs show Fos-positive cell nuclei in the periaqueductal gray 
(PAG) of rats fed a high fat diet (HFD) and rats fed a normal diet (ND) following 
centrally administered saline (5 μl; control), leptin (7 μg) or resistin (7 μg). Scale bar 
represents 100 µm. Abbreviations: Aq, aqueduct; Con, control; Lep, leptin; Res, 
resistin.  
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Figure  4.13: Photomicrographs of the effect of leptin and/or resistin on the 
distribution of Fos-positive cell nuclei in the RPA of rats fed a high fat diet (HFD) 
and rats fed a normal diet (ND) 
The photomicrographs show Fos-positive cell nuclei in the raphe pallidus nuclei 
(RPA) of rats fed a high fat diet (HFD) and rats fed a normal diet (ND) following 
centrally administered saline (5 μl; control) leptin (7 μg) or resistin (7 μg) or leptin 
combined with resistin. Scale bar represents 100 µm. Abbreviations: Con, control; 
Lep, leptin; Res, resistin.  
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Figure  4.14: Photomicrographs of the effect of resistin alone or combined with leptin 
on the distribution of Fos-positive cell nuclei in the NTS of rats fed a high fat diet 
(HFD) and rats fed a normal diet (ND) 
The photomicrographs show Fos-positive cell nuclei in the nucleus tractus solitarius 
(NTS) of rats fed a high fat diet (HFD) and rats fed a normal diet (ND) following 
centrally administered saline (5 μl; control), resistin (7 μg) or leptin combined with 
resistin. The dashed lines outline the NTS. Scale bar represents 100 µm. 
Abbreviations: Con, control; Lep, leptin; Res, resistin.  
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Figure  4.15: Photomicrographs of the effect of leptin and/or resistin on the 
distribution of Fos-positive cell nuclei in the RVMM of rats fed a high fat diet (HFD) 
and rats fed a normal diet (ND) 
The photomicrographs show Fos-positive cell nuclei in the rostral ventromedial 
medulla (RVMM) of rats fed a high fat diet (HFD) and rats fed a normal diet (ND) 
following centrally administered saline (5 μl; control) leptin (7 μg) or resistin (7 μg) 
or leptin combined with resistin. Scale bar represents 100 µm. Abbreviations: Con, 
control; Lep, leptin; Res, resistin.  
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Figure  4.16: Photomicrographs of the effect of leptin and resistin on the distribution 
of Fos-positive cell nuclei in the RVLM of rats fed a high fat diet (HFD) and rats fed 
a normal diet (ND) 
The photomicrographs show Fos-positive cell nuclei in the rostral ventrolateral 
medulla (RVLM) of rats fed a high fat diet (HFD) and rats fed a normal diet (ND) 
following centrally administered saline (5 μl; control) or leptin combined with resistin 
(7 μg). Scale bar represents 100 µm. Abbreviations: NA, nucleus ambiguous; Con, 
control; Lep+Res, leptin + resistin.  
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4.3.3. Metabolic parameters in rats fed HFD versus ND  
The average body weight prior to the start of the diet was 278±5 grams in ND group 
and 293±6 grams in the HFD group. There was a greater increase in body weight 
(P < 0.01) and calorie intake (P < 0.0001) in the HFD group compared to the ND 
group over time (Figure 4.17). However, there was no significant difference in food 
intake over time between the HFD and ND groups (Figure 4.17). The percentage of 
whole-body fat (P < 0.001) and the amount of the epidydimal fat (P < 0.001) at the 
end of the diet was higher in rats fed the HFD compared with ND rats (Figure 4.18). 
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Figure  4.17: Effect of high fat diet (HFD) and normal diet (ND) on metabolic 
parameters (weight, food and calorie intake)  
The effect of high fat diet (HFD; n = 18) and normal diet (ND; n = 13) on the change 
in body weight, food intake per day and average calorie intake per day over time. * 
P < 0.01 compared with control. ** P < 0.0001 compared with control. 
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Figure  4.18: Effect of high fat diet (HFD) and normal diet (ND) on metabolic 
parameters (body fat) 
The effect of high fat diet (HFD) and normal diet (ND) on the epididymal fat (n = 15 
ND, n = 15 HFD) and on the whole body fat percentage (n = 10 ND, n = 12 HFD). * 
P < 0.001 compared with control. 
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4.4. Discussion 
In the present work, I investigated the production of Fos as a marker of activated 
neurons in the brain following resistin and leptin alone or combined in rats fed a high 
fat diet (HFD) and compared it to the effects in rats fed a normal diet (ND). The 
findings are summarized in table 4.1. The data showed that high fat feeding reduced 
the number of activated neurons especially when resistin and leptin were combined in 
many brain nuclei examined. This suggests that the sensitivity to the effects of resistin 
and leptin may be reduced. 
HFD influences the neuronal activation induced by resistin and leptin alone 
In rats fed a HFD, the effects of central administration of resistin alone did not show 
any significant differences in the number of Fos-positive cell nuclei compared to the 
control in all brain regions that were examined, except in the RVMM in which central 
resistin showed a significant reduction. In contrast, rats fed a ND receiving central 
resistin alone showed a significant increase in Fos-positive cell nuclei in the PVN, 
ARC, LHA and PAG. The findings confirm previous reports in the PVN and ARC 
(177, 180) and highlight the findings in the LHA and PAG. Thus, the present findings 
suggest that HFD may decrease the sensitivity to resistin in the brain. 
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Table 4.1: Summary of changes in the number of Fos-positive cell nuclei 
compared to control 
 
 
 
 
 
 
 
 
 
 
 
 
NSD - No significant differences  
       Significant increase 
       Significant decrease 
 
Abbreviations: organum vasculosum of the lamina terminalis (OVLT), median 
preoptic nucleus (MnPO), paraventricular nucleus (PVN), arcuate nucleus (ARC), 
lateral hypothalamic area (LHA), periaqueductal gray (PAG), and rostral 
ventromedial medulla (RVMM). 
 
 
 
Brain 
areas 
Resistin Leptin Resistin + Leptin 
ND HFD ND HFD ND HFD 
OVLT NSD NSD NSD NSD  NSD 
MnPO NSD NSD NSD NSD  NSD 
PVN  NSD  NSD  NSD 
ARC  NSD  NSD  NSD 
LHA  NSD  NSD   
PAG  NSD NSD NSD NSD NSD 
RVMM NSD  NSD  NSD  
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Following the central administration of leptin, there was a significant increase in the 
number of activated neurons in the PVN, ARC and LHA in rats fed the ND as 
previously reported (174-176, 179, 183, 450). However, in rats fed a HFD, we found 
no significant differences from control in those areas, implying that the sensitivity of 
leptin was decreased by HFD feeding. Such a conclusion was also reached in a study 
using rabbits fed a high fat diet (17). The results in the ARC are particularly 
interesting given that the ARC is a key brain nucleus mediating the dietary effects of 
leptin. Thus, the decrease in Fos-positive cell nuclei in the ARC following central 
leptin administration corresponds with the decreased sensitivity to the anorexigenic 
actions of leptin in rats fed a HFD (349). It is unknown if similar functional changes 
elicited by central resistin are affected by HFD.  
In the RVMM of rats fed a HFD, we found that central resistin decreased the number 
of activated neurons in this brain region compared to control, although no differences 
were observed in the other areas of the medulla oblongata (i.e. RVLM, NTS, and 
RPA). Similarly, we found that central administration of leptin also decreased the 
number of activated neurons in the RVMM of rats fed a HFD.  
A comparison between the HFD and ND shows significantly less activated neurons in 
the RVMM in the HFD group following resistin, suggesting that the sensitivity to 
resistin is reduced in this region as well. This interpretation is complicated, however, 
by the finding that in the control groups, there was a significantly greater number of 
Fos-positive cell nuclei in the RVMM in the HFD compared to the ND groups. 
Following leptin, there were less activated neurons in the RVMM of the HFD 
compared to the ND group but this did not attain statistical significance.  
Central resistin alone had no effect on Fos production in the PAG of rats fed a HFD 
compared to control but was able to increase it in rats fed a ND. Thus, in rats fed the 
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HFD, the number of activated neurons was significantly less than in the ND group 
following resistin alone. In contrast, central leptin alone showed no changes in Fos 
production in both HFD and ND when compared to their respective controls. Thus, 
the PAG appears to be selectively activated following resistin administration to rats 
fed a ND, but this sensitivity was attenuated in the rats fed the HFD.   
Similarly, when the effects in HFD and ND groups were compared, resistin or leptin 
alone in the HFD group elicited significantly less Fos production in the RPA. This 
nucleus plays a key role in thermogenesis by mediating sympatho-excitation to brown 
adipose tissue, thereby regulating non-shivering thermogenesis (463). However, since 
resistin and leptin have opposing actions on this output (177, 309), the functional 
consequences of an attenuated sensitivity in the RPA to both hormones on 
thermogenesis needs to be investigated. 
HFD influences the neuronal activation induced by the combined treatment of 
resistin and leptin 
In the HFD group, resistin and leptin combined had no significant effect on the 
number of activated neurons in most areas examined (exceptions were in the LHA 
and RVMM) when compared to the saline control. This was in contrast to the findings 
in ND where the number of activated neurons increased in five brain regions (ie 
OVLT, MnPO, PVN, ARC and LHA). Thus, in the HFD group, the numbers of 
activated neurons were significantly less than in the ND in each of those five brain 
nuclei. This data suggests that the sensitivity to the combined effects of resistin and 
leptin was decreased in these areas by the HFD.  
Further, in specific brain regions, the combination of resistin and leptin in the HFD 
group resulted in less activated neurons than either hormone alone (OVLT, MnPO), 
or resistin alone (LHA) or leptin alone (NTS). This suggests that in these brain 
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regions, there may be a complex interaction whereby the two hormones attenuate each 
other’s actions. 
What are the mechanisms responsible for the sensitivity changes?  
The mechanisms responsible for the decreased sensitivity to resistin in HFD are not 
known. For leptin, however, it has been reported that suppressor of cytokine 
signalling 3 (SOCS3) protein and protein tyrosine phosphatase 1B (PTP1B) 
negatively regulate leptin receptor signalling (464-467). In overweight/obese 
conditions, increased intracellular levels of SOCS3 and PTP1B appear to mediate the 
decreased sensitivity to the anorexigenic effects of leptin (464-467). It will be of 
interest if similar intracellular mechanisms mediate the reduced sensitivity to resistin. 
Metabolic effects of the HFD 
The metabolic measurements monitored in the present study show that there was a 
small but significantly greater weight gain in the rats fed the HFD compared to the 
ND. There was marked redistribution of adipose tissue with a 50% increase in percent 
body fat and a large increase in the amount of epididymal fat, even though the rats on 
the HFD ate less food. Our results suggest that the changes observed in the brain 
pathways activated by resistin and leptin can be observed without overt obesity.   
Limitations of the current study  
In the present study, we have investigated the distribution of Fos protein as a marker 
of activated neurons but it does not provide us with any information on whether the 
neurons are directly activated by the respective hormones or on the potential 
functional responses involved.   
With respect to brain sites directly activated by resistin, there is little information 
since the receptors for resistin in the brain have not been identified. Thus, the findings 
are indicative of pathways that are activated following centrally administered resistin. 
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These pathways may be related to the metabolic or the autonomic actions of resistin 
such as changes in renal sympathetic nerve activity (177). In contrast, the receptors 
for leptin and their distribution in the brain have been well documented (205, 207, 
450).  
Interpreting my findings with respect to potential functional roles is, of course, 
difficult. In the case of leptin, apart from the reduced anorexigenic effects, the 
responses to centrally administered leptin on sympathetic nerve activity to the lumbar 
region and to brown adipose tissue are also attenuated by HFD (468). Thus, functional 
correlates exist and the reduced sensitivity shown by the decreased expression of Fos 
in the HFD are in agreement with the functional data known about leptin. However, 
for RSNA responses, there is no evidence of correlation. In particular, a greater 
increase in RSNA occurred following the combination of resistin and leptin than 
either hormone alone (469). Thus, the current findings of reduced sensitivity 
following combined actions of resistin and leptin in HFD do not appear to be related 
to the RSNA responses.  
Finally, anaesthesia can influence the activity of neurons and this may limit our 
ability to determine the number of activated neurons. This could account for our 
inability to show a significant increase in the DMH as has been reported previously 
(10). However, this would suggest that brain regions in which I did observe 
statistically significant changes may well be very important. Further, I have assumed 
that the effect of anaesthesia is not influenced by diet. 
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Conclusion 
In conclusion, diets that are high in fat may lead to reduced sensitivity in the brain to 
resistin whether ‘alone’ or when it is present with leptin. This is similar to the reduced 
sensitivity that has been observed previously with leptin in rats fed a HFD (17). The 
present study is in agreement with those reports. The reduced sensitivity to leptin 
correlates with the anorexigenic and sympathetic nerve responses to some tissues. 
Whether there are such functional correlates for resistin needs investigation. 
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Chapter 5: The effect of central administration of resistin or 
leptin alone and in combination on the activated 
catecholaminergic, serotonergic and orexinergic neurons in 
the brain of rats fed a normal diet vs. high fat diet 
5.1. Introduction 
In previous chapters, neurons in the brain that are activated by centrally administered 
resistin or leptin were identified. In this chapter, the neurochemical content of the 
neurons activated by these adipokines will be investigated. There is little information 
regarding the nature of the neurochemical content of neurons activated by resistin. In 
contrast, leptin is known to act in various brain areas important in regulating 
metabolic and cardiovascular function, and the neurochemical content of neurons 
influenced has been investigated in some instances.  
Leptin receptors are located in brain regions such as the hypothalamus, midbrain, and 
medulla oblongata (18, 190, 470). Leptin can act on neurons in hypothalamus, such as 
the paraventricular nucleus (PVN) in the hypothalamus which is known to be 
involved in feeding behaviour and cardiovascular regulation (49), and leptin plays a 
role in modulating these functions (471). In the lateral hypothalamic area (LHA), 
leptin induces decreases in food intake and body weight, as well as influencing 
sympathetic nerve activity (SNA) (183, 206).  
Additionally, leptin can act in the nucleus tractus solitarius (NTS) and the rostral 
ventrolateral medulla (RVLM) of the medulla oblongata to influence renal 
sympathetic nerve activity (RSNA) and blood pressure (223, 227, 228, 472). The 
periaqueductal gray (PAG) and dorsal raphe (DR) of the midbrain are known to 
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contain leptin receptors (190, 214, 215); however the action of leptin in these areas 
has not been extensively investigated. 
We focused on the neurons containing (i) tyrosine hydroxylase (TH) as a marker of 
catecholaminergic neurons, (ii) serotonin identified by the presence of tryptophan 
hydroxylase, and (iii) orexin; as these neurons have important roles in obesity and 
cardiovascular function. Several studies have found neurons coexpressing these 
neurochemicals and leptin receptors, which suggests that leptin is able mediate some 
of the functions of these neurons. 
Tyrosine hydroxylase (TH) is an enzyme known to be involved in the synthesis of 
catecholamines including norepinephrine, epinephrine, and dopamine which are 
found in neurons located in the PVN, PAG, DR, NTS, and RVLM (254-256), and 
these neurons are involved in energy homeostasis and cardiovascular-related function 
including modulation of heart rate and blood pressure (248). Additionally, co-
localization of leptin receptors and catecholaminergic neurons are found in these brain 
regions (214, 216, 226, 297), and leptin can act on these neurons to modulate feeding 
behaviour, and cardiovascular function such as RSNA and blood pressure (226, 297, 
298, 301).  
Serotonin is a neurotransmitter commonly found in the periphery and the central 
nervous system (CNS), including neurons in the PAG, DR, raphe pallidus (RPA), and 
the rostral ventromedial medulla (RVMM) (268), and is known to regulate many 
functions such as hormone secretion, food consumption, energy homeostasis and 
blood pressure (264, 265). Leptin receptors are also co-localized with serotonergic 
neurons located in these brain regions (216, 306). These neurons are involved in the 
regulation of appetite and SNA, actions that are modulated by leptin (216, 307).  
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Orexin is a neuropeptide found in the LHA neurons (473, 474), and is important for 
several functions such as regulation of the sympathetic nervous system, energy 
homeostasis, feeding behaviour and cardiovascular function (251, 285, 287). Also, 
orexin neurons are known to express leptin receptors (297, 310).  
I have focused on catecholaminergic, serotonergic and orexinergic neurons because 
(i) they are important in cardiovascular and metabolic regulation, and (ii) they are 
found in the brain areas where Fos-positive cell nuclei has been detected as shown in 
chapters three and four of my thesis. Thus, the aim of the present work was to 
determine whether neurons activated by resistin or leptin were catecholaminergic, 
serotonergic, or orexinergic. Since HFD influenced the number of activated neurons, 
the effects of HFD on the neurochemical content of neurons activated by resistin and 
leptin were also examined.  
5.2. Methods 
The rats were divided into two groups with each group receiving either a high fat diet 
(HFD) (22 % fat) or a normal diet (ND). Anaesthetized rats received microinjections 
of saline (control, ND n = 4, HFD n = 4), resistin (ND n = 4, HFD n = 4) or leptin 
(ND n = 4, HFD n = 5) alone or in combination (ND n =5, HFD n = 6) into the lateral 
brain ventricle (ICV) as described in chapter 2. Three hours later, the brains were 
perfused and dual-label immunohistochemistry was performed to detect Fos protein 
and tyrosine hydroxylase (TH; for catecholamines) or tryptophan hydroxylase (for 
serotonin) or orexin as described in detail in the methods (Chapter 2).  
Quantitation and analysis 
The neurochemical-positive neurons and the activated neurochemical-positive 
neurons, characterised by the presence of Fos within the cell nucleus, were detected 
by using a normal light microscopy. Two sections were counted in the PVN, LHA, 
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NTS, RPA, RVMM and RVLM, and four sections were used in the PAG and DR 
regions. Counting was performed unilaterally in each brain area except in the mid-line 
structures; RPA and DR. The average number of neurochemical-positive neurons and 
the numbers of those activated neurons were counted in rats fed a normal diet or a 
high fat diet. Comparisons between adipokine treatment groups within diet were 
performed by using one-way ANOVA. When an overall difference between groups 
(within diet) was detected, the individual comparisons between groups were 
performed using the Holm-Sidak test. Comparisons between diets were performed by 
t-test and multiple comparisons were accounted for by the Holm-Sidak test. 
5.3. Results  
5.3.1. Catecholaminergic neurons 
Effects in rats fed a ND 
The number of catecholaminergic neurons in the hypothalamus (PVN), midbrain 
(PAG, DR) and medulla oblongata (NTS, RVLM) after ICV injection of resistin or 
leptin alone or in combination in rats fed a ND were not significantly different 
between all groups (Figures 5.1-5.5). 
Compared to control, the number of activated catecholaminergic neurons in the PVN, 
NTS and RVLM increased after central administration of resistin (PVN, NTS and 
RVLM (P < 0.005; P < 0.005; and P < 0.01 respectively), leptin (PVN, NTS and 
RVLM (P < 0.005; P < 0.05; and P < 0.005 respectively) or the combination of leptin 
and resistin (PVN, NTS and RVLM (P < 0.005; P < 0.0001; and P < 0.05 
respectively)) (Figures 5.1, 5.4 and 5.5). However, there was no significant difference 
in the number of activated catecholaminergic neurons in the PAG and DR following 
administration of resistin or leptin alone or in combination, when compared to control 
(Figures 5.2 and 5.3). 
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When resistin and leptin were administered in combination, the number of activated 
catecholaminergic neurons was greater than leptin alone (P < 0.05) in the NTS 
(Figure 5.4). In all other areas, the combined administration of resistin and leptin did 
not induce any significant changes in the numbers of activated catecholaminergic 
neurons compared to either hormone alone (Figures 5.1-5.5).  
Effects in rats fed a HFD 
In rats fed a HFD, the number of catecholaminergic neurons in the NTS and RVLM 
was increased following administration of resistin alone (NTS and RVLM (P < 0.005 
and P < 0.05 respectively) or leptin alone (NTS and RVLM (P < 0.001 and P < 0.005) 
respectively) or in combination (NTS and RVLM (P < 0.001 and P < 0.005) 
respectively) compared to control (Figures 5.4 and 5.5). In addition, the number of 
catecholaminergic neurons in the DR was increased following administration of 
resistin  compared to control (P < 0.05) (Figure 5.3). However, there was no 
significant difference in the number of catecholaminergic neurons in the DR 
following administration of leptin alone, or resistin and leptin in combination 
compared to control (Figure 5.3). The number of catecholaminergic neurons in the 
PVN and PAG was not significantly different between all groups (Figures 5.1 and 
5.2).  
In rats fed a HFD, the number of activated catecholaminergic neurons in the NTS and 
RVLM increased after central administration of resistin (NTS and RVLM (P < 0.001 
and P < 0.0005) respectively), leptin (NTS and RVLM (P < 0.001 and P < 0.0005) 
respectively) or a combination of leptin and resistin (NTS and RVLM (P < 0.0005 
and P < 0.005) respectively) compared to the control (Figures 5.4 and 5.5). However, 
there was no significant difference in the number of activated catecholaminergic 
neurons in the PVN, PAG and DR following administration of resistin and leptin 
alone or in combination, when compared to control (Figures 5.1-5.3). 
126 
 
   
When resistin and leptin were combined, there were no significant differences 
compared to resistin or leptin alone in any region examined (Figures 5.1-5.5).  
Comparison of the effects observed in rats fed a HFD vs ND 
There were no significant differences between the numbers of catecholaminergic 
neurons in the PVN following the adipokine/control treatments in rats fed a HFD 
compared to ND (Figure 5.1). However, the number of activated catecholaminergic 
neurons were substantially less in HFD compared to ND following leptin (P < 0.01), 
resistin (P < 0.05), and leptin and resistin combined (P < 0.01) (Figure 5.1). 
In the PAG, the number of catecholaminergic neurons in HFD were less compared to 
ND when resistin (P < 0.05) was administered but no significant changes were 
observed for leptin alone and leptin and resistin combined (Figure 5.2). Nonetheless, 
there were no significant changes in the number of activated catecholaminergic 
neurons in the PAG of rats fed a HFD compared to ND (Figure 5.2). In the DR, there 
were no significant differences in the number of catecholaminergic neurons or in the 
number of activated catecholaminergic neurons between diets (Figure 5.3). 
In the NTS, the treatments did not significantly affect the number of 
catecholaminergic neurons when comparing between diets (Figure 5.4). However, 
there was a decrease in activated catecholaminergic neurons in HFD compared to ND 
when both leptin and resistin (P < 0.05) were administered together (Figures 5.4 and 
5.6). 
In the RVLM, the combination of leptin and resistin (P < 0.05) increased the number 
of catecholaminergic neurons in HFD than in ND (Figure 5.5). However, leptin or 
resistin alone did not have a significant effect on the number of catecholaminergic 
neurons when compared between diets (Figure 5.5). The number of activated 
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catecholaminergic neurons were not significantly different between rats fed a HFD or 
ND following the adipokine/control treatments (Figure 5.5). 
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Figure  5.1: Effect of leptin and/or resistin on the activation of catecholaminergic 
neurons in the PVN of rats fed a normal diet (ND) and a high fat diet (HFD) 
The number of TH-positive neurons and activated TH-positive neurons in the 
paraventricular nucleus (PVN) from rats fed a normal diet (ND) and a high fat diet 
(HFD), following intracerebroventricular (ICV) administration of saline (control, ND 
n = 4, HFD n = 4; 5 μl), leptin (ND n = 4, HFD n = 5; 7 μg in 5 μl), resistin (ND n = 
4,  HFD n = 4; 7 μg in 5 μl) and leptin + resistin (ND n = 5, HFD n = 6). * P < 0.005 
compared to control. # 0.01 < P < 0.05 HFD vs ND. Abbreviations: TH, tyrosine 
hydroxylase; Con, control; Lep, leptin; Res, resistin. 
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Figure  5.2: Effect of leptin and/or resistin on the activation of catecholaminergic 
neurons in the PAG of rats fed a normal diet (ND) and a high fat diet (HFD) 
The number of TH-positive neurons and activated TH-positive neurons in the 
periaqueductal gray (PAG) from rats fed a normal diet (ND) and a high fat diet 
(HFD), following intracerebroventricular (ICV) administration of saline (control, ND 
n = 4, HFD n = 4; 5 μl), leptin (ND n = 4, HFD n = 5; 7 μg in 5 μl), resistin (ND n = 
4, HFD n = 4; 7 μg in 5 μl) and leptin + resistin (ND n = 5, HFD n = 6). # P < 0.05 
HFD vs ND. Abbreviations: TH, tyrosine hydroxylase; Con, control; Lep, leptin; Res, 
resistin. 
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Figure  5.3: Effect of leptin and/or resistin on the activation of catecholaminergic 
neurons in the DR of rats fed a normal diet (ND) and a high fat diet (HFD) 
The number of TH-positive neurons and activated TH-positive neurons in the dorsal 
raphe (DR) from rats fed a normal diet (ND) and a high fat diet (HFD), following 
intracerebroventricular (ICV) administration of saline (control, ND n = 4, HFD n = 4; 
5 μl), leptin (ND n = 4, HFD n = 5; 7 μg in 5 μl), resistin (ND n = 4, HFD n = 4; 7 μg 
in 5 μl) and leptin + resistin (ND n = 5, HFD n = 6). * P < 0.05 compared to control. 
Abbreviations: TH, tyrosine hydroxylase; Con, control; Lep, leptin; Res, resistin. 
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Figure  5.4: Effect of leptin and/or resistin on the activation of catecholaminergic 
neurons in the NTS of rats fed a normal diet (ND) and a high fat diet (HFD) 
The number of TH-positive neurons and activated TH-positive neurons in the nucleus 
tractus solitarius (NTS) from rats fed a normal diet (ND) and a high fat diet (HFD), 
following intracerebroventricular (ICV) administration of saline (control, ND n = 4, 
HFD n = 4; 5 μl), leptin (ND n = 4, HFD n = 5; 7 μg in 5 μl), resistin (ND n = 4, HFD 
n = 4; 7 μg in 5 μl) and leptin + resistin (ND n = 5, HFD n = 6). * 0.001 < P < 0.005 
compared to control for TH; 0.0001 < P < 0.05 compared to control for Fos + TH 
ND; 0.0005 < P < 0.001 compared to control for Fos + TH HFD. + P < 0.05 
compared to resistin + leptin. # P < 0.05 HFD vs ND. Abbreviations: TH, tyrosine 
hydroxylase; Con, control; Lep, leptin; Res, resistin. 
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Figure  5.5: Effect of leptin and/or resistin on the activation of catecholaminergic 
neurons in the RVLM of rats fed a normal diet (ND) and a high fat diet (HFD) 
The number of TH-positive neurons and activated TH-positive neurons in the rostral 
ventrolateral medulla (RVLM) from rats fed a normal diet (ND) and a high fat diet 
(HFD), following intracerebroventricular (ICV) administration of saline (control, ND 
n = 4, HFD n = 4; 5 μl), leptin (ND n = 4, HFD n = 5; 7 μg in 5 μl), resistin (ND n = 
4, HFD n = 4; 7 μg in 5 μl) and leptin + resistin (ND n = 5, HFD n = 6). * 0.005 < P < 
0.05 compared to control for TH; 0.005 < P < 0.05 compared to control for Fos + TH 
ND; 0.0005 < P < 0.005 compared to control for Fos + TH HFD. # P < 0.05 HFD vs 
ND. Abbreviations: TH, tyrosine hydroxylase; Con, control; Lep, leptin; Res, resistin. 
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Figure  5.6: Photomicrographs of the effect of leptin and resistin on the activation of 
catecholaminergic neurons in the NTS of rats fed a normal diet (ND) and a high fat 
diet (HFD) 
The photomicrographs show TH-positive neurons, Fos-positive cell nuclei, and Fos + 
TH-positive neurons in nucleus tractus solitarius (NTS) of rats fed a high fat diet 
(HFD) vs normal diet (ND) following central administration of saline (control) or 
resistin combined with leptin. The black arrowheads represent Fos-positive cell 
nuclei, the black arrows represent the activated TH-positive neurons, and the white 
arrows represent the TH-positive neurons. Scale bar represents 50 µm. Abbreviations: 
TH, tyrosine hydroxylase; Con, control; Lep, leptin; Res, resistin.  
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5.3.2. Serotonergic neurons 
Effect in rats fed a ND 
In rats fed a ND, the central administration of resistin alone did not significantly 
affect the number of serotonergic neurons in the PAG, DR, RPA and RVMM (Figures 
5.7-5.10). Following leptin alone, there were no significant effects on the number of 
serotonergic neurons in the PAG, RPA and RVMM compared to control (Figures 5.7-
5.10). However, the number of serotonergic neurons was increased in the DR (P < 
0.05) following central administration of leptin compared to control (Figure 5.8). 
When leptin and resistin were administered in combination, there was a reduction in 
the number of serotonergic neurons compared to control in the RPA (P < 0.01) 
(Figure 5.9) and also compared to leptin alone in the RPA (P < 0.005) and in the PAG 
(P < 0.05) (Figures 5.7 and 5.9).  
The number of activated serotonergic neurons following central administration of 
resistin alone was not significantly different between all groups in all brain areas that 
were examined (Figures 5.7-5.10). When leptin was administered alone, the number 
of activated serotonergic neurons was increased compared to the control only in the 
DR (P < 0.001) (Figure 5.8). Following central administration of leptin and resistin in 
combination, the number of activated serotonergic neurons was increased 6 fold only 
in the RVMM when compared to the control (P < 0.0005), or to each drug 
administered alone (3.8 fold for resistin (P < 0.005), 1.8 fold for leptin (P < 0.05)) 
(Figure 5.10). However, the combination of resistin and leptin reduced the number of 
activated serotonergic neurons in the DR compared to leptin alone (P < 0.005) (Figure 
5.8). 
Effect in rats fed a HFD 
The number of serotonergic neurons and activated serotonergic neurons in the 
midbrain (PAG, DR) and medulla oblongata (RPA, RVMM) after ICV injection of 
135 
 
   
resistin or leptin alone or in combination in rats fed a HFD were not significantly 
different between groups (Figures 5.7-5.10). 
Comparison of the effects observed in rats fed a HFD vs ND 
In the PAG, the number of serotonergic neurons were less in rats fed a HFD than in 
rats fed a ND following leptin alone (P < 0.05) but not in the resistin alone or resistin 
and leptin combined groups (Figure 5.7). The number of activated serotonergic 
neurons was not significantly different between diets (Figure 5.7). 
In the DR, there were no significant differences in the number of serotonergic neurons 
for all treatment groups when comparing HFD to ND (Figure 5.8). Only leptin (P < 
0.01) administered alone decreased activated serotonergic neurons in HFD than in ND 
with the other treatment groups showing no significant differences (Figure 5.8). 
In the RPA, there was a reduction in serotonergic neurons in the control (P < 0.05) 
HFD group compared to the ND group (Figure 5.9). No significant differences 
between diets and other treatment groups were observed (Figure 5.9). There were no 
significant differences between the numbers of activated serotonergic neurons in all 
treatment groups when comparing HFD to ND (Figure 5.9). 
In the RVMM, there were no significant differences in the number of serotonergic 
neurons when comparing diets following each treatment (Figure 5.10). In regards to 
activated neurons, the combination of leptin and resistin (P < 0.01) resulted in a 
substantial decrease in activated serotonergic neurons in HFD compared to ND 
(Figures 5.10 and 5.11). The other treatments had no significant effects on the number 
of activated serotonergic neurons when compared between diets (Figure 5.10). 
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Figure  5.7: Effect of leptin and/or resistin on the activation of serotonergic neurons in 
the PAG of rats fed a normal diet (ND) and a high fat diet (HFD) 
The number of serotonergic (5HT) and activated serotonergic (Fos + 5HT) neurons in 
the periaqueductal gray (PAG) from rats fed a normal diet (ND) and a high fat diet 
(HFD), following intracerebroventricular (ICV) administration of saline (control, ND 
n = 4, HFD n = 4; 5 μl), leptin (ND n = 4, HFD n = 5; 7 μg in 5 μl), resistin (ND n = 
4, HFD n = 4; 7 μg in 5 μl) and leptin + resistin (ND n = 5, HFD n = 6). + P < 0.05 
compared to leptin and resistin combined. # P < 0.05 HFD vs ND. Abbreviations: 
Con, control; Lep, leptin; Res, resistin. 
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Figure  5.8: Effect of leptin and/or resistin on the activation of serotonergic neurons in 
the DR of rats fed a normal diet (ND) and a high fat diet (HFD) 
The number of serotonergic (5HT) and activated serotonergic (Fos + 5HT) neurons in 
the dorsal raphe (DR) from rats fed a normal diet (ND) and a high fat diet (HFD), 
following intracerebroventricular (ICV) administration of saline (control, ND n = 4, 
HFD n = 4; 5 μl), leptin (ND n = 4, HFD n = 5; 7 μg in 5 μl), resistin (ND n = 4, HFD 
n = 4; 7 μg in 5 μl) and leptin + resistin (ND n = 5, HFD n = 6). * P < 0.05 compared 
to control for 5HT; * P < 0.001 compared to control for Fos + 5HT. + P < 0.005 
compared to leptin and resistin combined. # P < 0.01 HFD vs ND. Abbreviations: 
Con, control; Lep, leptin; Res, resistin. 
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Figure  5.9: Effect of leptin and/or resistin on the activation of serotonergic neurons in 
the RPA of rats fed a normal diet (ND) and a high fat diet (HFD) 
The number of serotonergic (5HT) and activated serotonergic (Fos + 5HT) neurons in 
the raphe pallidus (RPA) from rats fed a normal diet (ND) and a high fat diet (HFD), 
following intracerebroventricular (ICV) administration of saline (control, ND n = 4, 
HFD n = 4; 5 μl), leptin (ND n = 4, HFD n = 5; 7 μg in 5 μl), resistin (ND n = 4, HFD 
n = 4; 7 μg in 5 μl) and leptin + resistin (ND n = 5, HFD n = 6). * P < 0.01 compared 
to control. + P < 0.005 compared to leptin and resistin combined. # P < 0.05 HFD vs 
ND. Abbreviations: Con, control; Lep, leptin; Res, resistin. 
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Figure  5.10: Effect of leptin and/or resistin on the activation of serotonergic neurons 
in the RVMM of rats fed a normal diet (ND) and a high fat diet (HFD) 
The number of serotonergic (5HT) and activated serotonergic (Fos + 5HT) neurons in 
the rostral ventromedial medulla (RVMM) from rats fed a normal diet (ND) and a 
high fat diet (HFD), following intracerebroventricular (ICV) administration of saline 
(control, ND n = 4, HFD n = 4; 5 μl), leptin (ND n = 4, HFD n = 5; 7 μg in 5 μl), 
resistin (ND n = 4, HFD n = 4; 7 μg in 5 μl) and leptin + resistin (ND n = 5, HFD n = 
6). * P < 0.0005 compared to control. + 0.005 < P < 0.05 compared to leptin and 
resistin combined. # P < 0.01 HFD vs ND. Abbreviations: Con, control; Lep, leptin; 
Res, resistin. 
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Figure  5.11: Photomicrographs of the effect of leptin and resistin on the activation of 
serotonergic neurons in the RVMM of rats fed a normal diet (ND) and a high fat diet 
(HFD)  
The photomicrographs show Fos-positive cell nuclei, serotonergic (5HT) and 
activated serotonergic (Fos + 5HT) neurons in the rostral ventromedial medulla 
(RVMM) of rats fed a high fat diet (HFD) vs normal diet (ND) following central 
administration of saline (control) or resistin combined with leptin. The black 
arrowheads represent Fos-positive cell nuclei, the black arrows represent the activated 
5HT-positive neurons, and the white arrows represent the 5HT-positive neurons. 
Scale bar represents 50 µm. Abbreviations: Con, control; Lep, leptin; Res, resistin. 
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5.3.3. Orexinergic neurons 
Effects in rats fed a ND 
The number of orexinergic neurons in the LHA after ICV injection of resistin or 
leptin alone or the combination in rats fed a ND was not significantly different 
between the groups (Figure 5.12). However, the number of activated orexinergic 
neurons increased in the LHA following central administration of leptin (P < 0.0001) 
or resistin (P < 0.001), alone and the combination (P < 0.0001), compared to the 
control (Figure 5.12). The combined administration of resistin and leptin induced a 
similar increase in the number of activated orexinergic neurons to that seen follow 
each hormone alone.  
Effects in rats fed a HFD 
The number of orexinergic neurons and activated orexinergic neurons in the LHA 
after ICV injection of resistin or leptin alone or in combination in rats fed a HFD were 
not significantly different between groups (Figure 5.12). 
Comparison of the effects observed in rats fed a HFD vs ND 
The numbers of activated orexinergic neurons were reduced in rats fed the HFD 
compared to ND following leptin (P < 0.0001), resistin (P < 0.005), and the 
combination of leptin and resistin (P < 0.0005) (Figures 5.12 and 5.13). The numbers 
of orexinergic neurons in the LHA were not significantly affected by diet except in 
the group administered leptin, where there was a small, but statistically significant, 
lower number of orexinergic neurons in the LHA of the HFD group (P < 0.05) (Figure 
5.12). 
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Figure  5.12: Effect of leptin and/or resistin on the activation of orexinergic neurons in 
the LHA of rats fed a normal diet (ND) and a high fat diet (HFD) 
The number of orexin-positive neurons and activated orexin-positive neurons in the 
lateral hypothalamic area (LHA) from rats fed a normal diet (ND) and a high fat diet 
(HFD), following intracerebroventricular (ICV) administration of saline (control, ND 
n = 4, HFD n = 4; 5 μl), leptin (ND n = 4, HFD n = 5; 7 μg in 5 μl), resistin (ND n = 
4, HFD n = 4; 7 μg in 5 μl) and leptin + resistin (ND n = 5, HFD n = 6). * 0.0001 < P 
< 0.001 compared to control. # P < 0.05 HFD vs ND for orexin; 0.0001< P < 0.005 
HFD vs ND for Fos + orexin. Abbreviations: Con, control; Lep, leptin; Res, resistin. 
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Figure  5.13: Photomicrographs of the effect of leptin and resistin on the activation of 
orexinergic neurons in the LHA of rats fed a normal diet (ND) and a high fat diet 
(HFD) 
The photomicrographs show orexin-positive neurons, Fos-positive cell nuclei, and 
Fos + orexin-positive neurons in lateral hypothalamic area (LHA) of rats fed a high 
fat diet (HFD) vs normal diet (ND) following central administration of saline 
(control) or resistin combined with leptin. The black arrowheads represent Fos-
positive cell nuclei, the black arrows represent the activated orexin-positive neurons, 
and the white arrows represent the orexin-positive neurons. Scale bar represents 50 
µm. Abbreviations: Con, control; Lep, leptin; Res, resistin. 
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5.4. Discussion 
The potential sites of actions for resistin in the brain, particularly in autonomic and 
cardiovascular nuclei, has been described in chapters three and four which have been 
published (177-180). Such studies provide an insight into the pathways in the brain 
contributing to central actions of resistin in metabolic or autonomic functions. 
However, the neurochemical identity of neurons that are activated by resistin remains 
poorly described. Thus, to better understand the nature of the neurochemical content 
of neurons that were affected by resistin; we investigated TH as a marker of 
catecholaminergic neurons, tryptophan hydroxylase as a marker of serotonergic 
neurons, and orexin as a marker of orexinergic neurons.  
The main findings in this report include (i) ICV injection of resistin, leptin, or resistin 
and leptin in combination significantly increased the number of activated 
catecholaminergic neurons in the PVN in ND, in the NTS and RVLM in both HFD 
and ND rats; (ii) ICV injection of leptin significantly increased the number of 
activated serotonergic neurons in the DR; (iii) resistin and leptin in combination 
significantly increased activated serotonergic in the RVMM compared to control and 
to each drug administered alone in rats fed a ND; (iv) ICV injection of resistin, leptin, 
or resistin and leptin in combination significantly increased the number of activated 
orexinergic neurons in the LHA of rats fed a ND.  
The effect of resistin and leptin alone in rats fed a ND  
In rats fed a ND, resistin increased the number of activated catecholaminergic neurons 
in the PVN, NTS and RVLM. Likewise, leptin has a similar effect on 
catecholaminergic neurons in these brain areas. Thus, this report suggests that 
catecholaminergic neurons in the PVN, NTS and RVLM were responsive to resistin 
and leptin. Our data are in agreement with previous findings showing that leptin 
receptors co-localize with catecholaminergic neurons in the PVN, NTS and RVLM 
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(216, 226). The effects of leptin mediated by catecholaminergic neurons in those 
brain regions are not known. However, leptin receptors are expressed abundantly in 
the PVN and it is known that the PVN is important in regulating body weight and 
neuroendocrine function (297). Thus, the activated catecholaminergic neurons we 
have identified in the present study may be involved in such actions.  
In the RVLM, microinjection of leptin elicited increases in RSNA and blood pressure 
(227). Catecholaminergic neurons are located in this area and have the anatomical 
connections that affect RSNA (227). Thus, the activated catecholaminergic neurons 
identified in the RVLM in this study may mediate the increase in RSNA induced by 
leptin (179, 184, 475). In the NTS, a direct injection of leptin induces increases in 
RSNA and arterial pressure (223); and together with the current study, it is suggested 
that the activated catecholaminergic neurons may be involved in this response.  
In contrast, the receptors for resistin have not been identified and the present study is 
the first to examine the neurochemical content of neurons responsive to resistin in 
these brain areas. In the present study, resistin induced similar increases in activated   
catecholaminergic neurons in the PVN, NTS and RVLM as leptin. Work from our 
laboratory has shown that resistin and leptin can induce similar increases in RSNA 
(179) and the present work would support the hypothesis that resistin acts on the same 
catecholaminergic neurons as leptin in those brain regions.  
Also, we found that resistin or leptin alone significantly increased the number of 
activated orexinergic neurons in the LHA of rats fed a ND. It is known that 
orexinergic neurons in the LHA express leptin receptors (216, 297, 310), and the 
present study supports this finding.  
On the other hand, it is not known if the receptors for resistin are expressed on 
orexinergic neurons located in the LHA and this study is the first to examine the 
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effects of resistin on orexinergic neurons in the LHA. The findings from the present 
study indicate that resistin activates orexinergic neurons in the LHA, similar to the 
effects of leptin. Since orexinergic neurons are also involved in mediating 
sympathetic outflow (251), and resistin and leptin have similar actions on 
cardiovascular outputs like RSNA, the present finding may reflect a role of 
orexinergic neurons in the action of resistin and leptin on RSNA.  
In regards to effects on serotonergic neurons, resistin did not affect the number of 
activated serotonergic neurons in any of the brain areas that were examined. 
However, leptin significantly increased the number of activated serotonergic neurons 
in the DR of rats fed a ND. This result is in agreement with previous findings that 
determined that leptin receptors are co-localized with serotonergic neurons in DR 
(216, 306). The serotonergic neurons in the DR are able to influence food 
consumption, body weight, and neuroendocrine function through projections to other 
brain areas (216, 306), thus leptin can potentially mediate these effects by activating 
serotonergic neurons in the DR. 
Our findings from the current study suggest that resistin and leptin have similar 
effects on the brain areas containing catecholaminergic neurons or orexinergic 
neurons, however resistin and leptin have different effects on serotonergic neurons. 
The effect of the combination of resistin and leptin in rats fed a ND   
Resistin and leptin in combination increased the number of activated 
catecholaminergic neurons in the PVN, NTS and RVLM of rats fed a ND but the 
increase was not greater than either hormone alone. This suggests that resistin and 
leptin may activate common catecholaminergic neurons in these brain areas. The 
combination of the two hormones also increased the number of activated orexinergic 
neurons in LHA of rats fed a ND but this increase was also not greater than that seen 
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with either hormone alone. This result suggests that leptin and resistin may activate 
common orexinergic neurons in the LHA.  
Resistin and leptin in combination significantly increased activated serotonergic 
neurons in the RVMM of rats fed a ND compared to each hormone administered 
alone, suggesting that resistin and leptin may activate independent subpopulations of 
serotonergic neurons in the RVMM. Serotonergic neurons in the RVMM are known 
to project to sympathetic preganglionic neurons located in the intermediolateral cell 
column of the spinal cord (143), and these neurons may be involved in the modulation 
of RSNA (146). Thus, this finding may support the enhancement of RSNA following 
ICV injection of resistin and leptin in combination compared with each hormone 
alone, as reported previously (179), and suggest that serotonergic neurons in the 
RVMM may be involved in this response. 
The effect of resistin and leptin alone in rats fed a HFD    
This is the first study to investigate the neurochemical content of activated neurons by 
resistin in rats fed a HFD. In these rats, resistin increased activated catecholaminergic 
neurons in the NTS and RVLM. Similar to resistin, leptin also had the same effect in 
these brain areas in HFD rats. Therefore, catecholaminergic neurons in the NTS and 
RVLM were activated by both resistin and leptin during HFD and ND feeding. This 
finding suggests that HFD does not influence the effects of resistin and leptin on 
activated catecholaminergic neurons in these brain areas compared to ND. Data from 
our laboratory indicates that resistin and leptin increases RSNA in rats fed a HFD to a 
similar level as seen in ND (469). The present finding is in agreement with the 
possibility that activation of catecholaminergic neurons in the NTS and RVLM could 
contribute to the increased RSNA.  
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On the other hand, resistin significantly reduced the number of activated 
catecholaminergic neurons in the PVN of the HFD group compared to the ND group, 
which was also observed with leptin. This implies that HFD feeding decreases the 
sensitivity of catecholaminergic neurons to resistin and leptin in the PVN.  
Also in rats fed a HFD, resistin reduced the number of activated orexinergic neurons 
in the LHA compared to the ND group. A similar result was observed with leptin, 
suggesting that HFD feeding also decreases the sensitivity of orexinergic neurons to 
resistin and leptin in the LHA. These findings in the PVN and in the LHA, would 
argue against catecholaminergic neurons in the PVN, and orexinergic neurons in the 
LHA playing a key role in the RSNA effect of resistin and leptin. These findings in 
HFD, therefore, do not support earlier views based on the findings with the ND.   
In rats fed a HFD, resistin did not affect the number of activated serotonergic neurons 
in any of the brain areas examined. This finding is also similar to that observed in rats 
fed a ND. In contrast, leptin reduced the number of activated serotonergic neurons in 
the DR of the HFD group compared to ND, suggesting that there is decreased 
sensitivity to leptin observed in this brain area due to HFD feeding. 
The effect of resistin and leptin in combination in rats fed a HFD    
In rats fed the HFD, resistin and leptin in combination increased the number of 
activated catecholaminergic neurons in the NTS and RVLM which was similar to the 
ND, suggesting that those neurons NTS and RVLM were still responsive to both 
resistin and leptin combined in HFD feeding 
However, the number of activated catecholaminergic neurons in the PVN induced by 
combined administration of resistin and leptin in HFD were less than with the ND. 
Thus, the catecholaminergic neurons in the PVN were desensitized to the combined 
effect of resistin and leptin in HFD. A similar conclusion can be made for the 
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activated orexinergic neurons in the LHA, and the activated serotonergic neurons in 
the RVMM.   
Conclusion 
In conclusion, following resistin and leptin administration, there was activation of 
catecholaminergic neurons in the PVN, NTS and RVLM and orexinergic neurons in 
the LHA. These neurons may contribute to the actions of resistin and leptin such as 
influencing RSNA but this will require specific investigation. A HFD can reduce the 
sensitivity of catecholaminergic neurons in the PVN and orexinergic neurons in the 
LHA. Thus, increased dietary fat can influence the responsiveness of some CNS 
pathways to resistin as well as leptin.  
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Chapter 6: Comparison between HFD and ND in the 
activation of catecholaminergic, serotonergic and 
orexinergic neurons after ICV injection of insulin or leptin 
combined with insulin  
6.1. Introduction  
Insulin has a well-established role in regulating plasma glucose levels. Insulin is also 
known to reduce food consumption and body weight via several mechanisms, 
including central pathways (476). Furthermore, insulin can act centrally to induce 
sympatho-excitation, especially to organs known to be involved in cardiovascular 
function such as the kidney, and the hindlimb and metabolic tissues like brown 
adipose tissue (BAT) (37). 
Leptin is known to be secreted by adipose tissue (7) and is an important adipokine and 
hormone involved in many functions in the body such as food intake, body weight 
and energy homeostasis, especially through various actions in the brain (190). Also, it 
has been reported that leptin can act on central pathways to induce increased 
sympathetic outflow to the kidney, hindlimb, and BAT (15); indicating that both 
leptin and insulin have a similar effect on these sympathetic nerve activity (SNA) 
outflows. Thus, the interaction of both these hormones is of interest.  
It is known that insulin and leptin act on neurons in various brain nuclei to exhibit 
their central functions. These areas have been identified through studies investigating 
the distribution of Fos (174-176, 181, 182, 235), a marker for increased neuronal 
activation, and on the distribution of their respective receptors. It is widely known that 
leptin receptors are expressed in several brain nuclei located in the hypothalamus, 
midbrain, and medulla oblongata (18, 190, 470). Similarly, insulin receptors are also 
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located in hypothalamic nuclei such as the paraventricular nucleus (PVN), and the 
lateral hypothalamic area (LHA) (191-193), as well as in the nucleus tractus solitarius 
(NTS), and less abundantly in the raphe pallidus (RPA) and rostral ventrolateral 
medulla (RVLM) of the medulla oblongata (194, 244). In the midbrain, insulin 
receptors are not abundantly expressed, but in low levels, in the periaqueductal gray 
(PAG) and dorsal raphe (DR) (192, 194). 
The neurochemical content of the neurons activated by leptin have been examined 
and includes catecholamines, serotonin (5HT) and orexin as shown in chapter five. 
Leptin receptors are found on catecholaminergic neurons (216, 297), serotonergic 
neurons (216) and orexinergic neurons (297, 310). In contrast, less is known about the 
co-localization of insulin receptors and the neurons containing these neurochemicals. 
High fat feeding leads to elevated plasma levels of insulin and leptin and they are 
associated with an increase in blood pressure and renal SNA (352, 477). High fat 
feeding is also known to reduce the responsiveness of leptin, as shown in chapter five, 
in particular catecholaminergic neurons in the PVN and orexinergic neurons in the 
LHA which were less responsive to leptin in a high fat diet (HFD) than in normal diet 
(ND).  
Since insulin and leptin have similar effects on renal SNA, lumbar SNA, BAT SNA 
and dietary intake; the aim of this chapter was to investigate whether insulin activates 
catecholaminergic, serotonergic, or orexinergic neurons in the brain and whether a 
HFD influences the responses by insulin. The action of insulin was also compared to 
the actions of the combination of insulin and leptin. 
6.2. Methods 
The rats were divided into two groups with each group receiving different diets; a 
high fat diet (22 % fat) or normal diet. Anaesthetized rats received microinjections of 
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saline (control), insulin and leptin alone or leptin combined with insulin into the 
lateral brain ventricle (ICV). Three hours later, the brains were perfused and dual-
label immunohistochemistry was performed to detect Fos protein and tyrosine 
hydroxylase (TH; for catecholamines) or tryptophan hydroxylase (for serotonin) or 
orexin, as explained in chapter two. Counting for Fos-positive cell nuclei and for the 
neurochemical content was done in at least two sections per brain region as described 
in chapter two. Counting was performed unilaterally per brain area except in the mid-
line structures; RPA and DR. The average number of Fos-positive cell nuclei 
(activated neurons), and dual-labelled cells were compared between treatment groups 
within diet by using one-way ANOVA. Student’s t-test was used to compare between 
diets within treatment groups. Multiple comparisons were accounted for by the Holm-
Sidak comparison test. The data following leptin alone have been discussed in chapter 
four and five and are depicted in the figures of this chapter for ease of comparison.  
6.3. Results 
6.3.1. The effect of insulin alone or combined with leptin on neuronal 
activation and catecholaminergic neurons in rats fed a ND versus HFD 
Effects in the normal diet (ND) 
Neuronal activation 
In the PVN of ND rats, the number of Fos-positive cell nuclei was increased 
following central administration of insulin alone, and the combined treatment of 
insulin and leptin compared to control (P < 0.01) (Figure 6.1). When insulin and 
leptin were combined, the effect was not significantly different from each hormone 
alone (Figure 6.1).  
In the PAG of rats fed a ND, there was a decrease in the number of Fos-positive cell 
nuclei following central administration of insulin alone or combined with leptin 
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compared to control (P < 0.05) (Figure 6.2). When insulin and leptin were 
administered together, the number of Fos-positive cell nuclei was less compared to 
leptin alone (P < 0.0005) (Figure 6.2), but there was no significant difference 
compared to insulin alone (Figure 6.2). 
In the DR, NTS, and RVLM of rats fed a ND; there were no significant differences in 
the number of Fos-positive cell nuclei following central administration of insulin 
alone or combined with leptin compared to control (Figures 6.3-6.5). When insulin 
and leptin were combined, there were no significant differences compared to the 
effects following each hormone alone (Figures 6.3-6.5).  
Activation of catecholaminergic neurons  
There were no significant differences in the number of catecholaminergic neurons 
counted in all the brain regions examined (Figures 6.1-6.5). Of the brain areas 
examined, only in the medulla oblongata was there a significant activation of 
catecholaminergic neurons.  
In the NTS of rats fed a ND, central insulin alone or combined with leptin increased 
the number of activated catecholaminergic neurons compared to control (P < 0.005) 
(Figures 6.4 and 6.6). The effects of insulin or leptin alone were not significantly 
different from the combined treatment (Figure 6.4).  
Similarly, in the RVLM; insulin alone or combined with leptin increased the number 
of activated catecholaminergic neurons compared to control (P < 0.05) (Figure 6.5). 
There were no significant differences between the combined treatment and insulin or 
leptin alone (Figure 6.5). 
In all other regions examined (PVN, PAG and DR), there were no activated 
catecholaminergic neurons following insulin alone or combined with leptin (i.e. the 
average of activated catecholaminergic neurons was less than one) (Figure 6.1-6.3).  
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However, in the PVN, the effect of insulin and leptin combined on activated 
catecholaminergic neurons was less compared to leptin alone (P < 0.0005) (Figure 
6.1).  
Effects in the high fat diet (HFD) 
Neuronal activation 
In the PVN of rats fed a HFD, there were no significant changes in the number of 
Fos-positive cell nuclei following insulin alone or insulin combined with leptin 
compared to control (Figure 6.1). Combined treatment was also not significantly 
different compared to insulin or leptin administered alone (Figure 6.1).  
In the PAG, insulin (P < 0.01) alone or insulin combined with leptin (P < 0.05) 
decreased the number of Fos-positive cell nuclei compared to control (Figure 6.2). 
There were no significant effects observed between insulin and leptin combined 
compared to insulin or leptin alone (Figure 6.2). 
In the DR, the number of Fos-positive cell nuclei decreased following central 
administration of insulin alone (P < 0.05) compared to control. There were no other 
significant differences between groups (Figure 6.3). 
In the NTS, administration of insulin (P < 0.0005) alone or the combination of insulin 
and leptin (P < 0.01) resulted in a reduction in the number of Fos-positive cell nuclei 
compared to control (Figure 6.4). When insulin and leptin were administered together, 
the number of Fos-positive cell nuclei was less than following leptin alone (P < 
0.005), but not insulin alone (Figure 6.4). 
In the RVLM, the number of Fos-positive cell nuclei was reduced following central 
administration of insulin alone (P < 0.05) (Figure 6.5). However, there were no 
significant differences from the control following insulin and leptin combined, but the 
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combination did result in lower number of Fos-positive cell nuclei compared to leptin 
alone (P < 0.005) (Figure 6.5).  
Activation of catecholaminergic neurons  
There were no significant differences between treatments in the number of activated 
catecholaminergic neurons in the PVN, PAG, and DR of rats fed a HFD (Figures 6.1-
6.3). Only in the medulla oblongata was there a significant change in the number of 
activated catecholaminergic neurons in HFD rats. Compared to control, in the NTS, 
insulin alone had no significant effect on the number of activated catecholaminergic 
neurons. By contrast, the combination of insulin and leptin increased the number of 
activated catecholaminergic neurons (P < 0.0005) (Figures 6.4 and 6.6). This effect 
was similar to leptin alone (Figure 6.4).  
In the RVLM, central administration of insulin (P < 0.05), or insulin combined with 
leptin (P < 0.005) there was a higher number of activated catecholaminergic neurons 
of rats fed a HFD when compared to the control (Figure 6.5). However, the 
combination of insulin and leptin did not induce a significantly different response 
than each hormone alone (Figure 6.5). 
There were some effects on the number of catecholaminergic neurons following the 
hormone treatment. In the RVLM, insulin alone and in combination with leptin there 
was a higher the number of catecholaminergic neurons compared to control (P < 
0.0001) (Figure 6.5).  
In the DR, this was also observed with insulin alone (P < 0.05) (Figure 6.3). By 
contrast, insulin alone reduced the number of catecholaminergic neurons in the PAG 
compared to control (P < 0.01) (Figure 6.2).  
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In the PVN and NTS, insulin alone had no effect, but when combined with leptin, 
there was an increase in the number of catecholaminergic neurons compared to 
control (P < 0.05, P < 0.001 respectively) (Figures 6.1 and 6.4). 
Compared to insulin alone, the combination of insulin and leptin saw an increase in 
the number of catecholaminergic neurons in the PAG and NTS (P < 0.05) (Figures 6.2 
and 6.4). 
Effects of the HFD versus ND 
Neuronal activation 
Between diets, there were significant differences in the number of Fos-positive nuclei 
after administration of insulin alone or in combination with leptin in the PVN, NTS 
and RVLM (Figures 6.1, 6.4 and 6.5) but not in the midbrain regions (Figures 6.2 and 
6.3). The number of Fos-positive nuclei in each region was lower in rats fed a HFD 
following central insulin administration (P < 0.0005 PVN; P < 0.005 NTS; P < 0.05 
RVLM) (Figures 6.1, 6.4 and 6.5). Only in medulla oblongata did the combination of 
insulin and leptin reduce the number of Fos-positive nuclei in rats fed a HFD (P < 
0.05 NTS; P < 0.005 RVLM) (Figures 6.4 and 6.5).  
Activation of catecholaminergic neurons  
The number of catecholaminergic neurons were not significantly different following 
central administration of insulin alone or insulin with leptin together in all brain 
regions examined (Figures 6.1-6.5).  
Central insulin decreased the number of activated catecholaminergic neurons in the 
NTS of rats fed a HFD compared to ND (P < 0.05) (Figure 6.4). This was the only 
significant difference detected between the diets (Figures 6.1-6.5).  
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Figure  6.1: Effect of insulin and/or leptin on the distribution of Fos-positive cell 
nuclei and the activation of catecholaminergic neurons in the PVN of rats fed a 
normal diet (ND) and a high fat diet (HFD) 
The number per section of Fos-positive cell nuclei, TH-positive, and activated TH-
positive neurons in the paraventricular nucleus (PVN) of rats fed a normal diet (ND) 
or high fat diet (HFD) after central administration of saline (control, ND n = 4, HFD n 
= 4; 5 μl), insulin (ND n = 4, HFD n = 5;  500mU/5 μl), leptin (ND n = 4, HFD n = 5; 
7 μg in 5 μl) and insulin + leptin (ND n = 4, HFD n = 6). * 0.005 < P < 0.01 for Fos, P 
< 0.05 for TH and P < 0.0001 for Fos + TH compared to control. + P < 0.0005 
compared to insulin + leptin. # P < 0.0005 for Fos HFD vs ND, and P < 0.05 for Fos 
+ TH. Abbreviations: TH, tyrosine hydroxylase; Con, control; Ins, insulin; Lep, 
leptin. 
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Figure  6.2: Effect of insulin and/or leptin on the distribution of Fos-positive cell 
nuclei and the activation of catecholaminergic neurons in the PAG of rats fed a 
normal diet (ND) and a high fat diet (HFD) 
The number per section of Fos-positive cell nuclei, TH-positive, and activated TH-
positive neurons in the periaqueductal gray (PAG) of rats fed a normal diet (ND) or 
high fat diet (HFD) after central administration of saline (control, ND n = 4, HFD n = 
4; 5 μl), insulin (ND n = 4, HFD n = 5;  500mU/5 μl), leptin (ND n = 4, HFD n = 5; 7 
μg in 5 μl) and insulin + leptin (ND n = 4, HFD n = 6). * 0.01 < P < 0.05 for Fos and 
P < 0.01 for TH compared to control. + P < 0.0005 for Fos and + P < 0.05 for TH 
compared to insulin + leptin. Abbreviations: TH, tyrosine hydroxylase; Con, control; 
Ins, insulin; Lep, leptin. 
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Figure  6.3: Effect of insulin and/or leptin on the distribution of Fos-positive cell 
nuclei and the activation of catecholaminergic neurons in the DR of rats fed a normal 
diet (ND) and a high fat diet (HFD) 
The number per section of Fos-positive cell nuclei, TH-positive, and activated TH-
positive neurons in the dorsal raphe (DR) of rats fed a normal diet (ND) or high fat 
diet (HFD) after central administration of saline  (control, ND n = 4, HFD n = 4; 5 μl), 
insulin (ND n = 4, HFD n = 5;  500mU/5 μl), leptin (ND n = 4, HFD n = 5; 7 μg in 5 
μl) and insulin + leptin (ND n = 4, HFD n = 6). * P < 0.05 compared to control. 
Abbreviations: TH, tyrosine hydroxylase; Con, control; Ins, insulin; Lep, leptin. 
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Figure  6.4: Effect of insulin and/or leptin on the distribution of Fos-positive cell 
nuclei and the activation of catecholaminergic neurons in the NTS of rats fed a 
normal diet (ND) and a high fat diet (HFD) 
The number per section of Fos-positive cell nuclei, TH-positive, and activated TH-
positive neurons in the nucleus tractus solitarius (NTS) of rats fed a normal diet (ND) 
or high fat diet (HFD) after central administration of  (control, ND n = 4, HFD n = 4; 
5 μl), insulin (ND n = 4, HFD n = 5;  500mU/5 μl), leptin (ND n = 4, HFD n = 5; 7 μg 
in 5 μl) and insulin + leptin (ND n = 4, HFD n = 6).  * 0.0005 < P < 0.01 for Fos,   P 
< 0.0005 for TH, and 0.0005 < P < 0.005 for Fos + TH compared to control. + P < 
0.005 for Fos, P < 0.05 for TH, and P < 0.05 for Fos + TH compared to insulin + 
leptin. # 0.005 < P < 0.05 for Fos HFD vs ND, and P < 0.05 for Fos + TH HFD vs 
ND. Abbreviations: TH, tyrosine hydroxylase; Con, control; Ins, insulin; Lep, leptin. 
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Figure  6.5: Effect of insulin and/or leptin on the distribution of Fos-positive cell 
nuclei and the activation of catecholaminergic neurons in the RVLM of rats fed a 
normal diet (ND) and a high fat diet (HFD) 
The number per section of Fos-positive cell nuclei, TH-positive, and activated TH-
positive neurons in the rostral ventrolateral medulla (RVLM) of rats fed a normal diet 
(ND) or high fat diet (HFD) after central administration of saline (control, ND n = 4, 
HFD n = 4; 5 μl), insulin (ND n = 4, HFD n = 5;  500mU/5 μl), leptin (ND n = 4, 
HFD n = 5; 7 μg in 5 μl) and insulin + leptin (ND n = 4, HFD n = 6). * P < 0.05 for 
Fos, P < 0.0001 for TH and 0.005 < P < 0.05 for Fos + TH compared to control. + P < 
0.005 compared to insulin + leptin. # 0.005 < P < 0.05 HFD vs ND. Abbreviations: 
TH, tyrosine hydroxylase; Con, control; Ins, insulin; Lep, leptin. 
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Figure  6.6: Photomicrographs of the effect of insulin and leptin on the activation of 
catecholaminergic neurons in the NTS of rats fed a normal diet (ND) and a high fat 
diet (HFD) 
The photomicrographs show TH-positive neurons, Fos-positive cell nuclei, and Fos + 
TH-positive neurons in the nucleus tractus solitarius (NTS) of rats fed a high fat diet 
(HFD) vs normal diet (ND) following central administration of saline (control) or 
insulin combined with leptin. The black arrowheads represent Fos-positive cell nuclei, 
the black arrows represent the activated TH-positive neurons, and the white arrows 
represent the TH-positive neurons. Scale bar represents 50 µm. Abbreviations: TH, 
tyrosine hydroxylase; Con, control; Lep, leptin; Ins, insulin. 
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6.3.2. The effect of insulin alone or combined with leptin on neuronal 
activation and serotonergic neurons in rats fed a ND versus HFD  
Effects in the ND 
Neuronal activation 
In the RPA and RVMM of rats fed a ND, there were no significant changes between 
groups in the number of Fos-positive cell nuclei following central administration of 
insulin alone or combined with leptin (Figures 6.7 and 6.8). 
Activation of serotonergic neurons  
There were no activated serotonergic neurons (< 1 / section) following insulin alone 
or in combination with leptin in the PAG, DR, RPA and RVMM (Figures 6.7-6.11). 
Interestingly, leptin alone increased the number of activated serotonergic neurons in 
the DR compared to insulin and leptin combined (P < 0.0001) (Figure 6.10).  
In the RPA of ND rats, central insulin (P < 0.01) administration reduced the number 
of serotonergic neurons compared to the control (Figure 6.7). 
In the DR, there was an increase in the number of serotonergic neurons in the ND 
group following central administration of insulin and leptin combined (P < 0.005) 
(Figure 6.10). 
In the RVMM and PAG, there were no effects of insulin alone on the number of 
serotonergic neurons (Figures 6.8 and 6.9). 
By contrast, in the RPA and PAG, when insulin and leptin was combined, there was a 
reduced number of serotonergic neurons compared to leptin alone (P < 0.05) (Figures 
6.7 and 6.9).  
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Effects in the HFD 
Neuronal activation 
In the RVMM of rats fed a HFD, insulin alone reduced the number of Fos-positive 
cell nuclei compared to control (P < 0.05) (Figure 6.8). But when insulin and leptin 
were combined, there was no significant difference from control detected (Figure 
6.8). In the RPA of rats fed a HFD, there were no significant differences in the 
number of Fos-positive cell nuclei between groups (Figure 6.7). 
Activation of serotonergic neurons  
There were no significant differences between groups in the number of activated 
serotonergic neurons in all brain regions examined in HFD rats (Figures 6.7-6.11). 
In both the RVMM and PAG of HFD rats, only central administration of insulin 
combined with leptin increased the number of serotonergic neurons (P < 0.05) 
(Figures 6.8 and 6.9). No other significant effects on the number of serotonergic 
neurons were observed in the regions examined (Figures 6.7 and 6.10).  
Effects of the HFD versus ND 
Neuronal activation 
There were no significant differences between diets in the number of Fos-positive 
nuclei after central administration of insulin alone or in combination with leptin when 
comparing between diets in the RPA and RVMM (Figures 6.7 and 6.8). 
Activation of serotonergic neurons  
There were no significant differences in the number of activated serotonergic neurons 
or the number of serotonergic neurons after central administration of insulin alone or 
in combination with leptin between diets in the brain areas examined (Figures 6.7-
6.10).   
165 
 
   
 
Figure  6.7: Effect of insulin and/or leptin on the distribution of Fos-positive cell 
nuclei and the activation of serotonergic neurons in the RPA of rats fed a normal diet 
(ND) and a high fat diet (HFD) 
The number per section of Fos-positive cell nuclei, serotonergic (5HT) and activated 
serotonergic (Fos + 5HT) neurons in the raphe pallidus (RPA) of rats fed a normal 
diet (ND) or high fat diet (HFD) after central administration of saline (control, ND n 
= 4, HFD n = 4; 5 μl), insulin (ND n = 4, HFD n = 5;  500mU/5 μl), leptin (ND n = 4, 
HFD n = 5; 7 μg in 5 μl) and insulin + leptin (ND n = 4, HFD n = 6). * P < 0.01 
compared to control. + P < 0.05 compared to insulin + leptin. # P < 0.05 HFD vs ND. 
Abbreviations: Con, control; Ins, insulin; Lep, leptin. 
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Figure  6.8: Effect of insulin and/or leptin on the distribution of Fos-positive cell 
nuclei and the activation of serotonergic neurons in the RVMM of rats fed a normal 
diet (ND) and a high fat diet (HFD) 
The number per section of Fos-positive cell nuclei, serotonergic (5HT) and activated 
serotonergic (Fos + 5HT) neurons in the rostral ventromedial medulla (RVMM) of 
rats fed a normal diet (ND) or high fat diet (HFD) after central administration of 
saline (control, ND n = 4, HFD n = 4; 5 μl), insulin (ND n = 4, HFD n = 5;  500mU/5 
μl), leptin (ND n = 4, HFD n = 5; 7 μg in 5 μl) and insulin + leptin (ND n = 4, HFD n 
= 6). * P < 0.05 for Fos, P < 0.05 for 5HT compared to control. Abbreviations: Con, 
control; Ins, insulin; Lep, leptin. 
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Figure  6.9: Effect of insulin and/or leptin on the distribution of Fos-positive cell 
nuclei and the activation of serotonergic neurons in the PAG of rats fed a normal diet 
(ND) and a high fat diet (HFD) 
The number per section of Fos-positive cell nuclei, serotonergic (5HT) and activated 
serotonergic (Fos + 5HT) neurons in the periaqueductal gray (PAG) of rats fed a 
normal diet (ND) or high fat diet (HFD) after central administration of saline (control, 
ND n = 4, HFD n = 4; 5 μl), insulin (ND n = 4, HFD n = 5;  500mU/5 μl), leptin (ND 
n = 4, HFD n = 5; 7 μg in 5 μl) and insulin + leptin (ND n = 4, HFD n = 6). * 0.01 < P 
< 0.05 for Fos and P < 0.05 for 5HT compared to control. + P < 0.05 compared to 
insulin + leptin. # P < 0.05 HFD vs ND. Abbreviations: Con, control; Ins, insulin; 
Lep, leptin. 
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Figure  6.10: Effect of insulin and/or leptin on the distribution of Fos-positive cell 
nuclei and the activation of serotonergic neurons in the DR of rats fed a normal diet 
(ND) and a high fat diet (HFD) 
The number per section of Fos-positive cell nuclei, serotonergic (5HT) and activated 
serotonergic (Fos + 5HT) neurons in the dorsal raphe (DR) of rats fed a normal diet 
(ND) or high fat diet (HFD) after central administration of saline (control, ND n = 4, 
HFD n = 4; 5 μl), insulin (ND n = 4, HFD n = 5;  500mU/5 μl), leptin (ND n = 4, 
HFD n = 5; 7 μg in 5 μl) and insulin + leptin (ND n = 4, HFD n = 6). * P < 0.05 for 
Fos, 0.005 < P < 0.05 for 5HT and P < 0.0001 for Fos + 5 HT compared to control. + 
P < 0.0001 compared to insulin + leptin. # P < 0.005 HFD vs ND. Abbreviations: 
Con, control; Ins, insulin; Lep, leptin. 
0
1 0
2 0
3 0
4 0
F O S  p o s itiv e
C o n Ins In s  +  L e pL e p
N D
H F D
*
0
2
4
6
8
1 0
5 H T
C o n Ins L e p
*
In s  +  L e p
*
0
1
2
3
4
5
C o n Ins In s  +  L e pL e p
F o s  +  5 H T  p o s itiv e
*
+
#
D R
N
u
m
b
e
r 
p
e
r 
s
c
e
ti
o
n
169 
 
   
 
Figure  6.11: Photomicrographs of the effect of insulin and leptin on the activation of 
serotonergic neurons in the RVMM of rats fed a normal diet (ND) and a high fat diet 
(HFD) 
The photomicrographs show Fos-positive cell nuclei, serotonergic (5HT) and 
activated serotonergic (Fos + 5HT) neurons in the rostral ventromedial medulla 
(RVMM) of rats fed a high fat diet (HFD) vs normal diet (ND) following central 
administration of saline (control) or insulin combined with leptin. The black arrow 
heads represent Fos-positive cell nuclei and the white arrows represent the 
serotonergic neurons.  Scale bar represents 50 µm. Abbreviations: Con, control; Lep, 
leptin; Ins, Insulin.  
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6.3.3. The effect of insulin alone or combined with leptin on neuronal 
activation and orexinergic neurons in rats fed a ND versus HFD 
Effects in the ND 
Neuronal activation 
In the LHA, insulin alone or combined with leptin had no significant effects on the 
number of Fos-positive cell nuclei in rats fed a ND compared to control (Figure 6.12). 
However, it was noted that the combined treatment of insulin and leptin induced less 
Fos-positive cell nuclei compared to leptin alone (P < 0.0001) but was not 
significantly different from insulin alone (Figure 6.12). 
Activation of orexinergic neurons  
Following central administration of insulin alone or in combination with leptin, there 
were no activated orexinergic neurons (< 1 / section) in the LHA of rats fed a ND. In 
contrast, the number of activated orexinergic neurons was increased by leptin alone 
compared to the control and this was significantly different from the combination of 
insulin and leptin (P < 0.0001) (Figure 6.12). 
The number of orexinergic neurons in the LHA of the ND rats were not significantly 
different between groups except following insulin and leptin combined, in which 
there was an increase compared to control (P < 0.05) (Figure 6.12). 
Effects in the HFD 
Neuronal activation 
In the LHA of HFD rats, there were no significant changes in the number of Fos-
positive cell nuclei between groups (Figure 6.12). 
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Activation of orexinergic neurons  
In the HFD rats, there were virtually no activated orexinergic neurons observed in the 
LHA. Further, the number of orexinergic neurons were not significantly different 
between groups (Figure 6.12). 
Effects of the HFD versus ND 
Neuronal activation 
No significant differences in the number of Fos-positive nuclei after central 
administration of insulin alone or insulin and leptin together in the LHA was observed 
between diets (Figure 6.12). 
Activation of orexinergic neurons  
Similarly, there were no significant changes in the number of activated orexinergic 
neurons or orexinergic neurons following insulin alone or insulin and leptin combined 
between diets in the LHA (Figure 6.12).  
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Figure  6.12: Effect of insulin and/or leptin on the distribution of Fos-positive cell 
nuclei and the activation of orexinergic neurons in the LHA of rats fed a normal diet 
(ND) and a high fat diet (HFD) 
The number per section of Fos-positive cell nuclei, orexin-positive, and activated 
orexin-positive neurons in the lateral hypothalamic area (LHA) of rats fed a normal 
diet (ND) or high fat diet (HFD) after central administration of saline (control, ND n 
= 4, HFD n = 4; 5 μl), insulin (ND n = 4, HFD n = 5;  500mU/5 μl), leptin (ND n = 4, 
HFD n = 5; 7 μg in 5 μl) and insulin + leptin (ND n = 4, HFD n = 6). * P < 0.005 for 
Fos, P < 0.05 for oerxin and P < 0.0001 for Fos + orexin compared to control. + P < 
0.0001 compared to insulin + leptin. # P < 0.05 for orexin and   P < 0.0001 for Fos + 
orexin HFD vs ND. Abbreviations: Con, control; Ins, insulin; Lep, leptin. 
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Figure  6.13: Photomicrographs of the effect of insulin and leptin on the activation of 
orexinergic neurons in the LHA of rats fed a normal diet (ND) and a high fat diet 
(HFD) 
The photomicrographs show orexin-positive neurons, Fos-positive cell nuclei, and 
Fos + orexin-positive neurons in the lateral hypothalamic area (LHA) of rats fed a 
high fat diet (HFD) vs normal diet (ND) following central administration of saline 
(control) or insulin combined with leptin. The black arrowheads represent Fos-
positive cell nuclei and the white arrows represent the orexin-positive neurons. Scale 
bar represents 50 µm. Abbreviations: Con, control; Lep, leptin; Ins, insulin. 
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6.4. Discussion 
The present study investigated whether areas in the brain involved in cardiovascular 
and metabolic function were activated by insulin alone or in combination with leptin, 
and also determined whether these treatments activated catecholaminergic, 
serotonergic, or orexinergic neurons in these brain areas. 
Neuronal activation  
The main findings in the present work are that (i) only in the PVN of rats fed a ND 
did insulin alone or combined with leptin significantly increase neuronal activation, 
and this effect of insulin alone was attenuated by a HFD; (ii) in the PAG, a decrease 
in neuronal activation was observed following insulin alone or in combination with 
leptin and this was observed in both diets; (iii) in the NTS and RVLM, there was a 
decrease in neuronal activation due to administration of insulin alone in HFD rats, and 
this was significantly different from ND rats. 
In the current study, insulin alone significantly increased neuronal activation in the 
PVN of ND rats. Further, when the insulin and leptin combination was administered, 
the neuronal activation was not greater than each hormone alone. This result suggests 
that insulin and leptin may activate the same population of neurons in the PVN. These 
results differ from our previous findings, in which the effect of insulin alone or 
combined with leptin on neuronal activation in the PVN did not reach statistical 
significance, though the trend was for increased activation (235). The difference in 
the studies may be due to using more sections for the data collection in the present 
work.   
Also, the present work found that in rats fed a HFD, the response of insulin alone on 
neuronal activation in the PVN was attenuated. This finding is in agreement with an 
earlier study which found impaired insulin signalling in the hypothalamus of obese 
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rats (478). Therefore, taken together, these findings suggest that HFD-induced obesity 
can lead to insulin resistance in the hypothalamus.  
The PVN is known to mediate insulin-evoked increases in LSNA (237, 238), and the 
PVN may also mediate the effect of insulin on RSNA as neurons in the PVN express 
melanocortin-4 receptors (479). Activation of melanocortin-4 receptors mediate the 
RSNA response of insulin (475). Thus, increased neuronal activation by insulin in this 
brain area could be involved in these responses and a HFD may attenuate these effects 
of insulin. 
In contrast to the PVN, central administration of insulin alone significantly decreased 
neuronal activation in the PAG in both ND and HFD rats. This observation suggests 
that insulin has an inhibitory effect on PAG neurons. A previous study found that ICV 
injection of insulin was able to attenuate pressor responses elicited by electrical 
stimulation of the PAG (480), and this would support the present findings of insulin-
induced inhibition of PAG neurons. 
Furthermore, insulin combined with leptin significantly decreased neuronal activation 
in the PAG of rats fed a ND and a HFD compared to control. A decrease in neuronal 
activation was seen with insulin alone but not leptin alone which suggests that insulin 
may be the key mediator of the reduced responses in the PAG. 
In agreement with the data in the PVN, the findings in the RVLM and NTS suggest 
that HFD can influence the responses to insulin. It was found that the neuronal 
activation in response to insulin in the HFD was significantly less than in the ND in 
the RVLM and NTS. Thus, the data suggests that in some key brain nuclei involved in 
cardiovascular regulation, the effects of insulin are reduced by HFD.  
Furthermore, when insulin and leptin were combined in rats fed a HFD, there was a 
reduction in neuronal activation in the NTS and RVLM compared to ND. This may be 
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due to a reduced sensitivity to insulin. Additionally, since insulin has been shown to 
impair leptin signalling in peripheral tissues (481, 482), and the brain (483), it may be 
possible that this action could contribute to the reduced neuronal activation seen with 
the combination of insulin and leptin. However, it is unlikely to be a major 
contributor in the NTS and RVLM in a normal condition since no such interaction 
was observed in rats fed a ND.  
Activation of catecholaminergic neurons  
The main findings with respect to the activation of catecholaminergic neurons is that 
(i) insulin alone or in combination with leptin increased activation of 
catecholaminergic neurons in the RVLM of both ND and HFD rats; (ii) the activation 
of catecholaminergic neurons was increased following insulin alone or in combination 
with leptin in the NTS of ND rats, but there was an increase only following the 
combination of insulin and leptin in HFD rats.  
Of the all the brain regions examined in rats fed a ND, only in the medulla oblongata 
were significant effects on catecholaminergic neurons observed. Insulin alone or 
combined with leptin significantly increased activation of catecholaminergic neurons 
in the NTS and RVLM of ND rats. These findings are in agreement with studies that 
show insulin receptors are present in the NTS and RVLM (194, 244), and that they 
are co-localized with catecholaminergic neurons in the RVLM (325). Furthermore, 
infusion of insulin directly into the RVLM caused activation of catecholaminergic 
neurons in this region (325). The sympathetic premotor neurons in the RVLM are 
known to project to the intermediolateral cell column of the spinal cord and their 
activation leads to sympatho-excitation and increases in blood pressure (51, 148, 
149). Findings in our laboratory showed that there was an increase in RSNA 
following insulin alone and the combination of insulin and leptin (235). The present 
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findings suggest that catecholaminergic neurons in the RVLM may be involved in the 
RSNA response. However, this view is revisited later due to the finding in HFD rats.  
Following a HFD, there was also an increase in the number of activated 
catecholaminergic neurons in the RVLM and NTS following the combined treatment 
of insulin and leptin and this was similar to the response observed in the ND. 
Similarly in the RVLM, insulin induced an increase in the number of activated 
catecholaminergic neurons following HFD which was not significantly different from 
that seen in ND. The results suggest that catecholaminergic neurons in the RVLM and 
NTS contribute to the actions of insulin and leptin in combination. There are no 
studies that have examined the actions of insulin and leptin on catecholaminergic 
neurons in animals fed a HFD. However, unpublished observations from our 
laboratory have examined the RSNA responses. Those observations show, 
unexpectedly, that insulin and leptin combined induced a reduction in RSNA in rats 
fed a HFD (unpublished observations) despite each hormone alone having sympatho-
excitatory effects on RSNA in HFD (unpublished observations) (469). Thus, taking 
the data from ND and HFD together, it would appear that our earlier suggestion of a 
role of the catecholaminergic neurons in the RSNA response may not be correct.  
Activation of serotonergic neurons  
The main findings observed in regards to serotonergic neurons are that insulin alone 
or in combination with leptin do not activate serotonergic neurons in the brain areas 
examined.  
However, leptin administered alone did increase the activation of serotonergic 
neurons in the DR and this was significantly different from insulin and leptin 
combined. Thus, this suggests that insulin interferes with the action of leptin on 
serotonergic neurons in this brain area. 
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Activation of orexinergic neurons  
No significant effects on orexinergic neurons were observed following administration 
of insulin in the LHA, an area that expresses low density of insulin receptors 
compared to other brain areas examined in these studies (192, 194). Thus, the 
evidence supports the view that insulin does not have a marked action on the 
orexinergic neurons in this brain area. 
However, leptin alone increased activation of orexinergic neurons but insulin and 
leptin in combination did not. This is consistent with the findings in the previous 
chapter which suggested that orexinergic neurons in the LHA are sensitive to leptin, 
and with the current suggestion that insulin may interfere with the action of leptin in 
the LHA as well as the DR.  
Limitations of the present study  
The limitation of the present study is the small numbers of activated neurons 
observed. This is particularly relevant to the catecholaminergic neurons. Thus, one 
needs to keep this limitation in mind.  
Conclusion 
In conclusion, insulin induced neuronal activation in the PVN in rats fed a ND but 
this was attenuated by a HFD. Also, insulin induced activation of catecholaminergic 
neurons in the RVLM in both dietary conditions. Despite the limitations, the data 
could suggest that catecholaminergic neurons in the RVLM are involved in the 
actions of insulin and leptin alone or in combination but based on unpublished 
observations, the actions are unlikely to involve the RSNA. Metabolic and other 
cardiovascular functions may be involved but this requires further investigation. 
Finally, my findings also suggest that insulin may reduce the action of leptin on 
catecholaminergic neurons of the PVN, serotonergic neurons of the DR, and 
orexinergic neurons in the LHA. 
179 
 
   
Chapter 7: Comparison between HFD and ND in the 
activation of catecholaminergic, serotonergic and 
orexinergic neurons after ICV injection of insulin combined 
with resistin 
7.1. Introduction 
Insulin and its receptors are present in the brain (191-194, 244, 484) and it is known 
that central insulin exerts its effects on food intake and body weight via these 
receptors (476, 485). Also, insulin can act centrally to induce an increase in 
sympathetic nerve activity (SNA) to brown adipose tissue (BAT), hindlimb and the 
kidney (37).  
Similar to insulin, central resistin can induce increases in renal sympathetic nerve 
activity (RSNA) and lumbar sympathetic nerve activity (LSNA), although SNA to the 
BAT is reduced (177, 458). Resistin has been found to be expressed in the 
hypothalamus (230) and also acts to regulate energy homeostasis (178), and food 
intake (178, 365, 486). The central sites of action for resistin are not well understood, 
although several studies have used the distribution of Fos to determine neuronal 
activation by central resistin and identify potential sites of action (177-179). 
Earlier in this thesis, I investigated the effects of insulin or resistin on 
catecholaminergic, serotonergic, and orexinergic neurons. Both insulin and resistin 
were found to mainly affect medullary catecholaminergic neurons. Resistin was also 
found to influence the activity of orexinergic neurons, however both insulin and 
resistin did not alter the activity of serotonergic neurons. These findings suggest that 
insulin and resistin may have some similar actions that are mediated by medullary 
catecholaminergic neurons.  
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Increased adiposity leads to increases in resistin and insulin plasma levels (21, 477, 
487, 488). There is a possibility of the combination of insulin and resistin interacting 
on some catecholaminergic neurons, since resistin has been previously shown to have 
a role in the development of insulin resistance (362, 489, 490).  
The present study will investigate the effects of insulin and resistin in combination on 
the activation of catecholaminergic, serotonergic, and orexinergic neurons in the brain 
of rats fed a normal diet (ND). Since a high fat diet (HFD) may influence the effects 
of insulin on catecholaminergic neurons (as shown in chapter six), the effect of 
insulin and resistin in combination in HFD was also investigated.  
7.2. Methods 
Rats were separated into two groups; one receiving a high fat diet and the other 
receiving a normal diet. Anaesthetized rats received intracerebroventricular (ICV) 
injections of saline (control), resistin and insulin alone or insulin combined with 
resistin. Three hours later, the brains were perfused and dual-label 
immunohistochemistry was performed to detect Fos protein and tyrosine hydroxylase 
(TH; for catecholamines) or tryptophan hydroxylase (for serotonin) or orexin. 
Detection and quantification of neurons containing these were conducted using 
methods described in chapter two. The average number of Fos-positive cell nuclei, 
neurochemical-positive neurons and activated neurons containing a neurochemical 
were compared between treatment groups within diet by using one-way ANOVA. The 
student’s t-test was used to compare between diets within each treatment group. 
Multiple comparisons were accounted for by the Holm-Sidak comparison test. The 
data following insulin (chapter six) or resistin alone (chapter four and five) have been 
previously discussed and are depicted in the figures of this chapter for comparison. 
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7.3. Results 
7.3.1. The effect of insulin combined with resistin on neuronal activation and 
catecholaminergic neurons in rats fed a ND versus HFD 
Effects in the normal diet (ND) 
Neuronal activation 
In the brain areas examined of ND rats that contained catecholaminergic neurons 
(Figures 7.1, 7.3, 7.4, and 7.5), only in the PAG was there a lower number of Fos-
positive cell nuclei following central administration of insulin combined with resistin 
(P < 0.01 compared to control) (Figure 7.2).  
In some brain areas, the effects of insulin and resistin combined were significantly 
lower than either hormone alone. In the PVN, PAG and NTS, the number of Fos-
positive cell nuclei was lower than resistin alone (P < 0.05, P < 0.0001 and P < 0.05 
respectively) (Figures 7.1, 7.2 and 7.4). Only in the PVN, was the number of Fos-
positive cell nuclei less than insulin alone (P < 0.05) (Figure 7.1).  
Activation of catecholaminergic neurons 
In all brain areas examined there were no significant differences in the number of 
activated catecholaminergic neurons following the administration of resistin and 
insulin in combination compared to control (Figures 7.1-7.6). However, there were 
significant differences compared to either hormone alone. Of the areas examined, 
only in the PVN, NTS and RVLM did the combination of both hormones result in less 
numbers of activated catecholaminergic neurons compared to resistin alone (P < 
0.0001, P < 0.0005 and P < 0.05 respectively) (Figures 7.1, 7.4 and 7.5). Compared to 
insulin alone, there was less number of activated catecholaminergic neurons following 
the combined treatment only in the medulla oblongata (P < 0.05 NTS and RVLM) 
(Figures 7.4 and 7.5).  
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There were no significant differences between control and the combination of resistin 
and insulin in the number of catecholaminergic neurons in the PVN, DR, and RVLM 
of rats fed a ND (Figures 7.1, 7.3, and 7.5). Significant differences were found only in 
the PAG and NTS compared to resistin alone. In those regions insulin and resistin in 
combination reduced the number of catecholaminergic neurons (P < 0.01 and P < 0.05 
respectively compared to resistin alone) (Figures 7.2 and 7.4).  
Effects in the high fat diet (HFD) 
Neuronal activation 
In rats fed a HFD, insulin combined with resistin reduced the number of Fos-positive 
cell nuclei in the PAG, NTS and RVLM compared to control (P < 0.01 PAG; P < 
0.005 NTS and RVLM) (Figures 7.2, 7.4 and 7.5). The combined treatment also 
resulted in lower number of Fos-positive cell nuclei than resistin alone in the NTS (P 
< 0.005) and RVLM (P < 0.0005) (Figures 7.4 and 7.5). However, there were no 
significant differences in the number of Fos-positive cell nuclei in the PVN and DR 
between groups (Figures 7.1 and 7.3).  
Activation of catecholaminergic neurons 
Significant changes in the number of activated catecholaminergic neurons were only 
detected in the medulla oblongata, and not the other brain areas that were examined, 
of rats fed a HFD (Figures 7.1-7.3). The combination of insulin and resistin was found 
to have a lower number of activated catecholaminergic neurons in the NTS and 
RVLM compared to resistin alone (P < 0.05) (Figures 7.4 and 7.5). The number of 
activated catecholaminergic neurons in these regions, however, was not significantly 
different from control (Figures 7.4-7.6). 
The number of catecholaminergic neurons, were increased following insulin and 
resistin in combination in the DR, NTS and RVLM of rats fed a HFD compared to 
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control (P < 0.05, P < 0.01 and P < 0.05 respectively) (Figures 7.2, 7.4, and 7.5); with 
no significant changes in the PVN or PAG (Figures 7.1 and 7.3).  
Effects of the HFD versus ND 
Neuronal activation 
There were no significant differences in the number of Fos-positive cell nuclei when 
comparing between diets in all brain areas examined (Figures 7.1, 7.2, 7.3, and 7.5), 
except in the NTS in which the combination of insulin and resistin reduced the 
number of Fos-positive cell nuclei in rats fed a HFD compared to ND (P < 0.005) 
(Figure 7.4).  
Activation of catecholaminergic neurons 
There were no significant changes in the number of activated catecholaminergic 
neurons when comparing between diets in the all the brain areas examined (Figures 
7.1-7.5). However, the number of catecholaminergic neurons was increased in the 
NTS following insulin combined with resistin in rats fed a HFD compared to ND (P < 
0.05) (Figure 7.4). 
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Figure  7.1: Effect of insulin and/or resistin on the distribution of Fos-positive cell 
nuclei and the activation of catecholaminergic neurons in the PVN of rats fed a 
normal diet (ND) and a high fat diet (HFD) 
The number per section of Fos-positive cell nuclei, TH-positive, and activated TH-
positive neurons in the paraventricular nucleus (PVN) of rats fed a normal diet (ND) 
or high fat diet (HFD) after central administration of saline (control, ND n = 4, HFD n 
= 4; 5 μl), insulin (ND n = 4, HFD n = 5;  500mU/5 μl), resistin (ND n = 4, HFD n = 
4; 7 μg in 5 μl) and insulin + resistin (ND n = 4, HFD n = 5). * 0.005 < P < 0.01 for 
Fos, and P < 0.0001 for Fos + TH compared to control. + P < 0.05 for Fos, and P < 
0.0001 for Fos + TH compared to insulin + resistin. # P < 0.0005 for Fos HFD vs ND, 
and P < 0.05 for Fos + TH HFD vs ND. Abbreviations: TH, tyrosine hydroxylase; 
Con, control; Ins, insulin; Res, resistin. 
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Figure  7.2: Effect of insulin and/or resistin on the distribution of Fos-positive cell 
nuclei and the activation of catecholaminergic neurons in the PAG of rats fed a 
normal diet (ND) and a high fat diet (HFD) 
The number per section of Fos-positive cell nuclei, TH-positive, and activated TH-
positive neurons in the periaqueductal gray (PAG) of rats fed a normal diet (ND) or 
high fat diet (HFD) after central administration of saline (control, ND n = 4, HFD n = 
4; 5 μl), insulin (ND n = 4, HFD n = 5;  500mU/5 μl), resistin (ND n = 4, HFD n = 4; 
7 μg in 5 μl) and insulin + resistin (ND n = 4, HFD n = 5). * 0.001 < P < 0.05 for Fos 
ND, P < 0.01 for Fos HFD, and P < 0.05 for TH HFD compared to control. + P < 
0.0001 for Fos, and P < 0.01 for TH compared to insulin + resistin. # P < 0.05 HFD vs 
ND. Abbreviations: TH, tyrosine hydroxylase; Con, control; Ins, insulin; Res, resistin. 
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Figure  7.3: Effect of insulin and/or resistin on the distribution of Fos-positive cell 
nuclei and the activation of catecholaminergic neurons in the DR of rats fed a normal 
diet (ND) and a high fat diet (HFD) 
The number per section of Fos-positive cell nuclei, TH-positive, and activated TH-
positive neurons in the dorsal raphe (DR) of rats fed a normal diet (ND) or high fat 
diet (HFD) after central administration of saline (control, ND n = 4, HFD n = 4; 5 μl), 
insulin (ND n = 4, HFD n = 5;  500mU/5 μl), resistin (ND n = 4, HFD n = 4; 7 μg in 5 
μl) and insulin + resistin (ND n = 4, HFD n = 5). * P < 0.05 compared to control. 
Abbreviations: TH, tyrosine hydroxylase; Con, control; Ins, insulin; Res, resistin. 
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Figure  7.4: Effect of insulin and/or resistin on the distribution of Fos-positive cell 
nuclei and the activation of catecholaminergic neurons in the NTS of rats fed a 
normal diet (ND) and a high fat diet (HFD) 
The number per section of Fos-positive cell nuclei, TH-positive, and activated TH-
positive neurons in the nucleus tractus solitarius (NTS) of rats fed a normal diet (ND) 
or high fat diet (HFD) after central administration of saline (control, ND n = 4, HFD n 
= 4; 5 μl), insulin (ND n = 4, HFD n = 5;  500mU/5 μl), resistin (ND n = 4, HFD n = 
4; 7 μg in 5 μl) and insulin + resistin (ND n = 4, HFD n = 5). * 0.0005 < P < 0.005 for 
Fos HFD, 0.0005 < P < 0.01 for TH, 0.001 < P < 0.05 for Fos + TH ND, and P < 
0.0005 for Fos + TH HFD compared to control. + P < 0.05 for Fos and for TH, 0.0005 
< P < 0.05 for Fos + TH ND, and P < 0.05 for Fos + TH HFD compared to insulin + 
resistin. # 0.005 < P < 0.05 for Fos, P < 0.05 for TH, and P < 0.05 for Fos + TH HFD 
vs ND. Abbreviations: TH, tyrosine hydroxylase; Con, control; Ins, insulin; Res, 
resistin. 
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Figure  7.5: Effect of insulin and/or resistin on the distribution of Fos-positive cell 
nuclei and the activation of catecholaminergic neurons in the RVLM of rats fed a 
normal diet (ND) and a high fat diet (HFD) 
The number per section of Fos-positive cell nuclei, TH-positive, and activated TH-
positive neurons in the rostral ventrolateral medulla (RVLM) of rats fed a normal diet 
(ND) or high fat diet (HFD) after central administration of saline (control, ND n = 4, 
HFD n = 4; 5 μl), insulin (ND n = 4, HFD n = 5;  500mU/5 μl), resistin (ND n = 4, 
HFD n = 4; 7 μg in 5 μl) and insulin + resistin (ND n = 4, HFD n = 5).  * 0.005 < P < 
0.01 for Fos, 0.001 < P < 0.05 for TH, P < 0.05 for Fos + TH ND, and 0.005 < P < 
0.05 for Fos + TH HFD compared to control. + P < 0.0001 for Fos, and P < 0.05 for 
Fos + TH compared to insulin + resistin. # P < 0.05 HFD vs ND. Abbreviations: TH, 
tyrosine hydroxylase; Con, control; Ins, insulin; Res, resistin. 
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Figure  7.6: Photomicrographs of the effect of insulin and resistin on the activation of 
catecholaminergic neurons in the NTS of rats fed a normal diet (ND) and a high fat 
diet (HFD) 
The photomicrographs show TH-positive neurons, Fos-positive cell nuclei, and Fos + 
TH-positive neurons in the nucleus tractus solitarius (NTS) of rats fed a high fat diet 
(HFD) vs normal diet (ND) following central administration of saline (control) or 
resistin combined with insulin. The black arrowheads represent Fos-positive cell 
nuclei, the black arrows represent the activated TH-positive neurons, and the white 
arrows represent the TH-positive neurons. Scale bar represents 50 µm. Abbreviations: 
TH, tyrosine hydroxylase; Con, control; Ins, insulin; Res, resistin. 
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7.3.2. The effect of insulin combined with resistin on neuronal activation and 
serotonergic neurons in rats fed a ND versus HFD 
Effects in the ND 
Neuronal activation 
In the ND group, there were no significant changes in the number of Fos-positive cell 
nuclei in the RPA and RVMM (Figures 7.7 and 7.8).  
Activation of serotonergic neurons 
Compared to control, no significant changes in the number of activated serotonergic 
neurons were observed in all the brain regions examined; RPA, RVMM, PAG and DR 
in the ND group (Figures 7.7-7.11). However, the combination of insulin and resistin 
increased the number of serotonergic neurons in the DR (P < 0.0005) and reduced the 
number of serotonergic neurons in the RPA (P < 0.05) of ND rats compared to control 
(Figures 7.7 and 7.10). There were no significant differences in the number of 
serotonergic neurons in the RVMM and PAG of rats fed a ND (Figures 7.8 and 7.9).  
Effects in the HFD 
Neuronal activation 
In the RVMM of rats fed a HFD, insulin combined with resistin showed a reduction 
in the number of Fos-positive cell nuclei compared to control (P < 0.05) (Figure 7.8). 
However, in the RPA, there were no significant changes in the number of Fos-positive 
cell nuclei (Figure 7.7).  
Activation of serotonergic neurons 
In HFD rats, the number of activated serotonergic neurons in all the brain regions 
examined was not significantly affected by insulin combined with resistin (Figures 
7.7-7.11). Only in the RVMM of rats fed a HFD was the number of serotonergic 
neurons higher following the combination of insulin and resistin compared to the 
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control (P < 0.05) (Figure 7.8). Also, compared to resistin, the combined treatment 
increased the number of serotonergic neurons in the RVMM and DR (P < 0.05) 
(Figure 7.8 and 7.10). 
Effects of the HFD versus ND 
Neuronal activation 
Central administration of insulin combined with resistin had no significant effects on 
the number of Fos-positive cell nuclei in the medulla oblongata (RPA and RVMM) 
between diets (Figures 7.7 and 7.8).  
Activation of serotonergic neurons 
There were no significant differences in the number of serotonergic neurons or 
activated serotonergic neurons following the combination of insulin with resistin 
between diets in all brain areas examined (Figures 7.7-7.10). 
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Figure  7.7: Effect of insulin and/or resistin on the distribution of Fos-positive cell 
nuclei and the activation of serotonergic neurons in the RPA of rats fed a normal diet 
(ND) and a high fat diet (HFD) 
The number per section of Fos-positive cell nuclei, serotonergic (5HT) and activated 
serotonergic (Fos + 5HT) neurons in the raphe pallidus (RPA) of rats fed a normal 
diet (ND) or high fat diet (HFD) after central administration of saline (control, ND n 
= 4, HFD n = 4; 5 μl), insulin (ND n = 4, HFD n = 5;  500mU/5 μl), resistin (ND n = 
4, HFD n = 4; 7 μg in 5 μl) and insulin + resistin (ND n = 6, HFD n = 5).* P < 0.05 
compared to control. # P < 0.05 HFD vs ND. Abbreviations: Con, control; Ins, 
insulin; Res, resistin. 
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Figure  7.8: Effect of insulin and/or resistin on the distribution of Fos-positive cell 
nuclei and the activation of serotonergic neurons in the RVMM of rats fed a normal 
diet (ND) and a high fat diet (HFD) 
The number per section of Fos-positive cell nuclei, serotonergic (5HT) and activated 
serotonergic (Fos + 5HT) neurons in the rostral ventromedial medulla (RVMM) of 
rats fed a normal diet (ND) or high fat diet (HFD) after central administration of 
saline (control, ND n = 4, HFD n = 4; 5 μl), insulin (ND n = 4, HFD n = 5;  500mU/5 
μl), resistin (ND n = 4, HFD n = 4; 7 μg in 5 μl) and insulin + resistin (ND n = 6, 
HFD n = 5). * 0.0005 < P < 0.05 for Fos, and P < 0.05 for 5HT compared to control. 
+ P < 0.05 compared to insulin + resistin. # P < 0.05 HFD vs ND. Abbreviations: 
Con, control; Ins, insulin; Res, resistin. 
0
5
1 0
1 5
2 0
F O S  p o s itiv e
N D
H F D
C o n Ins In s  +  R e sR e s
*
*
*# #
0
5
1 0
1 5
5 H T
*
C o n Ins In s  +  R e sR e s
+
0
1
2
3
4
5
F O S  +  5  H T  p o s itiv e
C o n Ins In s  +  R e sR e s
R V M M
N
u
m
b
e
r 
p
e
r 
s
c
e
ti
o
n
194 
 
   
 
Figure  7.9: Effect of insulin and/or resistin on the distribution of Fos-positive cell 
nuclei and the activation of serotonergic neurons in the PAG of rats fed a normal diet 
(ND) and a high fat diet (HFD) 
The number per section of Fos-positive cell nuclei, serotonergic (5HT) and activated 
serotonergic (Fos + 5HT) neurons in the periaqueductal gray (PAG) of rats fed a 
normal diet (ND) or high fat diet (HFD) after central administration of saline (control, 
ND n = 4, HFD n = 4; 5 μl), insulin (ND n = 4, HFD n = 5;  500mU/5 μl), resistin 
(ND n = 4, HFD n = 4; 7 μg in 5 μl) and insulin + resistin (ND n = 6, HFD n = 5). * 
0.001 < P < 0.05 for Fos ND, P < 0.01 for Fos HFD compared to control. + P < 
0.0001 compared to insulin + resistin. Abbreviations: Con, control; Ins, insulin; Res, 
resistin. 
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Figure  7.10: Effect of insulin and/or resistin on the distribution of Fos-positive cell 
nuclei and the activation of serotonergic neurons in the DR of rats fed a normal diet 
(ND) and a high fat diet (HFD) 
The number per section of Fos-positive cell nuclei, serotonergic (5HT) and activated 
serotonergic (Fos + 5HT) neurons in the dorsal raphe (DR) of rats fed a normal diet 
(ND) or high fat diet (HFD) after central administration of saline (control, ND n = 4, 
HFD n = 4; 5 μl), insulin (ND n = 4, HFD n = 5;  500mU/5 μl), resistin (ND n = 4, 
HFD n = 4; 7 μg in 5 μl) and insulin + resistin (ND n = 6, HFD n = 5). * P < 0.05 for 
Fos, and 0.0005 < P < 0.05 for 5HT compared to control. + P < 0.05 compared to 
insulin + resistin. Abbreviations: Con, control; Ins, insulin; Res, resistin. 
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Figure  7.11: Photomicrographs of the effect of insulin and resistin on the activation of 
serotonergic neurons in the RVMM of rats fed a normal diet (ND) and a high fat diet 
(HFD) 
The photomicrographs show Fos-positive cell nuclei, serotonergic (5HT) and 
activated serotonergic (Fos + 5HT) neurons in the rostral ventromedial medulla 
(RVMM) of rats fed a high fat diet (HFD) vs normal diet (ND) following central 
administration of saline (control) or resistin combined with insulin. The black 
arrowheads represent Fos-positive cell nuclei and the white arrows represent the 
serotonergic neurons. Scale bar represents 50 µm. Abbreviations: Con, control; Ins, 
insulin; Res, resistin.  
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7.3.3. The effect of insulin combined with resistin on neuronal activation and 
orexinergic neurons in rats fed a ND versus HFD 
Effects in the ND 
Neuronal activation 
In the LHA of rats fed a ND, the combined treatment reduced the number of Fos-
positive cell nuclei compared to resistin alone (P < 0.0001) (Figure 7.12). 
Activation of orexinergic neurons  
The number of activated orexinergic neurons in the LHA of the ND group was lower 
following the combined treatment compared to resistin alone (P < 0.0001) (Figure 
7.12). No significant difference was seen compared to control, and there were also no 
significant differences between the groups in the number of orexinergic neurons in the 
LHA of rats fed a ND (Figures 7.12 and 7.13). 
Effects in the HFD 
Neuronal activation 
In the LHA of HFD rats, the number of Fos-positive cell nuclei was not significantly 
different following the combination of insulin and resistin compared to control or 
either hormone alone (Figure 7.12). 
Activation of orexinergic neurons  
There were no significant changes in the number of orexinergic neurons or activated 
orexinergic neurons in the LHA of rats fed a HFD was observed following insulin and 
resistin in combination (Figures 7.12 and 7.13). 
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Effects of the HFD versus ND 
Neuronal activation 
When comparing between diets, there were no significant differences in the number 
of Fos-positive cell nuclei after the administration of insulin combined with resistin in 
the LHA (Figure 7.12). 
Activation of orexinergic neurons  
The number of orexinergic neurons or activated orexinergic neurons in the LHA 
following insulin combined with resistin were not significantly different between 
diets (Figure 7.12). 
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Figure  7.12: Effect of insulin and/or resistin on the distribution of Fos-positive cell 
nuclei and the activation of orexinergic neurons in the LHA of rats fed a normal diet 
(ND) and a high fat diet (HFD) 
The number per section of Fos-positive cell nuclei, orexin-positive and activated 
orexin-positive neurons in the lateral hypothalamic area (LHA) of rats fed a normal 
diet (ND) or high fat diet (HFD) after central administration of saline (control, ND n 
= 4, HFD n = 4; 5 μl), insulin (ND n = 4, HFD n = 5;  500mU/5 μl), resistin (ND n = 
4, HFD n = 4; 7 μg in 5 μl) and insulin + resistin (ND n = 6, HFD n = 4). * P < 0.005 
for Fos, and P < 0.0001 for Fos + orexin compared to control. + P < 0.0001 compared 
to insulin + resistin. # P < 0.005 HFD vs ND. Abbreviations: Con, control; Ins, 
insulin; Res, resistin. 
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Figure  7.13: Photomicrographs of the effect of insulin and resistin on the activation of 
orexinergic neurons in the LHA of rats fed a normal diet (ND) and a high fat diet 
(HFD) 
The photomicrographs show orexin-positive neurons, Fos-positive cell nuclei, and 
Fos + orexin-positive neurons in the lateral hypothalamic area (LHA) of rats fed a 
high fat diet (HFD) vs normal diet (ND) following central administration of saline 
(control) or resistin combined with insulin. The black arrowheads represent Fos-
positive cell nuclei and the white arrows represent the orexin-positive neurons. Scale 
bar represents 50 µm. Abbreviations: Con, control; Ins, insulin; Res, resistin. 
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7.4. Discussion 
This is the first study that investigated the combined effect of insulin and resistin on 
brain areas known to be involved in cardiovascular and metabolic function, and the 
activation of catecholaminergic, serotonergic, or orexinergic neurons in these brain 
areas. 
Neuronal activation 
The main findings in regards to neuronal activation in this chapter were that (i) the 
combination of insulin and resistin resulted in less neuronal activation in the PAG of 
ND and HFD fed rats compared to control, but only in the HFD was there less 
activation observed in the NTS, RVLM, and RVMM; (ii) insulin and resistin together 
resulted in less neuronal activation in the PVN, PAG, NTS, and LHA of rats fed a ND 
compared to resistin alone, and in the PVN also compared to insulin alone; and (iii) in 
the NTS and RVLM of HFD rats, there was less neuronal activation compared to 
resistin alone. 
In the PAG, insulin and resistin in combination elicited less neuronal activation than 
control and resistin alone, but was similar to insulin alone. This observation suggests 
that insulin may inhibit the response of resistin in the PAG. Previous studies found 
that resistin can induce insulin resistance (362, 489, 490). However, the current 
finding suggests that insulin may induce the development of resistance to the effects 
of resistin in the PAG. Furthermore, the response of the combined treatment in the 
PAG was similar in both diets, suggesting that the combined effect of these hormones 
is not influenced by a HFD.  
In the NTS, RVLM and RVMM, there was less neuronal activation following the 
combination of insulin and resistin compared to the saline control in rats fed the HFD. 
The effect of insulin combined with resistin in the NTS and RVLM was lower than 
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resistin alone but similar to insulin alone, which was also observed in the PAG. This 
suggests that insulin may also inhibit the effect of resistin in those regions.  
Overall, the data suggests that in the PAG, NTS and RVLM, insulin combined with 
resistin was less effective due to insulin reducing the effects of resistin. A HFD can 
contribute to this and make the effect more apparent in the NTS where neuronal 
activation, in response to insulin and resistin combined, was significantly less than in 
ND.  
In the PVN, the response to the combined treatment was not different between ND 
and HFD. However, in rats fed a ND, the combined treatment had less neuronal 
activation compared to insulin or resistin alone. This was not seen in the HFD. 
Furthermore, the sensitivity to insulin alone in the PVN was reduced in the HFD, 
since the neuronal activation induced by insulin was significantly less than in rats fed 
the ND.  
Activation of catecholaminergic neurons 
The main findings observed with respect to the activation of catecholaminergic 
neurons is that when insulin and resistin were combined, there was no evidence of 
activation of catecholaminergic neurons in any brain region examined in rats fed ND 
or HFD.  
In the PVN of ND rats, the combination of insulin and resistin resulted in a lack of 
activation of catecholaminergic neurons which was also found following insulin 
alone, but contrasted with the increase seen with resistin alone. Thus, insulin may be 
exhibiting inhibitory effects on the action of resistin in the PVN.  
In the NTS and RVLM of ND, the combined treatment resulted in a lack of activation 
of catecholaminergic neurons but each hormone alone increased the number of   
catecholaminergic neurons activated. In the HFD group, only resistin increased the 
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number of activated catecholaminergic neurons. These findings suggest that in ND, 
insulin and resistin combined appears to inhibit each other’s ability to activate 
catecholaminergic neurons. The inhibitory interaction of insulin and resistin 
combined was still evident in HFD which suggests that the interaction may be 
independent of the diet.  
Activation of serotonergic neurons 
Insulin and resistin in combination were not effective at activating serotonergic 
neurons in any of the brain areas examined in this study. Earlier in this thesis, we also 
found that insulin or resistin did not activate on serotonergic neurons.  
Activation of orexinergic neurons 
The main finding in regards to the activation of orexinergic neurons is that when 
insulin and resistin were combined, there was no evidence of activation of orexinergic 
neurons in the LHA in rats fed ND or HFD. In HFD, the combined effect of insulin 
and resistin was similar to the response of each hormone alone, but in the ND, it was 
less than the effect of resistin alone. This suggests that insulin may have an inhibitory 
effect on the action of resistin on orexinergic neurons in the LHA in rats fed a ND.  
Conclusion 
The main conclusion from the work presented in this chapter is that combining insulin 
and resistin in the brain results in an inhibitory interaction, such that there was little 
activation of neurons in the brain regions investigated. The mechanism is unknown. 
Interestingly, unpublished observations from our laboratory show that insulin 
combined with resistin does not increase RSNA, which contrasts with the effects of 
each alone. Thus, our present findings may have a functional correlation.     
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Chapter 8: The role of central administration of resistin, 
leptin, and the combination of resistin and leptin on brain 
inflammation in rats fed a high fat diet (HFD) or normal 
diet (ND).  
8.1. Introduction 
Resistin and leptin are adipokines synthesised and secreted by adipose tissue, and are 
known to be implicated in inflammatory responses and immune function (434, 443, 
491-494). Inflammation is a pathological condition which is designed to protect the 
body against harmful substances and stimuli, and usually occurs in response to tissue 
injury or damage. Inflammation is commonly linked to obesity due to the presence of 
low-grade inflammation in obese conditions (495). 
It is known that a high fat diet (HFD) can induce inflammation in both the peripheral 
tissues (373-375) and the central nervous system (CNS) (370-372). Adipose tissue 
secretes resistin and leptin which can contribute to the peripheral inflammation (442, 
496-498). It has been shown that resistin and leptin are both implicated in 
inflammatory responses associated with atherosclerosis (425-427, 440, 499-502).  
In addition to the role of leptin in peripheral inflammation and inflammatory diseases 
(493, 494, 503, 504), there is a considerable amount of evidence supporting a role of 
leptin in brain inflammation (424, 437, 439). Leptin receptors are expressed on 
microglia (435, 436, 438) which are immune cells in the CNS responsible for 
releasing pro-inflammatory cytokines such as tumor necrosis factor-alpha (TNF-α), 
interleukin 1 beta (IL-1β) and interleukin 6 (IL-6) (380), and are likely to contribute 
to the inflammatory responses of leptin. 
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In contrast to leptin, the role of resistin in brain inflammation has not been explored in 
great detail, especially the effect of resistin on microglia and cytokine activity. 
However, in a recent study, it was found that resistin upregulated IL-6 in the 
hypothalamus and also induced inflammation via toll-like receptor-4 (TLR4) 
signalling (343). Taken together, these studies suggest that leptin and resistin can 
potentially contribute to brain inflammation, thus it is important to investigate the 
combined effect of these adipokines on inflammatory responses. 
Therefore, this study investigated the effects of central resistin and leptin alone or in 
combination on (i) microglial activation, and (ii) the gene expression of the cytokines 
(TNF-α, IL-1β, IL-6) in the brain of rats fed a normal diet (ND) or high fat diet 
(HFD).  
8.2. Methods 
In this study, the rats were fed a normal diet or high fat diet (22% Fat). For each diet, 
the rats were divided into two groups; one group was used for immunohistochemistry 
to detect CD11b (clone OX42) as marker of microglia, and the other group of rats was 
used for cytokine gene expression measurements by Real-Time Polymerase Chain 
Reaction (RT-PCR).  
In the first group, anaesthetized rats received intracerebroventricular (ICV) injection 
of saline (control) (5 µl), resistin (7 µg), leptin (7 µg) or resistin and leptin in 
combination. Three hours later, the brains were perfused and immunohistochemistry 
was used to detect CD11b (clone OX42) microglial receptors and identify 
morphological changes in microglia cells. Counting was performed in accordance to 
methods described by Rana et al. (445), using light microscopy. Non-activated 
microglia were identified by their small soma and exhibited highly branched, long, 
and thin processes. Activated microglia were defined by two main criteria; (i) stronger 
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immunohistochemical staining for the marker CD11b (clone OX42) and (ii) the 
presence of a clearly enlarged soma with marked changes in the appearance with 
thicker and shorter branched processes. Only microglia with these changes were 
defined as activated. Counting was performed unilaterally as described in chapter two.  
The second group also received ICV injection of saline (control), resistin, leptin or 
resistin and leptin in combination. After three hours, the brains were removed and 
each brain was separated into four blocks (hypothalamus, ventral medulla, dorsal 
medulla and midbrain) with each tissue block divided into 2 halves, and one half was 
used to detect the expression of cytokines by PCR as described in chapter two. 
One-way ANOVA was used to compare between hormone treatment groups within 
diet for the average percentage of activated microglia and the gene fold change of 
cytokines using GraphPad Prism 7. Multiple comparisons were accounted for by the 
Holm-Sidak test. Between diets, the average percentage of activated microglia, and 
the gene fold change in cytokines were compared by using unpaired t-test and the P 
value was adjusted for multiple comparisons using the Holm-Sidak test. 
8.3. Results 
8.3.1. The percentage of activated microglia following central administration 
of resistin, leptin alone or in combination 
Lamina Terminalis 
In the OVLT and MnPO, there were no significant differences in the percentage of 
activated microglia in rats fed a normal diet (ND) or high fat diet (HFD) following 
administration of leptin or resistin alone or in combination (Figure 8.1). 
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Figure  8.1: Effect of leptin and/or resistin on microglial activation in the OVLT and 
MnPO of rats fed a normal diet (ND) and a high fat diet (HFD) 
The percentage of activated microglia in the OVLT and MnPO from rats fed a normal 
diet (ND) and a high fat diet (HFD), after intracerebroventricular (ICV) injection of 
saline (control, ND n = 4, HFD n = 4; 5 μl), leptin (ND n = 4 [n= 3 for MnPO], HFD 
n = 5; 7 μg in 5 μl), resistin (ND n = 3, HFD n = 4; 7 μg in 5 μl), or leptin combined 
with resistin (ND n = 5, HFD n = 5). Abbreviations: OVLT, organum vasculosum of 
the lamina terminalis; MnPO, median preoptic nucleus; Con, control; Lep, leptin; Res, 
resistin. 
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Hypothalamus 
Central administration of resistin and leptin alone or in combination increased the 
percentage of activated microglia in the PVN in rats fed a normal diet (ND) compared 
to the control (P < 0.05) (Figures 8.2 and 8.3). In contrast, there were no effects in the 
PVN of rats fed a HFD. There were no significant differences in the percentage of 
activated microglia in the ARC, SON, LHA, and DMH in ND or HFD rats following 
leptin or resistin alone or in combination (Figures 8.2 and 8.4). 
Midbrain 
In the PAG and DR, there were no significant differences in the percentage of 
activated microglia in rats fed a ND or HFD following administration of leptin or 
resistin alone or in combination (Figure 8.5). 
Medulla oblongata  
In the NTS, RVLM and RPA, there were no significant differences in the percentage 
of activated microglia in rats fed a ND or HFD following administration of leptin or 
resistin alone or in combination (Figure 8.6). 
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Figure  8.2: Effect of leptin and/or resistin on microglial activation in the PVN, ARC, 
and SON from rats fed a normal diet (ND) and a high fat diet (HFD) 
The percentage of activated microglia in the hypothalamus (PVN, ARC and SON) 
from rats fed a normal diet (ND) and a high fat diet (HFD), after 
intracerebroventricular (ICV) injection of saline (control, ND n = 4, HFD n = 4; 5 μl), 
leptin (ND n = 4, HFD n = 5; 7 μg in 5 μl), resistin (ND n = 4, HFD n = 4; 7 μg in 5 
μl), or leptin combined with resistin (ND n = 5, HFD n = 5). * P < 0.05 compared to 
control in the PVN. Abbreviations: PVN, paraventricular nucleus; ARC, arcuate 
nucleus; SON, supraoptic nucleus; Con, control; Lep, leptin; Res, resistin. 
0
5
1 0
1 5
2 0
2 5
 P V N
C o n R e sL e p L e p  + R e s
 N D
H F D
* *
*
0
5
1 0
1 5
 A R C
C o n R e sL e p L e p  + R e s
0
5
1 0
1 5
2 0
2 5
 S O N
C o n R e sL e p L e p  + R e s
%
 o
f 
a
c
ti
v
a
te
d
 m
ic
ro
g
li
a
210 
 
   
 
Figure  8.3: Photomicrographs of CD11b (clone OX42)-labelled microglia in the PVN 
following leptin and/or resistin of rats fed a normal diet (ND) 
The photomicrographs show microglia stained using an antibody to CD11b (OX42 
clone) in the paraventricular hypothalamic nucleus (PVN) of rats fed a normal diet (ND) 
following centrally administered saline (control; 5 μl), leptin alone (7 μg), resistin 
alone (7 μg), or leptin combined with resistin. The two boxes represent the areas that 
were counted, each box of approximately 200 µm2. Scale bar represents 100 µm. 
Abbreviations: Con, control; Lep, leptin; Res, resistin. 
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Figure  8.4: Effect of leptin and/or resistin on microglial activation in the LHA and 
DMH of rats fed a normal diet (ND) and a high fat diet (HFD) 
The percentage of activated microglia in the hypothalamus (LHA and DMH) from 
rats fed a normal diet (ND) and a high fat diet (HFD), after intracerebroventricular 
(ICV) injection of saline (control, ND n = 4, HFD n = 4; 5 μl), leptin (ND n = 4, HFD 
n = 5; 7 μg in 5 μl), resistin (ND n = 4, HFD n = 4; 7 μg in 5 μl), or leptin combined 
with resistin (ND n = 5, HFD n = 5). Abbreviations: LHA, lateral hypothalamic area; 
DMH, dorsomedial hypothalamic nucleus; Con, control; Lep, leptin; Res, resistin. 
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Figure  8.5: Effect of leptin and/or resistin on microglial activation in the PAG and DR 
of rats fed a normal diet (ND) and a high fat diet (HFD) 
The percentage of activated microglia in the midbrain (PAG and DR) from rats fed a 
normal diet (ND) and a high fat diet (HFD), after intracerebroventricular (ICV) 
injection of saline (control, ND n = 4, HFD n = 4; 5 μl), leptin (ND n = 4, HFD n = 5; 
7 μg in 5 μl), resistin (ND n = 4, HFD n = 4; 7 μg in 5 μl), or leptin combined with 
resistin (ND n = 5, HFD n = 5). Abbreviations: PAG, periaqueductal gray; DR, dorsal 
raphe; Con, control; Lep, leptin; Res, resistin. 
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Figure  8.6: Effect of leptin and/or resistin on microglial activation in the NTS, 
RVLM, and RPA of rats fed a normal diet (ND) and a high fat diet (HFD) 
The percentage of activated microglia in the medulla oblongata (NTS, RVLM and 
RPA) from rats fed a normal diet (ND) and a high fat diet (HFD), after 
intracerebroventricular (ICV) injection of saline (control, ND n = 4, HFD n = 4; 5 μl), 
leptin (ND n = 4, HFD n = 5; 7 μg in 5 μl), resistin (ND n = 4, HFD n = 4; 7 μg in 5 
μl), or leptin combined with resistin (ND n = 5, HFD n = 5). Abbreviations: NTS, 
nucleus tractus solitarius; RVLM, rostral ventrolateral medulla; RPA, raphe pallidus; 
Con, control; Lep, leptin; Res, resistin. 
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8.3.2. Cytokine (TNF-α, IL-1β, IL-6) gene expression in rat brain following 
central administration of resistin, leptin alone or in combination 
Hypothalamus 
There were no significant differences in the cytokine (TNF-α, IL-1β, IL-6) gene 
expression in the hypothalamus of rats fed a ND or HFD following central 
administration of resistin and leptin alone or in combination (Figure 8.7). 
Midbrain 
Central administration of resistin combined with leptin increased TNF-α gene 
expression by 10 fold in the midbrain of rats fed a ND compared to control (P < 
0.0005), whilst this increase was 3 fold and 2.3 fold compared to when resistin (P < 
0.01) or leptin (P < 0.005) were administered alone, respectively (Figure 8.8). In the 
HFD group, only central administration of resistin increased TNF-α gene expression 
in the midbrain compared to control (P < 0.05) (Figure 8.8). There were no significant 
differences between diet except following resistin and leptin in combination where 
TNF-α gene expression was less than ND (P < 0.01) (Figure 8.8). 
Central administration of resistin increased IL-1β gene expression in the midbrain of 
rats fed a HFD compared to control (P < 0.0001) or compared to when resistin and 
leptin were administered in combination (P < 0.0005) (Figure 8.8). There were no 
significant differences in IL-1β gene expression in midbrain of rats fed a ND or HFD 
following central administration of leptin alone or leptin combined with resistin 
(Figure 8.8). 
There were no significant differences in IL-6 gene expression in midbrain of rats fed a 
ND or HFD between all groups following central administration of resistin and leptin 
alone or in combination (Figure 8.8). 
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Figure  8.7: Effect of leptin and/or resistin on cytokine gene expression (TNF-α, IL-
1β, IL-6) in the hypothalamus of rats fed a normal diet (ND) and a high fat diet (HFD) 
The fold change of gene expression (TNF-α, IL-1β, IL-6) in the hypothalamus from 
rats fed a normal diet (ND) and a high fat diet (HFD), after intracerebroventricular 
(ICV) injection of saline (control, ND n = 4, HFD n = 4; 5 μl), leptin (ND n = 4, HFD 
n = 4; 7 μg in 5 μl), resistin (ND n = 4, HFD n = 4; 7 μg in 5 μl), or leptin combined 
with resistin (ND n = 4, HFD n = 4). Abbreviations: TNF-α, tumor necrosis factor-
alpha; IL-1β, interleukin 1 beta; IL-6, interleukin 6; Con, control; Lep, leptin; Res, 
resistin. 
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Figure  8.8: Effect of leptin and/or resistin on cytokine gene expression (TNF-α, IL-
1β, IL-6) in the midbrain of rats fed a normal diet (ND) and a high fat diet (HFD) 
The fold change of gene expression (TNF-α, IL-1β, IL-6) in the midbrain from rats 
fed a normal diet (ND) and a high fat diet (HFD), after intracerebroventricular (ICV) 
injection of saline (control, ND n = 4, HFD n = 4; 5 μl), leptin (ND n = 4, HFD n = 4; 
7 μg in 5 μl), resistin (ND n = 4, HFD n = 4; 7 μg in 5 μl), or leptin combined with 
resistin (ND n = 4, HFD n = 4). * P < 0.0005 compared to control for ND; 0.0001 < P 
< 0.05 compared to control for HFD. + 0.005 < P < 0.01 compared to leptin + resistin 
for ND; P < 0.0005 compared to leptin + resistin for HFD. # P < 0.01 HFD vs ND. 
Abbreviations: TNF-α, tumor necrosis factor-alpha; IL-1β, interleukin 1 beta; IL-6, 
interleukin 6; Con, control; Lep, leptin; Res, resistin. 
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Ventral Medulla  
In rats fed a ND, the combination of resistin and leptin increased TNF-α gene 
expression in the ventral medulla compared to control (P < 0.01) and compared to 
when leptin was administered alone (P < 0.05) (Figure 8.9). In rats fed a HFD, central 
administration of resistin alone increased TNF-α gene expression in the ventral 
medulla compared to control (P < 0.05) (Figure 8.9). Apart from these effects, no 
other significant changes in TNF-α gene expression were detected in either diet group 
(Figure 8.9).  
Central administration of resistin combined with leptin increased IL-1β gene 
expression in the ventral medulla compared to control and compared to leptin 
administered alone (P < 0.05) (Figure 8.9). Also, resistin administered together with 
leptin increased IL-6 gene expression in the ventral medulla compared to control (P < 
0.01) and compared to when resistin (P < 0.01) or leptin (P < 0.05) were administered  
alone (Figure 8.9). No other significant changes in IL-1β or IL-6 gene expression in 
the ventral medulla were detected (Figure 8.9).  
Dorsal Medulla 
In ND, combined administration of resistin with leptin increased TNF-α gene 
expression in the dorsal medulla compared to control (P < 0.05) (Figure 8.10). In 
HFD, resistin alone increased IL-1β gene expression in the dorsal medulla compared 
to control (P < 0.05) (Figure 8.10). There were no significant differences in IL-6 gene 
expression in the dorsal medulla of rats fed a ND or HFD between all groups 
following central administration of resistin and leptin alone or in combination (Figure 
8.10). 
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Figure  8.9: Effect of leptin and/or resistin on cytokine gene expression (TNF-α, IL-
1β, IL-6) in the ventral medulla of rats fed a normal diet (ND) and a high fat diet 
(HFD) 
The fold change of gene expression (TNF-α, IL-1β, IL-6) in the ventral medulla from 
rats fed a normal diet (ND) and a high fat diet (HFD), after intracerebroventricular 
(ICV) injection of saline (control, ND n = 4, HFD n = 4; 5 μl), leptin (ND n = 4, HFD 
n = 4; 7 μg in 5 μl), resistin (ND n = 4, HFD n = 4; 7 μg in 5 μl), or leptin combined 
with resistin (ND n = 4, HFD n = 4). * 0.01 < P < 0.05 compared to control for ND; P 
< 0.05 resistin compared to control for HFD. + 0.01 < P < 0.05 compared with leptin 
+ resistin for ND. Abbreviations: TNF-α, tumor necrosis factor-alpha; IL-1β, 
interleukin 1 beta; IL-6, interleukin 6; Con, control; Lep, leptin; Res, resistin. 
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Figure  8.10: Effect of leptin and/or resistin on cytokine gene expression (TNF-α, IL-
1β, IL-6) in the dorsal medulla of rats fed a normal diet (ND) and a high fat diet 
(HFD) 
The fold change of gene expression (TNF-α, IL-1β, IL-6) in the dorsal medulla from 
rats fed a normal diet (ND) and a high fat diet (HFD), after intracerebroventricular 
(ICV) injection of saline (control, ND n = 4, HFD n = 4; 5 μl), leptin (ND n = 4, HFD 
n = 4; 7 μg in 5 μl), resistin (ND n = 4, HFD n = 4; 7 μg in 5 μl), or leptin combined 
with resistin (ND n = 4, HFD n = 4). * P < 0.05 compared to control for ND; P < 0.05 
compared to control for HFD. Abbreviations: TNF-α, tumor necrosis factor-alpha; IL-
1β, interleukin 1 beta; IL-6, interleukin 6; Con, control; Lep, leptin; Res, resistin. 
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8.4. Discussion 
This chapter investigated inflammatory markers in the brain by using; 
immunohistochemistry for CD11b (clone OX42) as a marker for activated microglia; 
and RT-PCR for gene expression of pro-inflammatory cytokines (TNF-α, IL-1β and 
IL-6), following central administration of resistin and leptin alone or combined in rats 
fed a ND or HFD. 
The main findings in this chapter are that (i) resistin and leptin alone or in 
combination significantly increased microglial activation only in the PVN of rats fed 
a ND compared to the control; (ii) resistin alone increased the gene expression of 
TNF-α in the midbrain and ventral medulla, and IL-1β in the midbrain and dorsal 
medulla of rats fed a HFD; and (iii) resistin combined with leptin increased TNF-α 
gene expression in all brain regions that were examined except the hypothalamus, and 
(iv) resistin combined with leptin increased IL-1β and IL-6 gene expression in the 
ventral medulla of rats fed a ND. 
Microglia activation and the gene expression of cytokines (TNF-α, IL-1β and IL-6) 
are influenced by resistin and leptin alone 
This is the first study to determine that resistin induces microglial activation in the 
PVN of rats fed a ND. No other hypothalamic subnucleus examined showed 
significant activation of microglia. The activation of microglia, which are important 
immune cells in the CNS, induces brain inflammation by releasing the cytokines 
TNF-α, IL-1β, and IL-6 (380, 437, 438). However, in the current study, there was no 
change in gene expression of TNF-α, IL-1β, and IL-6 in the hypothalamus.  
Similar to resistin, from all the brain nuclei that were examined in this study including 
the OVLT and MnPO and the hypothalamus, only in the PVN of rats fed a ND did 
leptin induce microglial activation. Also, no changes in the gene expression of the 
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cytokines were detected following leptin. Previous studies have found that leptin 
activates microglia in vitro and induces the release of cytokines TNF-α, IL-1β, and 
IL-6 (380, 436-438). The current study investigated the effects of leptin in vivo with 
ICV injections of leptin compared to direct injections of leptin into microglia in 
culture. The findings suggest that ICV leptin may act selectively to activate microglia 
in the hypothalamic PVN. 
A recent study showed that central leptin infusion significantly increased TNF-α, IL-
1β, and IL-6 mRNA expression in the PVN, accompanied by increased microglial 
activation and this is in agreement with the present findings with microglia (424). 
Increased microglial activation has been observed in the lamina terminalis following 
central chronic infusion of leptin (424). Thus, contrasts with the present findings. The 
difference is likely due to the fact that a single dose was used in the present study 
compared to one week ICV infusion of leptin in the previous report (424). Further, 
TNF-α expression in the ARC of the hypothalamus was reduced in another study but 
this was in response to multiple injections of leptin over four days (439). Since there 
was no significant changes in gene expression of TNF-α, IL-1β, and IL-6 in the 
hypothalamus tissue block and no microglial activation in the ARC in the current 
study, my work suggests that a single ICV injection of leptin does not influence the 
level of these cytokines in these regions.  
In HFD, resistin and leptin alone did not affect microglial activation in the PVN or 
any other brain region examined. The finding in the PVN suggests that the microglia 
were desensitized to the effect of these hormones by the HFD. 
In the midbrain and medulla of rats fed a ND, resistin alone did not affect the gene 
expression of the cytokines (TNF-α, IL-1β, and IL-6). This finding is consistent with 
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the results showing that resistin did not affect microglial activation in these brain 
regions. Also, there were similar observations for leptin.  
However, in rats fed a HFD, resistin alone increased TNF-α gene expression in the 
midbrain and ventral medulla, and increased IL-1β gene expression in the midbrain 
and dorsal medulla. However, no significant microglial activation by resistin was 
observed in these brain regions. An explanation for these observations is that the 
investigation of microglial activation involved specific brain areas whilst 
investigation of gene expression of the cytokines was measured in midbrain or 
medulla tissue blocks. 
In contrast to resistin, leptin did not activate microglia or increase gene expression of 
cytokines in the midbrain or medulla in HFD. Taken together, it is suggested that a 
HFD may enhance the production of some cytokines induced by resistin in the 
midbrain and medulla.  
Microglia activation and the gene expression of cytokines (TNF-α, IL-1β and IL-6) 
are influenced by resistin and leptin combined 
Of all the brain nuclei that were examined, only in the PVN of rats fed a ND did the 
combination of resistin and leptin induce increased microglial activation. However, 
this response was not seen in the HFD which supports the previous suggestion that a 
HFD leads to desensitization of the microglia in the PVN to the effect of resistin and 
leptin.  
Moreover, resistin and leptin in combination did not affect the gene expression of the 
cytokines (TNF-α, IL-1β, and IL-6) in the hypothalamus of rats fed a ND or HFD. 
This response is consistent with the observations seen with either hormone alone in 
the hypothalamus. 
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In the midbrain of rats fed a ND, resistin combined with leptin only increased TNF-α 
gene expression compared to control and this was greater than resistin or leptin alone. 
This finding suggests that combining resistin and leptin together can result in 
enhanced TNF-α production in the midbrain. In HFD, there was no effect of resistin 
and leptin in combination suggesting HFD attenuated the increase in TNF-α. 
In the midbrain of rats fed a HFD, the expression of IL-1β following resistin 
combined with leptin was lower than resistin alone, but similar to leptin alone, 
suggesting that the response of resistin in the midbrain was attenuated by the action of 
presence of leptin.  
In the ventral medulla oblongata of rats fed a ND, the gene expression of TNF-α, IL-
1β and IL-6 induced by resistin and leptin in combination were greater than control. 
This suggests that combining resistin and leptin enhances the production of the 
cytokines in the ventral medulla.  
In the dorsal medulla, the combination of resistin and leptin only increased TNF-α 
gene expression compared to control. Overall, the cytokine results in the midbrain and 
medulla were not consistent with the observations seen with the lack of microglial 
activation in these regions. This suggests that increased cytokine productivity may be 
occurring in subnuclei of the midbrain and medulla not that were examined.  
Limitations of this study 
The activation of microglia was detected in specific brain nuclei located in the 
hypothalamus, midbrain, or medulla oblongata. However, the gene expression of 
cytokines was measured in larger tissue blocks of the hypothalamus, midbrain, or 
medulla oblongata. This could account for some of apparent disparity in some of the 
findings. 
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Conclusion 
In conclusion, resistin and leptin can induce microglial activation in the PVN, and 
consuming a HFD may reduce the sensitivity of the microglia to these hormones. 
With respect to the cytokines, the most consistent finding was that the combination of 
resistin and leptin increased TNF-α production in rats fed a ND in all regions 
examined except the hypothalamus. In HFD, TNF-α was not increased by resistin and 
leptin combined suggesting an attenuation by HFD. This is the first study to suggest 
resistin may influence inflammation in parts of the brain and that the combination of 
resistin and leptin may have greater inflammatory effects.  
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Chapter 9: General discussion and conclusion  
This thesis investigated neurons in the brain that were activated by resistin. This study 
was much more extensive than any previous work and, for the first time, investigated 
the midbrain and medulla oblongata. In contrast, the brain nuclei activated by leptin 
are widely known, and this thesis expands on this knowledge. Both resistin and leptin 
can act centrally to induce similar increases in RSNA and LSNA, but opposing effects 
in BAT SNA (14, 16, 177, 179, 458). Thus, I speculated that similar mechanisms or 
pathways appear to be mediating the central actions of leptin and resistin for certain 
outputs but different mechanisms or pathways may be involved for other outputs. We 
also investigated whether the number of activated neurons correlated with 
administration of the hormones alone and in combination in brain regions known to 
be involved in cardiovascular and metabolic functions. These used Fos protein as a 
marker of activated neurons in the brain.  
In this project, in rats fed a normal diet, resistin induced activation of neurons in the 
ARC, PVN, LHA and PAG providing some insight into the potential sites of action 
for resistin. Furthermore, combining resistin and leptin induced activation of neurons 
in the lamina terminalis, ARC, PVN, and LHA. In the PVN and LHA, the number of 
activated neurons following resistin and leptin in combination resulted in significant 
increases in the number of activated neurons which were similar to the numbers seen 
with each hormone alone. This result suggests that leptin and resistin activated the 
same population of neurons in the PVN and LHA. In the ARC, resistin and leptin 
combined resulted in significantly more activated neurons than the increases seen 
with each hormone alone. This suggests that resistin and leptin may also act on 
different populations of neurons. Since the PVN and LHA receives projections from 
the ARC (66-68, 454), the present finding may suggest that the actions of the 
hormones may involve a network in which resistin and leptin activate different 
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neuronal populations in the ARC which project onto the same population of neurons 
in the PVN or LHA. This interpretation is shown in Figure 9.1.  
 
 
Figure  9.1. Diagram showing some potential neuronal pathways of resistin and leptin in 
the hypothalamic nuclei which includes projections from the ARC to the PVN and LHA. 
This diagram shows the potential pathway, suggested by the data, that resistin and 
leptin act on different populations of neurons in the ARC and on the same population 
of neurons in the PVN and LHA via projections from the ARC neurons. 
Abbreviations: ARC, arcuate nucleus; PVN, paraventricular nucleus; LHA, lateral 
hypothalamic area; R, resistin; L, leptin. 
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The physiological relevance of the increase in activated neurons in the ARC, PVN, 
LHA and the lamina terminalis following leptin and resistin were not the subject of 
this thesis. The ARC is known to have roles in metabolic and cardiovascular function 
(63, 64, 457), and it may mediate the effects of leptin (205, 206, 456), but this is not 
known for resistin. However, resistin can act centrally to acutely influence food intake 
(178). Since the ARC mediates the anorexic actions of leptin, the current work 
suggest that resistin may also act within the ARC to affect feeding behaviour. 
Additionally, resistin and leptin alone can increase RSNA, and the combined response 
of leptin and resistin resulted in a greater effect than either hormone alone (179). In 
the present work, neuronal activation was greater with resistin and leptin combined 
than either hormone alone. Thus, the ARC may be a key brain site mediating the 
RSNA response to resistin and leptin. 
Resistin and leptin levels are increased with overweight / obese conditions. Dietary 
intake of fat is known to affect leptin responses and I investigated whether this could 
be correlated to the number of neurons activated not only with leptin but also with 
resistin and both hormones given in combination (13, 17). The present findings in rats 
fed a HFD showed a reduction in the number of activated neurons in the brain 
following resistin and leptin. This suggests that HFD reduces sensitivity to resistin 
and leptin in the brain. This may correlate with the reduced anorexigenic and LSNA 
effects of leptin in HFD compared to ND fed rats (13, 350, 505). However, the effect 
of resistin on dietary intake and LSNA in HFD need to be investigated.  
In chapter three and four, I described the distribution of activated neurons following 
centrally administered resistin or leptin. Therefore, next I wanted to expand on this 
knowledge, by investigating the neurochemical content of the neurons activated. 
There is little information known regarding the nature of the neurochemical content of 
neurons activated by resistin. In contrast, leptin is known to act in various brain areas 
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important in regulating metabolic and cardiovascular function and involve 
catecholaminergic, serotonergic, and orexinergic neurons (216, 226, 297, 298, 301, 
307, 312). The present finding suggests that resistin and leptin can activate 
catecholaminergic neurons in the PVN, NTS and RVLM, and orexinergic neurons in 
the LHA. Catecholaminergic neurons in the PVN, NTS and RVLM and orexinergic 
neurons in the LHA can influence sympathetic nerve activity (142, 249, 262, 293, 
506-511). Thus, the catecholaminergic and orexinergic neurons activated by resistin 
and leptin may contribute to the increases in SNA (e.g. RSNA) induced by these 
hormones. Also, I found that HFD reduced the sensitivity of catecholaminergic 
neurons in the PVN and orexinergic neurons in the LHA to these adipokines. 
However, in the RVLM, and NTS, there was no reduction in the sensitivity of 
catecholaminergic neurons activated by the hormones. Thus, the results suggest that 
increased dietary fat can selectively influence the responsiveness of some central 
neural pathways used by resistin and leptin. 
Similar to resistin and leptin, insulin can act on neurons in various brain nuclei to 
influence cardiovascular and metabolic functions (476). Additionally, these hormones 
all increase RSNA and LSNA, but leptin and insulin increases BAT SNA whilst 
resistin decreases SNA to BAT (14, 16, 37, 177, 179, 458). Thus, the current work 
also investigated whether insulin has any similarities compared to leptin or resistin in 
activating catecholaminergic, serotonergic, orexinergic neurons in the brain and 
whether this was affected by a HFD. Additionally, the effects of a combination of 
insulin with leptin or resistin were also investigated to examine any interactions 
between these hormones.  
Insulin alone induced neuronal activation in the PVN in rats fed a ND, and a HFD 
attenuated this response. The activation of catecholaminergic neurons was also 
induced by insulin in the RVLM regardless of diet, suggesting this response was not 
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influenced by dietary changes. Other findings of my work show that the increased 
number of activated catecholaminergic neurons in the PVN, serotonergic neurons in 
the DR, and orexinergic neurons in the LHA, following leptin was not observed in the 
presence of insulin. These findings suggest that insulin inhibited the actions of leptin 
on these neurons.  
I also found that insulin negatively interacts with resistin. It is known that resistin can 
induce the development of insulin resistance (362, 489, 490). However, the present 
study found that when insulin and resistin were combined, there was little activation 
of catecholaminergic, serotonergic and orexinergic neurons in the brain regions 
investigated. In the PVN and LHA, it appears that insulin inhibits resistin’s actions 
since resistin alone increased activation of catecholaminergic neurons in the PVN and 
orexinergic neurons in the LHA. In regions like the RVLM and NTS, the interaction 
is more complex since each hormone alone increased activation of catecholaminergic 
neurons. In these instances, it appears that insulin and resistin may inhibit each other’s 
actions. The mechanisms involved are unknown. However, studies suggest possible 
mechanisms which may be involved in this effect. For example, in peripheral tissues 
such as adipose tissues, resistin can reduce insulin receptor signalling via 
downregulation of insulin-mediated receptor 1 substrate, PI3K and Akt which is 
mediated by SOCS3 (512). Furthermore, ICV infusion of resistin over a 2 week 
period lead to reduced insulin signalling, also via downregulation of Akt as well as 
ERK1/2 and insulin receptor expression, and by upregulation of SOCS3 and 
phosphotyrosine phosphatase 1B (343). Additionally, it has been suggested that 
activation of TLR-4 increases inflammatory cytokines which can contribute to insulin 
resistance (343).  
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Resistin and leptin are known to make important contributions to peripheral 
inflammation by stimulating the release of pro-inflammatory cytokines (442, 496-
498), and these inflammatory responses can contribute to the development of 
atherosclerosis (425-427, 440, 499-502). In brain inflammation, the role of leptin has 
been investigated (424, 437, 439). This involves microglia in the brain, which are 
known to express leptin receptors (380, 435, 436, 438), and are responsible for 
releasing pro-inflammatory cytokines such as tumor necrosis factor-alpha (TNF-α), 
interleukin 1 beta (IL-1β) and interleukin 6 (IL-6), thus activation by leptin induces 
the microglia to release cytokines, providing evidence that leptin can contribute to 
brain inflammation. However, less is known regarding the role of resistin in brain 
inflammation, and thus this was investigated in the present work.  
The current project suggests that resistin and leptin, alone and combined, can induce 
activation of microglia in the PVN, and the sensitivity of these microglia to these 
hormones was reduced by a HFD. Moreover, the combination of resistin and leptin 
increased TNF-α production in rats fed a ND in all regions examined except the 
hypothalamus. A HFD can influence this response, since resistin and leptin in 
combination did not increase TNF-α expression, suggesting that consuming a HFD 
attenuates the response of resistin combined with leptin. In the present study in the 
areas I examined, the activation of microglia and gene expression of cytokines did not 
correlated in some regions. This may be due to our methodology, in which detection 
of microglial activation in specific brain nuclei was done in thin sections compared to 
the gene expression of cytokines measured in tissue blocks of the hypothalamus, 
midbrain, or medulla oblongata. Nonetheless, this is the first study to suggest that 
resistin may contribute to brain inflammation, by increasing TNF-α primarily, and 
that combining resistin with leptin may have an enhanced effect in the midbrain and 
ventral medulla.  
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In conclusion, this thesis provides novel information regarding the potential sites of 
action of resistin and the nature of the neurons activated in the brain. The potential 
sites of action in hypothalamic nuclei include the ARC, PVN, and LHA, and these are 
similar to that of leptin. In such regions, resistin was found to mainly activate 
catecholaminergic and orexinergic neurons, as observed with leptin. Furthermore, 
these responses can be reduced by a HFD. Moreover, when resistin was combined 
with leptin, catecholaminergic neurons in the PVN, serotonergic neurons in the RVMM, 
and orexinergic neurons in the LHA were activated. Thus, when combined resistin and 
leptin have an excitatory effect on these neurons. However, when insulin was combined 
with resistin or leptin, there was no activation of these neurons observed. Thus, the 
presence of insulin may inhibit the action of resistin or leptin.  
Limitation 
In the present study, we have investigated the distribution of Fos protein as a marker 
of activated neurons but it does not provide us with any information on whether the 
neurons are directly activated by the respective hormones or on the potential 
functional responses involved.   
Another limitation with the methods used in my work is that anaesthetized rats were 
used. In conscious rats, the basal levels of Fos are higher than those observed in 
anaesthetized rats, in which the levels were lower (513, 514). Therefore, the changes 
in Fos production compared to the anaesthetized control rats may have been 
underestimated. Nevertheless, as changes were observed in Fos production in the 
brain nuclei examined suggest that these areas are important. 
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